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Selenium Nanoparticles for Biomedical Applications: From
Development and Characterization to Therapeutics
Cláudio Ferro, Helena F. Florindo,* and Hélder A. Santos*
Selenium (Se) is an essential element to human health that can be obtained in
nature through several sources. In the human body, it is incorporated into
selenocysteine, an amino acid used to synthesize several selenoproteins,
which have an active center usually dependent on the presence of Se.
Although Se shows several beneficial properties in human health, it has also a
narrow therapeutic window, and therefore the excessive intake of inorganic
and organic Se-based compounds often leads to toxicity. Nanoparticles based
on Se (SeNPs) are less toxic than inorganic and organic Se. They are both
biocompatible and capable of effectively delivering combinations of payloads
to specific cells following their functionalization with active targeting ligands.
Herein, the main origin of Se intake, its role on the human body, and its
primary biomedical applications are revised. Particular focus will be given to
the main therapeutic targets that are explored for SeNPs in cancer therapies,
discussing the different functionalization methodologies used to improve
SeNPs stability, while enabling the extensive delivery of drug-loaded SeNP to
tumor sites, thus avoiding off-target effects.
1. Introduction
Selenium (Se), initially discovered by Jons Jacob Berzelius, is
a chemical element essential to human health.[1–3] The twenty-
first amino acid, selenocysteine (Sec),[4] is used to produce
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selenoproteins, whose function often de-
pends on the presence of Se in their ac-
tive site,[5] such as reactive oxygen species
(ROS) protection.[5,6] As a result, both Se
deficiency and excess can lead to toxicity
in humans,[7,8] being correlated with car-
diovascular and inflammatory diseases, im-
munodeficiency and brain disorders,[9,10]
type 2 diabetes,[11] fertility/reproduction
complications,[7,9] thyroid autoimmune dis-
eases, and cancer.[7,12]
Tumor cells seem to be more suscepti-
ble to the pro-oxidant and potential cytotoxic
effects induced by high doses of Se. How-
ever, Se-based therapeutic compounds have
a narrow therapeutic window, and there-
fore, have been mostly used against aggres-
sive late-stage cancers.[5,13]
Se nanoparticles (SeNPs) present lower
toxicity and higher biocompatibility than
organic or inorganic Se compounds,
attracting the attention of the scientific community for their ap-
plication as therapeutic and theranostic agents.[5,14–16] Herein,
SeNPs are described as nanomaterials that have a main inor-
ganic therapeutic core consisting of Se (0), that can be stabi-
lized/functionalized with specific compounds or loaded with
active drugs.[13] SeNPs led to the production of higher levels
of ROS than those obtained following the treatment of cancer
cells with selenite, therefore presenting better antitumor prop-
erties than the Se salts.[5,17] In addition, SeNPs present versatile
physical properties, such as the possibility of forming different
shapes depending on the chemicals or solvents used for their
preparation.[18,19]
The methods most frequently employed for SeNP synthesis in-
clude the use of chemical agents and biological organisms (both
plants, fungi, or bacteria) to reduce oxidized forms of Se to its ele-
mental form, biosynthesis or green synthesis, in addition to phys-
ical approaches, such as pulsed laser ablation (PLA).[16,20] How-
ever, bare SeNPs chemically synthesized are highly unstable, ag-
gregating, and precipitating in aqueous solutions, which trans-
lates into their lower bioactivity.[21–23] Several approaches have
been explored for decorating and/or functionalizing SeNPs in or-
der to improve formulation stability and targeted therapeutic ef-
fect. Several substances have been used to modify SeNP surface,
such as amino acids,[23] peptides[24] and proteins,[25] chitosan and
other polysaccharides,[21,26–28] folic acid (FA),[29,30] and hyaluronic
acid (HA),[29,30] among others[13,31] discussed in more detail in the
next sections of this review.
SeNPs have been studied for the treatment of several diseases,
such as diabetes, Alzheimer’s disease (AD)[32] and inflammation-
related diseases,[13] such as rheumatoid arthritis.[33] Additionally,
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Figure 1. U-shaped relationship between Se levels and human health. Adapted with permission.[7] Copyright 2020, SpringerLink.
they are being explored as a protector against potential toxic
agents, such as chromium, cadmium, and chemotherapeutics
agents, which side effects can be very harmful.[13] Also, by trigger-
ing ROS overproduction, SeNPs induce caspase-3 activation and
the PARP cleavage, thereby leading to mitochondria-mediated
apoptosis.[34–36]
SeNPs have shown an increasing potential as major ther-
apeutic platforms, especially in anticancer therapy,[13] in-
cluding in combination with well-known chemotherapeutic
agents like 5-Fluorouracil (5-Fu),[13,37] doxorubicin (DOX)[38] and
irinotecan,[39] as well as with oligonucleotides like small interfer-
ing RNA (siRNA),[31,40] exhibiting synergistic anticancer activity
and overcoming multidrug resistance.[13,41]
The main aim of this review is to present and discuss in de-
tail the effect of Se function in human body, and the current
methodologies used for SeNPs production, physical and antioxi-
dant properties highlighting the advantages of these nanocarriers
compared to Se compounds. We further address the main mech-
anisms behind the SeNPs major therapeutic applications, with
special focus toward cancer therapy.
2. Selenium Compounds and Their Physiological
Effects
Se is essential for human health, being involved in several phys-
iological functions (Figure 1), such as modulation of immune
system activity and ROS control. Therefore, the Se daily intake
should be monitored.[2,42] The recommended daily allowance
(RDA) is 60 µg/day for women, 70 µg d−1 for men,[3] 75 µg d−1 for
lactating women, and 65 µg d−1 for pregnant women according
to the European Food Safety Authority.[43,44] Approximately 20 µg
d−1 is the minimum quantity of Se required to prevent a dilated
cardiomyopathy, i.e., Keshan disease in adults,[3] and its tolera-
ble upper intake level for adults is set at 400 µg d−1,[42,45] being
pro-oxidant and cytotoxic at higher doses.[5]
The main form of Se in human diets is selenomethionine
(SeMet), the Se analog of the amino acid methionine.[4,46] Once
ingested, SeMet is absorbed and enters the methionine pool in
the body.[4,42] Inorganic Se, especially selenite and selenate, is
usually used for Se supplementation.[4] Once in the human body,
Se is mostly used for the production of selenoproteins, which are
essential to human health due to their antioxidant effect, and role
in controlling thyroid hormone metabolism, protein folding, re-
dox signaling, among other functions.[43]
Se has demonstrated antitumor, antiviral, antibacterial, and
antifungal properties,[3] decreasing the risk of tuberculosis in
HIV infected patients,[7,47] and is well correlated to cancer
prevention.[7,11] In addition, Se has been demonstrated to affect
neurological, thyroid, and cardiovascular function.[10,43] Also, ad-
equate Se intake plays an important role in the immune sys-
tem, by increasing T-cell proliferation and NK cell activity against
pathogens and cancer cells, and enhancing vaccine efficacy,[47]
while reducing the risk of diseases related to severe and chronic
inflammation, such as rheumatoid arthritis.[47,48] Se has shown
to protect against heavy metals and radiation toxicity[49,50] and
alcoholism-induced cirrhosis,[10] since it enhances DNA stability
and stabilizes ROS production, as well as decreases the hepatic
and renal side effects of the chemotherapeutic drugs, cisplatin,
and cyclophosphamide.[2]
2.1. Selenium Bioavailability, Metabolism, and Physiological
Functions
Se bioavailability depends on the food ingested,[12,42] being higher
in animal products than in vegetables. Se content in fish is also
elevated, although it can be highly influenced by its source and
animal species, as well as by the presence of heavy metal contam-
inants, such as mercury, which bind to Se to form insoluble inor-
ganic molecules.[42] SeMet is present in both plants and animals,
while selenocysteine mainly exists in animal products.[4] SeMet
more efficiently enhance Se status, since it is directly integrated
into proteins, even though it is necessary for its decomposition
into an inorganic precursor to enter the Se pool.[4,9]
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Figure 2. Brief description of selenoproteins function in human body.
Several Se forms present an absorption rate of 70–90% un-
der normal physiologic conditions, except for selenite, with an
absorption lower than 60%. Se bioavailability is also affected by
ethanol and sulfur agents, in addition to heavy metals other than
mercury, such as zinc and cadmium.[42,51] Moreover, food pro-
cessing can also influence Se bioavailability, since increased tem-
peratures improve protein digestibility, and enhance Se release
and bioavailability. The total fat, protein, carbohydrates, and fiber
within the food ingested can also influence the Se bioavailabil-
ity due to additive, antagonistic, or synergistic interactions with
Se.[42,51] The total Se quantity in the human body ranges from
10 to 20 mg, mainly as selenocysteine, contributing half of that
amount in the skeletal muscles. Although, the organs in which
Se is found to be more concentrated are the kidneys, testis, and
liver, where it is mostly used by the immune system, erythrocytes,
and platelets.[42] Several pathways of Se metabolism may occur,
according to its form. The inorganic forms are reduced to selen-
ite, while the organic forms are cleaved by 𝛽-lyase, and both will
be further used for selenoprotein synthesis.[52,53]
In intestinal mucosal cells, selenite is taken by red blood cells
and reduced by glutathione (GSH) and NADPH-dependent re-
ductases. Alternatively, selenite can be also used as a substrate
for the thioredoxin system.[4,10,42,49,52] However, selenite may not
be immediately subjected to GSH reduction, rather leaving the
bloodstream to be excreted in urine or to be metabolized in the
liver to selenide, is then used for the production of selenoproteins
or methylated compounds.[52] Main roles and properties are sum-
marized in Figure 2. The organic forms, such as SeMet, the main
form of Se present in the human diet,[4,10,42] enter the methionine
pool and are randomly inserted into proteins at methionine posi-
tions, being transported to the liver.[4] The liver is the main organ
responsible for Se metabolism, being responsible for most of the
selenoproteins synthesis and the regulation of Se metabolite ex-
cretion. Se excretion occurs mainly through urine, but Se is also
substantially excreted via feces.[42] Once fecal excretion becomes
saturated, Se excess detoxification is activated, and dimethylse-
lenide is excreted through respiration, in addition to enhanced
urinary excretion.[4,10]
2.2. Se Potential Therapeutic Impact
Since Se has anti-inflammatory and immunomodulatory ac-
tions, Se supplementation has been studied for the treatment
of several inflammatory diseases, such as asthma,[1,10] chronic
lymphedema,[50] rheumatoid arthritis, and Crohn’s disease.[10]
Kamer et al. demonstrated that children with a food allergy pre-
sented Se levels lower than children without any allergy, which
resulted in reduced values of glutathione peroxidase (GPx) and
superoxide dismutase (SOD), which suggests the role of Se in
the pathogenesis of food allergies.[54]
Se compounds can also be toxic, depending on their chemi-
cal composition, dose, and exposure time.[55] However, Se has
been studied as a cancer prevention agent, as several Se-based
compounds have shown to decrease ROS production, and pre-
vent DNA damage and gene dysfunction induced by the excessive
oxidative stress.[10,56,57] Se has also been studied for cancer treat-
ment as a radiotherapy and chemotherapeutic adjuvant since ma-
lignant cells are more susceptible to Se pro-oxidant effects than
healthy cells.[5,49]
Se deficiency has been correlated with several viral, bacterial,
and parasitic infections, which further demonstrates Se impact
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Figure 3. Main Se medicinal properties. Figure created with Biorender.
on immune system function.[45,47,58] Examples of these diseases
include Keshan disease,[9,58] influenza A, H1N1, HIV infection,
and infection by other viruses, such as hepatitis C virus (HCV),
Porcine Circovirus 2, and West Nile virus.[9] Se supplementa-
tion has been shown to be beneficial for the treatment of sev-
eral infections caused by several bacterial, such as Helicobacter
pylori. Escherichia coli,[45] methicillin-resistant Staphylococcus au-
reus (MRSA) and Mycobacterium tuberculosis,[45] especially as a
concomitant opportunistic infection in HIV patients.[47] Se sup-
plementation has been also related to antiparasitic properties
against Trypanosoma cruzi and Heligmosomoides bakeri,[47] besides
improving the immune responses for influenza A and poliovirus
vaccination.[45]
Several studies have shown the potential role of Se and seleno-
proteins in protecting the cardiovascular system against oxida-
tive damage and excessive platelet aggregation, ultimately pre-
venting several cardiovascular pathologies, such as atherosclero-
sis, hypertension, heart hypertrophy, and consequent congestive
failure.[9,10,59]
These Se-related antioxidant properties have been associated
with type 2 diabetes prevention,[10,60] due to the modulatory ac-
tion of selenoproteins in the insulin signaling cascade. Seleno-
protein P was shown to diminish pancreatic insulin production,
and thioredoxin reductases (TR) indirectly reduce insulin resis-
tance. Therefore, this Se insulin-mimetic property supports Se
supplementation benefits. However, other studies have also asso-
ciated Se supplementation and overexposure, or selenoproteins
overexpression, with higher risk for type 2 diabetes,[60,61] and
therefore the role of Se in diabetes not yet clear.[60]
Since the thyroid is the human organ with the highest con-
centration of Se,[46,62] Se supplementation has also shown ben-
eficial properties on the course of autoimmune thyroiditis and
other thyroid pathologies, such as Grave’s hyperthyroidism, and
chronic autoimmune Hashimoto’s thyroiditis. Se has been as-
sociated with thyroid protection from oxidative stress, especially
due to GPx3 activity,[46,62] as well as with metabolism regulation
of thyroid hormones and increased efficiency of IDIs,[10] con-
tributing to the conversion of T4 into T3. Se supplementation
has also shown benefits for the treatment of hyperthyroidism-
related pathologies, such as mild Graves’ orbitopathy, improving
the quality of life and slowing the disease progression in patients
treated with levothyroxine.[63]
Since Se is also present in higher concentrations in gray matter
regions and in the glandular sections,[10] participating in several
neurotransmission and dopaminergic pathways,[64] this element
has been studied as a biomarker for several neurological diseases,
such as epilepsy, Alzheimer disease, and Parkinson’s disease.[10]
Se antioxidant neuroprotective function, impact on the regula-
tion of cytoskeleton assembly, as well as the ability to bind to
several neurotoxic metals and attenuate A𝛽 deposition and tau
proteins hyperphosphorylation,[64–66] constitute some of the fac-
tors that have been identified as possible causes for the role of
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Table 1. Comparison between the main SeNPs production methods.
Production
method
Main materials SeNPs characteristics Advantages Disadvantages
Biosynthesis Reduction of inorganic Se form (e.g.,
selenite or selenate) by a
bioorganism (e.g., bacteria, fungi,
protozoan, plant extracts.)
Dependent on the bioorganism
used for SeNP preparation
• SeNPs already capped and
stabilized with biocompounds
specific of the bioorganism used
• Environment friendly
• Several parameters and steps to be
optimized in the SeNPs biosynthesis
Chemical
reduction
Reduction of inorganic Se form (e.g.,
selenite or selenate) using a
reducing chemical agent (e.g.,
ascorbic acid, GCH) and another
compound as a stabilizing agent
Dependent on the stabilizing
agent (bare SeNPs are not
stable and precipitate within a
few days)
• Simple process, without need of
bioorganism incubation or a
technologic instrument
• Least environment friendly method,
since it often uses harsh chemicals
Physical synthesis Use of physical-based methods (e.g.,
heating, laser ablation) to induce
changes in inorganic Se
compounds and produce SeNPs, in
the presence of a stabilizing agent
Dependent on the stabilizing
agent and the gamma ray
doses applied.
Possibility of production of
ultrasmall SeNPs
• Rapid and uniform production
• Rapid reaction time
• Increased reaction rates
• Less energy spent, therefore a
more economical method
• Environment friendly
• Necessity of specific instruments
Se in Alzheimer disease development. More recently, Vicente-
zurdo et al. studied the metal-chelating potential of several Se
species, such as SeMet, Sec, Se-methylselenocysteine and Se(VI),
concluding that although Cu(II) and Fe(II) interacted with all
Se species, Zn(II) only interacted with SeMet. However, these
Se species have shown to increase the A𝛽 fibrils width at the
same degree as the neurotoxic metals studied.[64] In addition,
several selenoproteins were shown to protect dopaminergic neu-
rons, reinforcing the beneficial property of Se against Parkinson’s
disease.[67,68] Se levels have also been correlated with mood al-
terations, depression, and aggressive behavior.[9] However, since
brain Se levels are rarely low, and excessive Se levels may also
be prejudicial, its application in neuronal disorders may only be
advantageous for patients with severe Se deficiency and/or with
mutations in genes related with Se delivery or selenoproteins
production.[67]
Se potential role in pregnancy[44] and reproduction,[69] as
well as in male fertility[70] has also been recently revealed.
Low levels of plasmatic Se have been connected to miscarriage
episodes, and other pregnancy-associated complications, such as
preeclampsia, preterm labor, and gestational diabetes.[44] More-
over, Se has proven to be an intracellular antioxidant in Leydig
cells[70,71] and to neutralize the H2O2 produced during testos-
terone biosynthesis.(50) Se supplementation seems to have an im-
portant role in spermatogenesis, as it was shown to decrease the
quantity of abnormal sperm in mice, and enhance the viability
of Sertoli cells and the expression of essential protein compo-
nents due to its antioxidant properties.[70,72] The main Se medic-
inal properties are summarized in Figure 3.
3. Preparation and Characterization Methods of Se
Nanoparticles (SeNPs)
3.1. SeNP Production Methods
SeNPs can be synthesized by chemical, physical, and biosynthe-
sis methods (Table 1).[14,20,73] Chemical methods require the use
of agents to induce the catalytic reduction of ionic Se, commonly
involving high temperatures, acidic pH, and dangerous chemi-
cals, which makes this method unsafe in several situations.[14,74]
Physical methods that are less used than the chemical method-
ologies, include photo-thermal-assisted synthesis approaches,
electrodeposition techniques, PLA, and microwave synthesis.[20]
The biosynthesis of SeNPs, also referred to as green chem-
istry, consists in the use of bacteria, fungi, yeasts, algae, and
plants as catalyst for SeNPs production,[73] resulting in inexpen-
sive, nontoxic and ecofriendly SeNPs.[14,75] Biosynthesis meth-
ods present several advantages when compared to physical and
chemical methods, such as inexistence of extreme conditions,[34]
fast growth rate of the microorganisms used, low cost, common
culture procedures,[76,77] low toxicity and ecofriendly,[74,78] and
unique spectroscopic characteristics.[77]
3.1.1. Biosynthesis of SeNPs
Biosynthesis methods reduce selenate or selenite to elemen-
tal Se by compounds existing in bioorganisms, such as phe-
nols, flavonoids amines, alcohols, proteins, and aldehydes, re-
sulting in specific red SeNPs.[14,16,34,79] Although, biogenic SeNPs
are more frequently produced by prokaryotic cells,[14,77] such as
anaerobic,[78] aerobic,[75,80] and anoxic bacteria,[14] both fungi,[81]
protozoan,[82] and plant extracts[74,83,84] have been used as well.
The latter is easily manipulated, converting selenate (SeO4
2−)
into red SeNPs, due to the action of selenate reductases, which
first reduce selenate to selenite (SeO3
2−), which will be subse-
quently reduced to elemental Se in the periplasm, by selenite re-
ductases, such as nitrite, nitrate, and sulfite reductase.[14,77] Thi-
ols, including GSH, cysteine, and cystine, and protein-bound thi-
ols, such as phytochelatins and metallothioneins, have been in-
volved in the SeNPs biosynthesis. Usually, GSH donates an elec-
tron to selenite, producing selenodiglutathione (GS-Se-SG) and
superoxide anion (O2
•−). GS-Se-GS, due to the activity of NADPH
and GSH reductase/TR, forms selenopersulfide (GS-Se−), which
breaks into reduced GSH and elemental Se0, being the O2
−
degraded by antioxidant enzymes.[34,77,85] Macromolecules, such
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Figure 4. a) TEM images of Se nanostructures produced by both a-I) gram-positive L. lactis and a-II) gram-negative bacteria P. putida KT2440. Reproduced
with permission.[78] Copyright 2019, Frontiers, and Reproduced with permission.[85] Copyright 2016, Nature, respectively. b) Acinetobacter sp. SW30
produces different Se nanostructures according to the concentration of Na2SO3: A) 0.3 × 10−3 m; B) 0.5 × 10−3 m; C) 1.0 × 10−3 m; D) 1.5 × 10−3 m;
E) 2.0 × 10−3 m; F) 2.5 × 10−3 m; G) 3.0 × 10−3 m; and H) 4.0 × 10−3 m. Reproduced with permission.[89] Copyright 2017, Dovepress.
as proteins, enzymes, cellular residues, and even membrane
phospholipids, may surround the SeNPs produced by biosynthe-
sis, which is indicated by the presence of C, O, P, and S in ele-
mental analysis assays.[78,82,86]
Both gram-positive and gram-negative bacteria have been used
to produce SeNPs (Figure 4a), such as Idiomarina sp. PR58-
8,[34] E. coli ATCC 35 218,[76] Stenotrophomonas maltophilia, Bacil-
lus mycoides,[86] Lactococcus lactis,[78] Enterococcus faecalis,[87] Ral-
stonia eutropha,[88] Acinetobacter sp. SW30,[89] Bacillus pumilus
sp. BAB-3706,[90] Pseudomonas putida KT2440,[85] Azospiril-
lum brasilense,[91] Bacillus licheniformis,[35] Vibrio natriegens,[92]
Rhodococcus aetherivorans,[80] Pseudomonas alcaliphila,[93] Alcali-
genes faecalis,[94] Pseudomonas stutzeri[95] and, more recently, Bacil-
lus amyloliquefaciens SRB04, which has been shown to produce
SeNPs smaller than 50 nm.[75]
The mechanisms behind bacterial SeNPs biosynthesis are di-
vided into three steps: 1) transport of Se oxyanions into the cell,
mainly by sulfate permeases; 2) reduction of these compounds
by bacteria proteins, producing the red amorphous Se0, followed
by its release from the cell; 3) assembly of elementary Se0 into
SeNPs by continuous reduction of Se oxyanions to Se0;[77,93] and
4) isolation of SeNPs from the bacteria by both centrifugation and
filtration methods.[91]
To optimize the biosynthesis of SeNPs, it is important to con-
trol several parameters, such as the: 1) bacterial culture tem-
perature and rotation;[88] 2) incubation time and the Se salt
concentration;[14,89] 3) culture growth pH;[95] 4) Se minimum in-
hibitory concentration (MIC) for the microorganism; 5) several
growth kinetics indicators, like specific growth rate, doubling
time and lag time, the selenite/selenate uptake rate;[14,34,80,85] and
6) microorganism reducing potential.[76,80] For example, Wad-
hwani et al. produced SeNPs using Acinetobacter sp. SW30, and
demonstrated that using 0.3 × 10−3 to 2.0 × 10−3 m Na2SO3 re-
sulted in spherical SeNPs, while concentrations of 3.0 × 10−3
m Na2SeO3 and higher produce rod-like SeNPs (Figure 4b).
[89]
Presentato et al. have also shown that the bioconversion in R.
aetherivorans BCP1 exposed for the first time to SeO3
2− was
inferior to the one obtained in R. aetherivorans BCP1 reinocu-
lated in fresh medium and reused.[80] In addition, the bacte-
rial medium culture can influence the characteristics of biogenic
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Figure 5. TEM images of Se nanostructures produced using plant extracts: a) V. vinifera extract. Reproduced with permission.[83] Copyright 2014,
Molecules. b) E. officinalis extract. Reproduced with permission.[74] Copyright 2019, PMC.
SeNPs. For example, Rajkumar et al. verified that the use of ba-
nana peel extracts a medium constituent for P. stutzeri led to bio-
genic SeNPs more stable than those obtained while using the
commercial media. The amorphous SeNPs presented a size of
75–200 nm and Fourier transform infrared (FTIR) assays indi-
cated the existence of functional groups responsible for the re-
duction and stability of SeNPs.[95]
Protozoan, such as Tetrahymena thermophila, were also used
for the synthesis of SeNPs. T. thermophila showed optimal pro-
duction with 150 × 10−6 m selenite, producing amorphous SeNPs
with a size ranging from 50 to 500 nm due to the reducing ac-
tion of GHS.[82] Faramarzi et al. used Saccharomyces cerevisiae to
produce SeNPs, employing amounts of sodium selenite ranging
from 5.0 to 25 µg. It was observed that S. cerevisiae growth in-
creased with higher amounts of sodium selenite, which affected
the physical and antioxidant characteristics of SeNPs, since the
use of the 5.0 µg selenite originated SeNPs with the smallest size
(75 nm) and also with the highest antioxidant activity. However,
intakes of 25 µg selenite originated more uniform SeNPs.[81]
Plant extracts also demonstrated potential for SeNPs biosyn-
thesis. For example, Vitis vinifera fruit extract has shown to re-
duce selenious acid, producing elemental Se. Sharma et al. in-
dicated that the biopolymer lignin, due to its phenolic group, is
responsible for the reduction and stabilization of SeNPs (Figure
5a).[83] Fruit extracts of Emblica officinalis also reduced sodium
selenite into elemental Se due to their high content of phenolics
(gallic acid), flavonoids (catechin), and tannins (tannic acid) (Fig-
ure 5b).[74] Capsicum annuum L. extract has also been shown to
reduce Se ions into amorphous elemental Se, controlling its nu-
cleation and growth. Transmission electron microscopy (TEM)
images revealed different SeNP shapes, according to the pH of
the reaction environment.[84]
The use of plant extracts is preferable to the use of fungi and
bacteria, since those are widely available and safer to manipulate,
requiring mild conditions and less damaging solvents, in addi-
tion of offering more effective and faster production of SeNPs.
In fact, the reduction of Se salts usually occurs in one step, allow-
ing for an effective control of SeNP size and shape.[36] Moreover, a
specific plant can be used for SeNPs production due to its benefi-
cial properties. For example, Qamar et al. used Trachyspermum
ammi seed extract, since this plant exhibits anti-inflammatory,
antioxidant, immunomodulatory, antimicrobial, antifilarial, an-
thelmintic, and gastroprotective abilities due to the presence of
thymol,[96] to produce biogenic SeNPs with an average size of
40 nm.
It is believed that in the future, SeNPs can be extracted us-
ing biomineralization, since this method can produce the purest
product.[20] Biosynthesized SeNPs have also already been sta-
bilized and functionalized, being capped with biocompounds.
However, since specific microorganisms have been used to pro-
duce SeNPs with different characteristics, more studies are re-
quired to match the microorganism to the corresponding cap-
ping biomolecules and therapeutic activity.[74,77] This is impor-
tant, since polysaccharide capping is preferred to coating with
phenolics or proteins, since the latter are susceptible to enzy-
matic degradation, while phenolics are auto-oxidized and aggre-
gate in the stomach’s acidic environment.[36]
3.1.2. Chemical Reduction Synthesis of SeNPs
Several Se reducing compounds can be used to produce
SeNPs, such as sodium selenite,[97,98] selenious acid[22,99] and Se
dioxide.[100] However, Kumar et al. used Se powder and sodium
sulfite at a ratio of 1:4 in an aqueous solution, which was kept un-
der stirring at 70 °C for 9 h, leading to a transparent sodium se-
lenosulfate solution. The carboxylic group of the reducing agents
acetic acid, pyruvic acid, and benzoic acid led to the SeNPs
synthesis.[101] Other reducing agents have been used, such as
GSH[102,103] and sodium borohydride,[104–106] although the most
environmental friendly and most common reducing agent used
is ascorbic acid.[15,97,107] Zeng et al. optimized the reaction con-
ditions and the ratios between ascorbic acid and selenite acid,
describing a temperature of 25 °C, a reaction time of 2 h and an
ascorbic acid: Se molar ratio of 4:1 as optimal conditions. The-
oretically, ascorbic acid would reduce Se in a stoichiometry of
2:1; however, the excess of reducing agent provided a more effi-
cient reducing environment and prevented the SeNPs oxidation,
thereby leading to smaller SeNPs.[97,107] Recently, an antioxidant
agent named phycocyanin, extracted from Spirulina, was also
used to reduce sodium selenite in order to produce SeNPs.[108]
The agitation submitted during the SeNPs formation also influ-
enced the SeNPs size.[97]
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Figure 6. a) Schematic of SeNPs production using PLA method. b) SEM image of the SeNPs produced by the initial 3000 Hz irradiation. c) SEM image
of the SeNPs produced by two sets of 3000 Hz irradiation, with a more delineated spherical shape than the SeNPs produced by only one irradiation set.
Reproduced with permission.[115] Copyright 2020, American Chemical Society.
Also, Ma et al. produced a block copolymer with diselenide
containing polyurethane (PUSeSe), with one water-insoluble dis-
elenide part and another part of soluble polyethylene glycol (PEG)
via polymerization of toluene diisocyanate. These diselenide-
containing polymers were amphiphilic and, therefore, could self-
assemble into micellar structures of 76 nm in an aqueous en-
vironment. Also, the block copolymer presented both oxidation
and reduction responsive behavior, being sensitive to external re-
dox behaviors, and consequently, with potential for production of
drug delivery systems[109]
3.1.3. Physical Synthesis of SeNPs
Physical methods include PLA, hydrothermal treatments,
microwave irradiation sonochemical processes, and physical
evaporation.[20,79] Microwave synthesis of SeNPs consists in
a traditional laboratory heating technique that uses Se salts
in an aqueous solution. It presents several advantages, such
as rapid and uniform heating, rapid reaction time, enhanced
reaction rates, and less energy spent.[110] Mellinas et al. used
microwave heating to produce trigonal and amorphous SeNPs
with Theobroma cacao L. bean shell extract as a stabilizer, with a
size of 1–3 nm, that was stable for 55 d at 4 °C.[111]
Ultrasmall SeNPs conjugated with PEG were produced by a
hydrothermal process, by dissolving gray Se powder in PEG so-
lution at 210–220 °C for 15–20 min, without the need for any re-
ducing reagent, therefore being a more accessible and ecological
method.[112] More recently, gamma irradiation was also used to
produce SeNPs, as the radiolysis of aqueous solutions reduces
metal ions[113,114] by creating solvated electrons, which then re-
duce the metallic ions into metal atoms that combinate and form
aggregates. Therefore, the SeNPs physicochemical properties de-
pended not only on the capping agent, but also on the gamma-
ray doses applied. For example, El-Batal et al. used gamma ray
doses ranging from 0 to 100 kGy to produce various types of
SeNPs capped by chitosan, sodium alginate, citrus pectin, and
biogenic SeNPs using Pleurotus ostreatus aqueous extract of fer-
mented powdered fenugreek seeds.[113]
Another popular physical method for SeNPs production is
the PLA in liquids, which creates SeNPs with sizes between 5
to 120 nm.[115] This method uses liquid phased PLA in deion-
ized water that turns Se pellets into colloidal solutions, where
the electrical charge prevents the SeNPs from agglomerating
by creating an electrical charge at its surface.[20,115] PLA has
the advantages of being ecologically friendly and an economi-
cal method,[115] in addition to not requiring the use of chem-
ical reagents, thereby avoiding the existence of contaminating
by-products. These SeNPs are also easily collected as in the col-
loidal solution their stability is elevated.[20,116] PLA method also
conserves the stoichiometry of the material and the sizes of the
SeNPs are easily controlled according to the laser parameters
used, e.g., fluence, wavelength, pulse duration, and ambient gas
conditions like pressure and flow parameters.[16]
PLA method was used to produce antibacterial SeNPs. A Q-
switched Nd:YAG laser with a wavelength of 1064 nm was used
to irradiate the solution of 2 nm Se pellets immersed in deion-
ized water, with the pulse frequency analyzed varying from 100 to
5000 Hz, and the pulse duration time from 70 to 200 ns according
to the repetition rate. The laser was redirected by a mirror at a 45°
and was focused by an 83 mm focal length lens to irradiate from
the top of the SeNPs, creating a high-temperature plasma. Af-
ter 5 min under radiation, the particles were irradiated to reduce
their size, and then subjected to an ice bath to prevent agglom-
eration, while a second irradiation was employed (Figure 6a).
However, when the frequency values surpassed 3000 Hz, the
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Figure 7. Effect of stabilizers on the size and stability of SeNPs: although the solutions of bare SeNPs (b) and SeNPs stabilized with Spirulina platen-
sis polysaccharide (a) initially appear homogenous, after 90 d, only the SeNPs capped with the polysaccharides remain stable, while the bare SeNPs
precipitated. Reproduced with permission.[117] Copyright 2020, Wiley-VCH GmbH.
production of SeNPs decreased, since the pulsed beam hit the
cavitation bubble. After the cavitation bubble collapsed, the
SeNPs were released into the solvent. In order to avoid the cavita-
tion bubble and increase the production of SeNPs, the repetition
rate chosen was 3000 Hz. The second set of irradiation helped to
stabilize and to diminish the size of the SeNPs, producing SeNPs
with a size and zeta potential values of 43 ± 20 nm and +66 ±
3 mV, respectively (Figure 6b,c).[115]
Guisbiers et al. also used the PLA method to produce antibac-
terial SeNPs. The neodymium-doped yttrium aluminum garnet
NT342B laser was used with a pulse duration of 3.6 nanoseconds,
a frequency of 20 Hz and a wavelength within the ultraviolet spec-
trum, 355 nm, for 15 min, producing stable SeNPs with a size and
zeta-potential of 115±38 nm and -45.6 mV, respectively.[116]
3.2. SeNP Stabilization and Functionalization Approaches
Since bare SeNPs produced by chemical synthesis are unstable
in aqueous solutions (Figure 7-b), leading to aggregates of sta-
ble gray/black Se,[15,106,117] stabilizers are usually added to pre-
serve SeNPs size and bioactivity.[40,23] In fact, small changes in the
SeNPs size may have an effect on their antioxidant activities, for
example, by promoting Se accumulation and GSH S-transferase
activity in vivo.[15] Several compounds have been used to stabi-
lize the SeNPs, such as aminoacids,[23] bovine serum albumin
(BSA),[97,103] polysaccharides (Figure 7-a) like chitosan[15,27] and
gum arabic,[15,22,106] and polymers as poly(lactic-co-glycolic acid)
(PLGA).[102]
SeNPs have shown potential to target specific cancer cells, by
passive targeting based on the fact that the tumor environment is
more acidic than the environment existing in healthy tissues.[36]
However, the active targeting, achieved through SeNPs function-
alization with ligands that bind to receptors overexpressed in can-
cer cells, is more successful in delivering compounds to the site
of interest, avoiding healthy tissues, thereby increasing the ther-
apeutic efficacy and reducing the toxicity.[118] SeNPs active target-
ing was demonstrated to be successful using folic acid,[100] trans-
ferrin (Tfr),[119] and HA.[120,121]
3.2.1. Chitosan
Chitosan is the N-deacetylated form of chitin found in crus-
taceans, insects, and fungi.[99] Although, Chitosan is not sol-
uble in aqueous or alkali solutions, and therefore acetic acid
is often added for its dissolution.[15,26,107] This polysaccharide
has been used in biomedical applications, including for oral de-
livery, due to its low toxicity, good bioavailability, and positive
charge,[27,122] which enhances drug bioadhesion,[99] while avoid-
ing pepsin and pancreatin degradation.[99,122] Moreover, chitosan
enables the drug release in the acidic tumor environments, as
well as within the lysosomes and endosomes, being capable of en-
hancing the passive targeting of NPs.[40] Therefore, several stud-
ies have demonstrated the potential application of chitosan as a
SeNPs stabilizing agent, and its antioxidant[26] and antitumor ef-
fect, while addressing the effect of the chitosan molecular weight
(high vs low) in the morphology and properties of SeNPs.[21,27,99]
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Table 2. Physicochemical differences between SeNPs capped with low and high molecular weight chitosan.
Process studied Type of chitosan used for SeNPs capping
High molecular weight Low molecular weight
Storage Particle size improved with time, being stable for
180 d: indicated for long-term storage
Presented some aggregation, being stable for 30 d
Heating Results in opaque solutions, due to the breakage of hydrogen bonds between chitosan and the SeNPs
Stayed below 200 nm and formed rod-like
structures when temperature reached 95 °C
400 nm aggregates at 70 °C
Freeze-drying Maintenance of the spherical shape, being
well-dispersed in water, although with size
increase
Possible flocculated morphology, with aggregation
Freeze-thawing Loss of stability, due to breakage of hydrogen bonds
Antioxidant
capacity
Effects Both showed better radical scavenging activity for ABTS than for DPPH
Higher antioxidant capacity, due to its loosened
structure
Decreased antioxidant capacity
Heating Decreased both the ABTS and DPPH free radical
scavenging activity
Increased both the ABTS and DPPH free radical
scavenging activity (improved Se release ratio)
Freeze-thawing Did not affect the antioxidant capacity
Rehydration Improved the antioxidant capacity
Antibacterial
activity
Effects Antibacterial properties against S. aureus, however without inhibition effects towards E. coli
Heating Only affected by 95 °C temperatures Heating above 70 °C decreased the antibacterial
activity
Rehydration Without significant effect Decreased the antibacterial activity
SeNPs reacted with the lateral groups NH2 and CH2OH of the
chitosan, forming Se–O bonds, while the positive NH3
+ groups
are present on the outer surface, enhancing its stability in aque-
ous solutions.[21,22,99] Although bare SeNPs presented a slightly
negative zeta-potential in aqueous solutions due to the existence
of trace elements HSe− and Se2− on the surface of the SeNPs,
chitosan–SeNPs were clearly positive and stable, because of the
existence of amino groups, that are protonated under acidic
conditions.[99,123] While chitosan(l)–SeNPs appeared as uniform
small spheres of 20–50 nm, chitosan(h)–SeNPs formed irregular
aggregates, cross-linking effects obtained due to the use of high
molecular weight macromolecular chitosan. Chitosan(l)–SeNPs
maintained their structure for 30 d, after which they started to
degrade leading to larger spherical aggregates,[27,99,122] probably
due to the reduction of the absolute 𝜁 -potential over time.[15]
Zhang et al. demonstrated that chitosan–SeNPs release in gas-
tric (pH 1.2), intestinal (pH 7.4), and sweat (pH 6.3) environ-
ments is almost insignificant, supporting the high stability pro-
vided by chitosan. Chitosan(h)–SeNPs demonstrated to have a re-
lease rate higher than chitosan(l)–SeNPs in all media, probably
due to the lower network impediment provided by the incom-
pact structure of chitosan(h)–SeNPs.[99] Chen et al. also studied
the impact of molecular weight of chitosan on the properties of
chitosan-SeNPs, using I− as a surface regulating agent. These
studies demonstrated that the chitosan concentration positively
affected the chitosan–SeNPs size due to the decrease of the dis-
tance between chitosan molecules, enhancing the intermolecular
hydrogen bond forces, which results in increased crosslinking
effects.[27] However, chitosan(h)–SeNPs presented higher cellu-
lar uptake by cancer cells lines than normal cell lines, probably
due to the higher amount of -NH3
+ groups, which permits an
enhanced electrostatic attraction between the positively charged
chitosan(h)–SeNPs and the phosphoryl groups of phospholipids
in the cancer cell membrane, that are more negatively charged
than normal cell membranes.[21,22]
Also, Song et al. analyzed the physicochemical characteristic
of Chitosan-SeNPs produced using both high and low molecular
weight chitosan, as summarized in Table 2.[124]
Chitosan–SeNPs exhibited higher radicals scavenging activity
in 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
than in 2,2-diphenyl-1-picrylhydrazyl (DPPH) and lipid perox-
idation assays, which indicated that chitosan-SeNPs presented
higher solubility in water phase than in lipid phase solvents,
showing more propensity to react by electron transfer based re-
action than hydrogen atom transfer reaction.[122] Chitosan(h)–
SeNPs scavenging activity for ABTS˙+ radical cation and super-
oxide anion radical (O2•
−) was the highest compared to SeNPs
stabilized by medium and low molecular weight chitosan (Fig-
ure 8).[27,124] The antioxidant activity of chitosan-SeNPs was
demonstrated in vitro, by inhibiting ROS production in a dose-
dependent manner and enhancing the viability of BABLC-3T3
cell lines. In vivo, the chitosan–SeNPs enhanced the GPx activity
and reduced the lipofuscin levels in mice subjected to UV radia-
tion during 15 d.[122]
Chitosan–SeNPs have also presented antitumor properties
against hepatic cancer cell lines, especially the chitosan(h)–
SeNPs,[21,27] promoting ROS generation and mitochondria
dysfunction.[21] These nanosystems also had the ability to load
Adv. Healthcare Mater. 2021, 10, 2100598 2100598 (10 of 50) © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
Figure 8. Antioxidant properties of chitosan–-SeNPs. Overall,
chitosan(h)–SeNPs has higher radical scavenging properties than
chitosan(l)–SeNPs; however, all chitosan–SeNPs presented higher
radicals scavenging activity in ABTS than in DPPH and lipid peroxidation
assays. Reproduced with permission.[122] Copyright 2017, BMC.
several anticancer drugs, such as DOX, providing a selective
drug release in acidic endosomes and lysosomes.[41,125] Chitosan–
SeNPs have been also explored as mRNA carriers for cancer
therapy,[126] as antidiabetic compounds,[107] and as a biocompati-
ble material for cardiac tissue engineering.[127]
More recently, a spray-drying technique was studied to in-
crease the stability of SeNPs, by adding a new layer of chitosan
to the already formed Chitosan-SeNPs, producing microspheres
(SeNPs-M) that remained stable for 60 days.[15] SeNPs were
purified by ultrafiltration in which soluble compounds crossed
the filtration membrane, while SeNPs-M were entrapped and
separated.[15,128] SeNPs-M presented toxicity lower than selenite,
with a LD50 value of 18–20 fold, and increased mice growth and
the levels of antioxidant enzymes in dosages considered toxic for
selenite administration.[15,123] SeNPs-M were studied as antioxi-
dant agents for the scavenging of hepatic radicals caused by alco-
hol overconsumption.[123,128]
Ionic gelation was also studied to increase the stability of
Chitosan-SeNPs. In this technique, chitosan–SeNPs were em-
bedded into a sodium citrate solution with moderate stirring, and
a crosslinking gelation occurred, resulting in a chitosan/citrate
gel. Afterwards, the gel was removed, and a spray-drying tech-
nique was applied to obtain solid red SeNPs-C/C, which were
stable for 60 d (Figure 9a). Although SeNPs-C were completely
dissolved in pH 2.0–2.5, suggesting its release in the stom-
ach, SeNPs-C were not soluble in pH above 3.0, due to the
non-ionization of the citrate at these pH values (Figure 9b,c).
SeNPs-C/C were stable in 60 °C in relative humidity for 10
d (stress conditions) and in 40 °C, in the dark for 6 months,
reaching the standard stability required for food storage and
transportation. Furthermore, in the presence of 1/11-1/4 of
the selenite toxicity, SeNPs-C presented antioxidant and protec-
tive effects against D-galactose (D-gal)-induced aging in mice,
decreasing the growth suppression caused by D-gal and di-
minishing liver damage, by increasing the level of antioxidant
enzymes.[26]
3.2.2. Folic Acid (FA)
FA has been widely studied as a ligand for the functionalization
of NPs for cancer treatment, as the folate receptor is frequently
overexpressed in several cancer types.[129] Thereby active target-
ing using FA has shown to increase NP uptake by cancer cells
through the receptor-mediated endocytosis,[130,131] improving the
overall antitumor effect of these carriers while avoiding off-target
effects in healthy cells.[100] SeNPs functionalized with FA (FA-
SeNPs) were studied for breast[100,131] and hepatocellular cancer
treatment.[130] FA-SeNPs were produced by chemical reaction, by
ionic or polar-polar interaction between the –NH2 and –COOH
groups of the FA, and the hydroxyl groups on the SeNPs, via
carbonyl bonds.[100,129] Active targeting using FA was studied us-
ing an excess of FA to inhibit the cellular uptake of FA-SeNPs,
demonstrating that the FA molecules on the surface of SeNPs
were available to specifically target cancer cells.[130,131]
3.2.3. Hyaluronic Acid (HA)
HA is a linear, negatively charged polysaccharide contain-
ing two alternating units of d-glucuronic acid and N-acetyl-d-
glucosamine.[30] As a result of its diverse sources, biocompatibil-
ity, biodegradability, nontoxicity, nonimmunogenicity, and abun-
dance of functional groups (─COOH and ─OH), HA has been
used for several pharmaceutical applications, such as for the tar-
geted delivery of antitumor drugs[29,30,120] by specifically binding
the CD44 receptors present in cancer cells.[29,120]The HA recep-
tor CD44 is abundant in several cancer cells, such as HepG2 (hu-
man liver carcinoma cells), HeLa (cervical adenocarcinoma can-
cer cells), and A549 cells (lung carcinoma cells). Thereby, anti-
tumor potential of HA–SeNPs has been studied, in which HA
not only stabilized, but functionalized the SeNPs toward cancer
cells.[30]
HA hydrogels have also shown potential for the delivery of
SeNPs for seborrheic dermatitis treatment, as a hydrogel con-
taining ketoconazole NPs and SeNPs, by employing the cross-
linking method. HA protects SeNPs from aggregation and pre-
serving their colloidal arrangement, resulting in a hydrogel with
potential to treat topical fungal infections.[132]
3.2.4. Other Polymers
Several other polymers have been used to stabilize SeNPs, such
as polyvinyl alcohol (PVA). Kumar et al. studied the anticancer
properties of SeNPs against Dalton’s lymphoma cells, using PVA
as a stabilizer agent, concluding that the concentration of PVA
did not affect the size and shape of the SeNPs.[101] The precipi-
tation of SeNPs in poly-l-lactic acid (PLLA) produced an antitu-
mor material against osteosarcoma cells, while promoting bone
regeneration. PLLA was coated with SeNPs, by adding GSH and
sodium selenite to PLLA, and NaOH to alkalize the medium and
precipitate the SeNPs onto the PLLA.[133]
PEG is an amphiphilic molecule soluble in both water and in
several organic solvents,[134] and it has been widely explored as
a stabilizer.[134,135] PEG is FDA approved for injectable, topical,
rectal, and nasal formulations.[40,112,136] Its popularity is mainly
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Figure 9. Effect of the ionic gelation process on Chitosan-SeNPs. a) Representative scheme of process of SeNPs-C/C preparation. b) SeNPs-C/C disso-
lution according to the solution (SeNPs-C/C are not soluble at pH equal or above 3). and c) TEM image of SeNPs-C/C dissolved in pH 2.5 solution for
8 h. Reproduced with permission.[26] Copyright 2017, BMC.
due to its favorable characteristics, such as overcoming several
physicochemical instabilities,[134] high safety and stability at high
temperatures, decreased nanoparticle clearance by the mononu-
clear phagocytic system, while preventing protein aggregation
and enzymatic degradation, which increase NPs accumulation
in the tumor site due to the enhanced permeability and reten-
tion (EPR) effect. In addition, PEG chains are used for NP func-
tionalization by enabling the binding of specific targeting an-
tibodies and other compounds identified by the cancer cells.
Accordingly, PEG–SeNPs presented potential for the treatment
of hepatic[112,134] and lung cancer.[137] During the production of
PEG-stabilized SeNPs at high temperatures, its oxygen atom is
sp3 hybridized and forms two carbon–oxygen covalent bonds and
two lone-pair electrons, which coordinate with the empty 4d or-
bitals of each Se atom. Thereby, PEG has not only enabled the
atomic clusterization of gray Se, but also controlled its size, pre-
venting SeNPs aggregation and reversion to its gray as the tem-
perature decreases.[112]
The cationic polymer polyethylenimine (PEI) has been shown
to enhance NP stability, in addition to having immunostimula-
tory properties, via Toll-like receptor (TLR) activation,[136] as well
as enabling the delivery of nucleic acids due to the electrostatic
interactions established between PEI ammonium groups and the
phosphate groups of DNA. Jalalian et al. used PEI linked to PEG
(PEI-PEG) to deliver SeNPs loaded with epirubicin and function-
alized with aptamers. The amine groups of PEI were activated
with sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxylate and covalently bound to the thiol group of PEG, pro-
viding a biocompatible environment for aptamer attachment.[136]
Selmani et al. studied the stabilization of SeNPs using four dif-
ferent polymers:polyvinylpyrrolydone (PVP), poly-l-lysine (PLL),
polyacrylic acid (PAA), and sodium bis(2-ethylhexyl) sulfosucci-
nate (AOT) (Figure 10). TEM analysis has shown that PLL-SeNPs
tended to aggregate and form clusters, while the stabilization us-
ing the other polymers resulted in spherical SeNPs with an aver-
age size ranging between 70 and 80 nm. The coating of SeNPs
with the negatively charged PAA or AOT resulted in SeNPs with
a negative zeta-potential, while a positive charge was obtained fol-
lowing their coating with PLL, as expected. However, in spite of
the positively charged PVP, PVP-SeNPs presented negative zeta-
potential values, which can be explained by the attachment of se-
lenite on the surface of the particles.[138]
3.2.5. Other Polysaccharides
Other polysaccharides have been chosen to stabilize SeNPs due to
their low toxicity, good water solubility, great amount of hydroxyl
groups, complex branch structures, and high surface area, which
enhances their connection to SeNPs and cell membranes.[139] For
example, gum arabic is an extensively used polysaccharide in the
food and pharmaceutical industry, and has allowed the produc-
tion of stabilized SeNPs (Figure 11a-I), which presented smaller
sizes, and thus, stronger oxidant scavenging activity than those
Se-based NP produced in the absence of this polymer, probably
due to the stronger interaction established between the SeNPs
surface and Gum Arabic terminal hydroxyl groups. This stabil-
ity is further enhanced under acid conditions (pH 2–4), resulting
in smaller SeNPs, which indicates that the hydrogen ions com-
pacted SeNP structure. However, under pH 4, their size barely
changed, which indicates that SeNP’s higher stability in aqueous
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Figure 10. TEM images of SeNPs stabilized with several polymers (PVP, PLL, AOT, and PAA). Reproduced with permission.[138] Copyright 2020, Elsevier.
solutions may be due to the highly branched structure of arabino-
galactan present in gum arabic.[106]
Several other polysaccharides used to stabilize SeNPs were ob-
tained from fungi, especially mushrooms.[28,140–142] Mushroom
polysaccharides have shown immunomodulatory and antitu-
mor activities, being used in chemotherapy in Asia for many
years.[28] For example, Cai et al. used polysaccharides from Lig-
nosus rhinocetis to stabilize SeNPs, producing amorphous SeNPs
with an average diameter of 50 nm, by both using the chemical
reduction and, after dialysis and freeze-drying, ultrasound tech-
nique, with the goal to decrease SeNPs size and increase their
stability, Moreover, SeNPs subjected to ultrasound exhibited the
strongest antioxidant activity in both DPPH and ABTS radical-
scavenging assays, by increasing the ratio surface area: volume,
offering more reacting sites with free radicals.[140]
Zeng et al. stabilized SeNPs with polysaccharides from the
fungi species Pleurotus tuber-regium (PTR), Polyporus rhinoceros,
Coriolus versicolor, and Ganoderma lucidum. All these SeNPs were
stable for 13 weeks and the FTIR spectroscopy analysis indi-
cated the bind of the polysaccharide ─OH and ─NH groups to
the SeNPs surface. The stabilization using polysaccharides from
PTR resulted in smaller SeNPs (around 12.5 nm), with high
anticancer potential, especially against gastric adenocarcinoma,
while having low cytotoxicity against normal cells.[28] Huang et al.
also produced SeNPs stabilized with PTR polysaccharides, pro-
ducing 30 nm SeNPs that were also stable for 13 weeks (Fig-
ure 11a-IV).[141]
The Catathelasma ventricosum is an edible mushroom from
southwest China, known for its protective effects on liver, kid-
ney, and pancreas tissues. Polysaccharides obtained from this
mushroom have been used for the chemical synthesis of spheri-
cal SeNPs, stabilized by the amino, hydroxyl, or carboxyl groups
of this polysaccharide (Figure 11a-II), while bare SeNPs aggre-
gated as clusters (Figure 11b-II).[142] Cordyceps sinensis polysac-
charide was also used for SeNPs stabilization (Figure 11a-III),
due to its high viscosity. SeNPs conjugation with Cordyceps
sinensis polysaccharides was accomplished by the formation of
electrostatic bonds between the polysaccharide’s ─OH groups
and SeNPs (C─O···Se), creating amorphous SeNPs more sta-
ble than those prepared without the polysaccharide (Figure 11b-
III). The optimal Se:polysaccharide ratio for SeNPs production
was 1:1, demonstrating better radical scavenging activity on su-
peroxide anion radical and ABTS radical cation assays than
the polysaccharides themselves or SeNPs produced with lower
Se:polysaccharide ratios. However, when the quantity of Se in-
creases beyond this ratio, the SeNPs tends to become more
unstable.[143] Polyporus umbellatus (PUP) polysaccharides also de-
creased the diameter of SeNPs, producing negatively charged
PUP-SeNPs with an average size of 82.5 ± 0.7 nm (Figure 11a-
VII), which were stable for 84 d at 4 °C in dark conditions.[144]
A water soluble 1,6-𝛼-d-glucan from Castanea mollissima was
also studied for SeNP stabilization due to its large number of
hydroxyl groups, producing homogenous and monodispersed
spherical SeNPs. The diameter of these SeNPs decreases with the
increase of 1,6-𝛼-d-glucan concentration until 5 mg mL−1 (53.7 ±
4.0 nm), although a net structure was formed at a 10 mg mL−1
concentration. More recently, Zhang et al. used polysaccharides
extracted from Spirulina platensis to produce stabilized and uni-
form SeNPs with an average diameter of 73.42 ± 0.69 nm. The
optimal conditions included a polysaccharide solution concentra-
tion of 100 mg L−1, an ascorbic acid:sodium selenite concentra-
tion ratio of 3:1 and a reaction time of 6 h. The hydroxyl groups
of the polysaccharides coated the SeNPs, conferring a negative
charge to the SeNPs, which remained stable for 75 d at 4 °C.
Also, the produced SeNPs have shown lower cytotoxicity when
compared with sodium selenite.[117]
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Figure 11. a) SeNPs stabilized with several polysaccharides: (I) Gum Arabic; (II) Catathelasma ventricosum polysaccharides; (III) Cordyceps sinensis
polysaccharides; (IV) PTR polysaccharides; (V) Castanea mollissima polysaccharides; (VI) PEC; and (VII) Polyporus umbellatus polysaccharide. Reproduced
with permission.[106] Copyright 2014, Elsevier. Reproduced with permission.[142] Copyright 2018, Elsevier. Reproduced with permission.[143] Copyright
2017, Elsevier. Reproduced with permission.[141] Copyright 2018, Royal Society of Chemistry. Reproduced with permission.[148] Copyright 2019, Elsevier.
Reproduced with permission.[145] Copyright 2018, Elsevier. Reproduced with permission.[144] Copyright, Elsevier, respectively. b) Images of SeNPs with-
out stabilization. Reproduced with permission.[106] Copyright 2014, Elsevier. Reproduced with permission.[142] Copyright 2018, Elsevier and reproduced
with permission.[143] Copyright 2017, Elsevier, respectively.
Qiu et al. stabilized SeNPs with pectin (PEC), a polysaccharide
used as a thickening and antioxidant agent in the food indus-
try, composed by an anionic heteropolysaccharide complex de-
rived from sequences of (1→4)-𝛼-d-galacturonosyl units and their
methyl esters interrupted by (1→2)-𝛼-L-rhamanopyranosyl units.
Spherical amorphous PEC-SeNPs were produced (Figure 11a-
VI) using an optimized Se/PEG ratio of 1:2, since a lower ra-
tio resulted in formation of large clusters and higher ratios pro-
duced heterogenous PEC–SeNPs, because the amount of PEC
was less than the required to decorate and stabilize SeNPs. Also,
the antioxidant properties of PEC-SeNPs decreased when the ra-
tio increased to 4:3. PEC bound to the SeNPs surface by hydro-
gen bonds (Se─O─H), forming PEC-SeNPs exhibited stability in
acidic solutions for 30 d; however, while the size of PEC–SeNPs
did not change, their absolute zeta-potential decrease overtime
due to the protonation of COO− groups of PEC under acidic con-
ditions. PEC–SeNPs demonstrated enhanced antioxidant activi-
ties in both DPPH radical scavenging and Trolox equivalent an-
tioxidant capacity (TEAC) assays.[145]
Stabilization of SeNPs was also studied using cationic pullu-
lan, a water-soluble nonionic polysaccharide, which presents sev-
eral advantages, such as low-toxicity and biocompatibility, linked
to FA, using chemical synthesis and cysteine as reducing agent,
producing Se microflowers, whose conformation seemed to be
dependent on the amount of cysteine used. These also pre-
sented antitumor properties by serving as DOX carriers, enhanc-
ing its antiproliferative effect toward cancer cells, while reduc-
ing their cytotoxicity against normal cells.[19] Also, Yu et al. stabi-
lized SeNPs with galactose (GA), producing GA–SeNPs used for
DOX loading, forming nanostructures stable for 16 d, with thera-
peutic potential against hepatocellular carcinoma.[146] Also, some
polysaccharides have been chosen for SeNPs production due to
their medicinal applications, with the goal of studying a poten-
tial synergy between the two compounds. For example, a water-
soluble 𝛽-(1,3)-d-glucan (BFP) with a triple-helix conformation,
isolated from the fruits of a black Chinese fungus known for its
anticancer activity, was used to produce BFP nanotubes to which
SeNPs were embedded, producing BFP-Se, with an average di-
ameter of 118 nm. The BFP nanotubes interacted with SeNPs
through its hydroxyl group, producing structures with high sta-
bility in water and with strong anticancer properties.[147]
3.2.6. Peptides and Other Compounds
Several other compounds have been used for stabilization and
functionalization of SeNPs. For example, Feng et al. studied
the decorated potential of the aminoacids valine (Val), aspartic
acid (Asp), and lysine (Lys) to produce smaller, more negatively
charged, and stable SeNPs. The aminoacids conjugated with
SeNPs though their ─NH3+ groups, producing uniform spher-
ical SeNPs with exception of Asp conjugation, which resulted
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Figure 12. Main compounds used in SeNPs functionalization. Figure created with Biorender.
in irregular SeNPs. Lys conjugation produced more stable SeNPs,
because Lys offers more two NH3
+ groups than Val and Asp to
bind to SeNPs.
Peptides have also been used in SeNPs functionalization due to
their ability to enhance cellular delivery via noncovalent binding
and as a result of the existence of a wide range of aminoacids with
several physicochemical properties.[149] For example, Shirazi et
al. stabilized SeNPs with a peptide synthesized by Fmoc/tBu-
based solid-phase chemistry, composed of four arginine, five tryp-
tophan, and one cysteine being that tryptophan is the aminoacid
with the highest reducing efficiency, arginine increased the re-
ducing activity and cysteine facilitated the SeNPs stabilization
through S─Se bonds. The stabilized SeNPs displayed an en-
hanced uptake in several cancer cell lines, by the interaction
of tryptophan and arginine with the lipid bilayer’s hydropho-
bic groups and the negatively charged phospholipids, causing
deformation of the exterior phospholipid monolayer and inter-
nalization of the nanosystem by caveolae-mediated and macro
pinocytosis pathways. Thereby, this nanosystem has shown syn-
ergic activities with several antitumor drugs, enhancing their an-
tiproliferative effects.[149] A synthetic peptide composed by 12
aminoacid denominated GE11 is another peptide used for SeNPs
functionalization. Pi et al. functionalized SeNPs with GE11 by
EDC chemistry, in which the ─NH2 groups of the loaded SeNPs
covalently bound to the ─COOH groups of GE11. The functional-
ized nanosystem was loaded with oridonin to study its antiprolif-
erative properties against esophageal cancer.[150] RGD, a peptide
composed by the sequence Arg-Gly-Asp, has also been used to
functionalize SeNPs, due to its unique ability to recognize 𝛼v𝛽3
and 𝛼v𝛽5 integrins on target cells (Figure 12).[24] A similar pep-
tide, RGDfC, constituted by Arg-Gly-Asp-d-Phe-Cys has also been
used due to its ability to specifically target 𝛼v𝛽3 integrin, com-
monly expressed in several types of cancer cells,[151] resulting in
nanosystems that remain stable for 16 d. RGDfC-SeNPs are also
able to load the chemotherapeutic drug DOX, resulting in effi-
cient antitumor nanosystems.[152]
Proteins have also been used for SeNP stabilization and func-
tionalization. Zhang et al. analyzed the properties of SeNPs stabi-
lized with 𝛽-lactoglobulin (𝛽Ig), the most abundant whey protein
in cow’s milk, which comprises a lot of properties such as strong
affinity for several cellular molecules, such as retinol, vitamin D,
fatty acids, phenolic compounds, and cholesterol. The stabiliza-
tion resulted in amorphous red SeNPs with a size of 40 nm, stable
in 4 °C for at least 30 d, although their size increased to 80 nm
when stored at room temperature. The conjugation was initiated
by the electrostatic attraction of the selenium precursor, HSeO3
−
and the protonated amino groups on 𝛽Ig, at a pH of around
3.5. Afterward, HSeO3
− was reduced to Se0, which agglomer-
ated, forming a Se nucleus that continuously grown, with 𝛽-
lactoglobulin bound through its hydrophobic groups. 𝛽Ig-SeNPs
were stable at pH 2.5–3.5 and 6.5–8.5, however was unstable at
4–6, near the 𝛽Ig isoelectric point (5.1), resulting in lower abso-
lute zeta-potential and aggregation. IgB-SeNPs was also shown
to reduce the toxicity when compared with selenite.[25] Tfr was
also studied to functionalize SeNPs for antineoplastic applica-
tions, since its receptor is usually overexpressed in cancer cells
compared with normal cells (Figure 12). Tfr-SeNPs have shown
potential to deliver DOX to several cancer cells, in a four-layer
structure, wherein Tfr is covalently linked to the NH3+ groups of
chitosan.[119]
Chung et al. demonstrated BSA has the potential to stabilize
SeNPs, producing SeNPs with a size below 50 nm when the
ratio Se salt:ascorbic acid (reducing agent used) was 1:4 or be-
low, that were then studied as antibacterial agents against of S.
aureus infections.[97] BSA contains three homologous domains
in their tertiary structure, and its cysteine residues create 17
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disulfide bonds to construct a double-loop bridging pattern.
Kalishwaralal et al. demonstrated that once exposed to 121 °C,
these disulfide bonds break, exposing ─SH groups, which can
be used for reduction of Se (IV) to Se (0). Interestingly, when the
same reaction was attempted using other proteins such as lipase
and protease, red SeNPs were not produced, probably due to the
lack of ─SH groups.[153]
Other compounds, such as ferulic acid (Fer), a substance de-
rived from Ferula foetida, that is known for its notable antithrom-
botic, hypolipidemic, and anti-inflammatory applications, was
used to decorate SeNPs, producing uniform spherical Fer-SeNPs
with an average diameter of 105 nm. It was observed that Fer’s
absorption peak corresponding to the ─OH group shifted from
3436 to 3396 cm−1 during SeNPs preparation, suggesting that
the SeNPs surface interacts with Fer molecules through their hy-
droxyl groups. These Fer-SeNPs were studied for their anticancer
properties.[31]
The stabilization of SeNPs using mesoporous silica (MS) orig-
inated nanosystems with prolonged release of both silica and
Se.[154,155] Chen et al. demonstrated that Se interacted with meso-
porous silica NPs (MSNPs), forming 3p BE shifts, being the sili-
con in the form of SiOn.
[155] The release of Se was higher in acidic
pH 5.5 than in physiologic pH 7.4.[155] The use of MS to stabilize
SeNPs has shown to have both antibacterial[155] and anticancer
potential.[154]
Furthermore, genetic material was also used for SeNPs func-
tionalization. Aptamers, such as NAS-24, are short single-
stranded DNA or RNA sequences that can specifically target
several molecules overexpressed in cancer cells. For example,
both aptamers NAS-24 and ETR1 were used to functionalized
SeNPs (Figure 12) loaded with epirubicin for antiproliferative
studies in breast cancer and hepatocellular carcinoma cells. NAS-
24 not only targets vimentin, a filament protein that modulates
cell migration and adhesion, and apoptosis, being a prospec-
tive biomarker for metastasis. Furthermore, NAS-24 possesses
a guanine-cytosine group, which is an ideal region to bind to an-
thracyclines, such as epirubicin. 5TR1 aptamer can bind to the
mucin-1 glycoform, which is overexpressed in several cancers,
such as breast cancer, despite it not being present in hepatocellu-
lar carcinoma cells. Therefore, the use of these aptamers to func-
tionalize SeNPs enhanced their uptake in cancer cells by induc-
ing receptor-mediated endocytosis.[136]
3.3. Main Properties and Advantages of SeNPs
SeNPs present better biocompatibility and efficacy than inor-
ganic and organic Se, as well as the opportunity to functional-
ize the surface with several compounds that may influence their
physicochemical properties and pharmacokinetics.[5,20] There-
fore, SeNPs functionalization can influence their toxicity, surface
charge, and surface hydrophobicity, which are considered crucial
for their therapeutic activity.[20]
3.3.1. Physical Properties of SeNPs
Properties of SeNPs depend on the method used for
their preparation[79] and on the compounds used for its
stabilization/functionalization.[40,156] SeNPs characteristics
like shape, size, and structure, are influenced by several parame-
ters during their preparation and storage, such as concentration,
temperature, nature of biomolecules, and pH of the reaction
mixture. For example, spherical SeNPs have been proved to
have high biological applications, while Se nanowires have high
photoconductivity.[79] Overall, SeNPs are produced by reduc-
ing Se oxyanions into elemental Se, leading to solutions with
color ranging from pink, orange, and red,[89,101,138] due to the
excitations of the SeNPs surface plasmon resonance formed in
the reaction mixture,[153] presenting a maximum absorption at
200–400 nm.[134] Therefore, SeNPs photoelectron spectroscopy
pattern includes the distinctive Se 3d peak around 54–56 eV, as
well as the Se 3p3, Se 3p1 and Sed3 peaks,[155,157] confirming
the formation of its zero-valent oxidation state, although usually
accompanied by the peak correspondent to a residual Se(IV),
around 56–60 eV.[26,123,157,158] Also, using X-ray diffraction analy-
sis, several studies identified a hexagonal ring lattice,[159–162] or a
trigonal phase.[163–166] The formation of SeNPs with a hexagonal
ring structure does not appear to be related to the production
method or the shape of the SeNPs produced, since this type of
crystal arrangement occurs in both biosynthesized[159–161] and
chemically synthesized SeNPs,[19] and with Se nanostructures
with rod-like,[161] spherical[160] and flower-like shape.[19] On the
other hand, the formation of trigonal SeNPs seems to be more
related to SeNPs physical synthesis methods.[163–166]
In general, the charge of SeNPs is negative,[37,138,121] however
surface modification with positive charged compounds such as
chitosan can also flip the charge of SeNPs to positive.[123,121]
Also, the coating with different enantiomers can produce SeNPs
with different characteristics.[108,167] For example, Hung et al.
produced chiral SeNPs using the L-, D-, and DL- forms of
GSH. While the L-GSH-SeNPs and D-GSH-SeNPs were well
dispersed and had average sizes of 126.7 and 142.6 nm, re-
spectively, the DL-GSH-SeNPs easily aggregated. Also, the 𝜁 -
potential of L-GSH-SeNPs and D-GSH-SeNPs were highly neg-
ative (-29.5 and -25.3 mV, respectively), suggesting the exis-
tence of a strong repulsion among the SeNPs produced using
the single chiral nanosystem, while DL-GSH-SeNPs were al-
most neutral (-9.1 mV). Furthermore, in vivo assays in mice
using 64Cu-radiolabeling positron emission tomography (PEM)
demonstrated that the chiral SeNPs presented different pharma-
cokinetics mechanisms. For example, L-GSH-SeNPs accumula-
tion in the liver, spleen, and intestines was significantly higher
than D-GSH-SeNPs accumulation, while DL-GSH-SeNPs and D-
GSH-SeNPs escaped liver uptake and presented a faster renal
clearance than its L-counterpart. Indeed, DL-GSH-SeNPs pre-
sented a stronger renal presence than the D-counterpart, specif-
ically due to its neutral charge and steric conformation, that en-
abled a better electrostatic interaction with kidney and reduced
the opsonization by the phagocytic system.[108]
It has been demonstrated that NPs tend to destabilize and
create precipitates when exposed to solutions with higher ionic
strengths, mostly due to the density of the electrical double layer
and the screening effect of the ions present in the solution. Sel-
mani et al. demonstrated that the stability of SeNPs depends on
the surface coating, studying the modifications of SeNPs stabi-
lized with PVP, PLL, PAA, and AOT in CaCl2 and NaCl solu-
tions. SeNPs were shown to have less stability and started to
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Figure 13. SeNPs shape can be influenced by a) their coating agents and b) the interactions among them; c) the Se reducing agent; d) the solvents used
and the storage conditions; e) the reaction temperature; and f) the production method itself. Reproduced with permission.[156] Copyright 2018, Elsevier.
Reproduced with permission.[169] Copyright 2016, Elsevier. Reproduced with permission.h Copyright 2018, Elsevier. Reproduced with permission.[18]
Copyright 2014, Elsevier. Reproduced with permission.[166] Copyright 2010, Elsevier. Reproduced with permission.[165] Copyright 2004, Elsevier, respec-
tively.
aggregate in CaCl2 solutions, since divalent cations have more
potential to decrease the electrostatic aggregation barrier than
monovalent ones, therefore decreasing more efficiently the ab-
solute zeta-potential. PLL coating offered the least cationic pro-
tection in both NaCl and CaCl2 solutions, with formation of
PLL-SeNPs precipitates ranging from few hundreds until few
thousands nm in low concentration of NaCl and CaCl2. After
24 h of incubation, PAA-SeNPs were shown to be unstable at
the highest CaCl2 concentration used (30 × 10−3 m), although
the size distribution increased in several NaCl solutions. AOT-
SeNPs presented the smallest size and were, therefore, more sta-
ble. Therefore, SeNPs depend on its size, coatings, and storage
medium.[138]
The study of other physical characteristics like the wetting
properties of SeNPs was also studied by Tran et al. on titanium
(Ti) hydrophilic implants. SeNPs formed air pockets that in-
creased the contact angles and implants’ roughness, which con-
tradicts Wenzel theory that affirmed that lower contact angles
exist on rougher hydrophilic surfaces. Therefore Tran et al. pro-
posed a new model to explain the wetting properties of the SeNP
coated Ti implants with a possible application for the develop-
ment of new nanomaterials with therapeutic applications.[168]
As already indicated, SeNPs can also present several shapes,
according to the stabilizer agent used and the prepara-
tion conditions.[18,156] Overall, spherical SeNPs have been
used for biological and medicinal purposes,[16,20] but reports
have also described methods to produce SeNPs with other
shapes, such as cubic-like,[169] nanorods,[93,156] nanowires and
nanotubes,[166] nanoribbons,[165] nanoneedles,[18,156] and “flower-
like” assemblies.[18,19]
Chaudhary et al. demonstrated that SeNPs shape can be in-
fluenced by their coating, using Brij-58, sodium dodecyl sulfate
(SDS) and hexadecyl trimethyl ammonium bromide (CTAB) sur-
factants as stabilizer agents. For example, Brij-58-SeNPs had rect-
angular and square morphology (Figure 13a-I), SDS-SeNPs ex-
hibited squared shape forms trapped in spiny needle shaped
structures (Figure 13a-II), and CTAB-SeNPs were spherical, how-
ever had the tendency to form rod shapes (Figure 13a-III).[156]
Moreover, SeNPs shape can also be influenced by the type of
interactions existing among the stabilizer molecules. Luesakul
et al. produced cubic SeNPs (Figure 13b) using FA, gallic acid,
and synthetic N,N,N-trimethyl chitosan. The cubic form was cre-
ated due to hydrogen bonding and 𝜋-𝜋 stacking of the phenyl
ring of gallic and FA among the neighboring particles.[169] The
reducing agent used during the chemical production of SeNPs
can also influence their morphology. The use of L-cysteine as
a reducing agent, made it possible to produce Se microflowers
(Figure 13c), when cationic pullulan and FA were used as coat-
ing agents and DOX was used as loading drug. However, both
Na2SeO3 to cysteine concentration ratios and the concentration
of cationic pullulan and FA were determinant for the production
of microflowers. These structures mainly appeared at Na2SeO3 to
cysteine concentration ratios from 1:1.6 to 1:2 and cationic pullu-
lan and FA concentrations of 0.45% (w/v). During the chemical
process, the mercapto group of L-cysteine oxidized into its disul-
fide derivative, which may play a crucial role in formation of the
hexagonal plated sheets formed among the stabilizer agents via
intermolecular interactions, such as electrostatic interaction, 𝜋–𝜋
interactions, hydrogen bonding, and van der Waals forces.[19]
The shape of SeNPs is also dependent on the conditions
of preparation and storage. Kumar et al. produced spherical
SeNPs using hydroquinone as reducing agent, but after alkalin-
ization using NaOH and further incubation at 40 °C, the SeNPs
color switched from red to black, with formation of Se hexag-
onal crystals (Figure 13d-I). Following the addition of ethanol,
SeNPs morphology changed into rod-like SeNPs that aggregated
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into “flower-like” assemblies (Figure 13d-II). The addition of cy-
clohexane gradually changed SeNPs from spherical to needle-
like forms (Figure 13d-III).[18] The temperature used for SeNPs
preparation also had an impact on the conformation of SeNPs.
Chen et al. produced trigonal Se (t-Se) nanowires in absolute
ethanol at room temperature (Figure 13e-I), while t-Se nanotubes
were achieved at 85 °C in aqueous solution (Figure 13e-I).[166] t-Se
was also used to produce nanoribbons (Figure 13f) that consisted
of beads in linear aggregates, using a vapor-liquid process, pro-
ducing nanostructures that may be used to fabricate nanoscale
optoelectronic tools.[165] Hageman et al. have also manipulated
SeNPs shape using changes in temperature and pH, in which
amorphous SeNPs were observed at 20 °C and pH 7, at 30 °C and
pH 7, at 40 °C and pH 7 and also at 20 °C and pH 6, while acicular
crystalline hexagonal SeNPs and rosettes were detected at 50 °C
and pH ≥ 7, at 40 °C and pH > 7, or at 30 °C and pH ≥ 8.[170]
3.3.2. Toxicity of SeNPs
SeNPs have presented lower toxicity than inorganic and organic
Se,[5,13,36] which indicates that reducing inorganic Se ions into el-
emental Se is a promising environmentally friendly technique to
remove Se from industrial water.[170] However, it is also important
to establish SeNPs toxicity and their effects on nature and in the
human body, since its optimal concentration largely depends on
the species, the development stage, and other environmental fac-
tors. Overall, SeNPs toxicity is related to it increasing ROS gener-
ation and cell membrane disruption.[36,138,171] Kalishwaralal et al.
have studied the effects of SeNPs on Zebrafish embryos, a species
that share 85% of human genome, demonstrating that although
no evident mortality appeared at lower concentrations (5–10 µg
mL−1), exposure to high concentrations (20–25 µg mL−1) resulted
in a considerable percentage of mortality, with abnormalities ap-
pearing, such as cardiac malfunction (blood congestion at the car-
diac inflow tract and resultant pericardial edema and decrease of
heart rate) and tail malfunction.[153]
Although SeNPs capped with a polysaccharide-protein com-
plex derived from Pleurotus tuberregium, improved the growth of
tilapia, showing potential as an aquatic feed additive,[172] other
recent studies have shown the dose-dependent aquatic toxic-
ity of SeNPs using the freshwater crustacean Daphnia magna
and marine bacterium Vibrio fischeri as standard organisms, us-
ing SeNPs stabilized with AOT; PAA, PVP, and PLL. All coated
SeNPs caused a 50% reduction in the bioluminescence of V. fis-
cheri and, although after 4 h of incubation the most toxic SeNPs
were those coated with PVP and PAA, with a minimum biocidal
concentration (MBC) of 50 mg Se L−1, while the SeNPs coated
with AOT and PLL presented MBC values of 100 mg Se L−1, after
24 h there were not any statistically significant differences be-
tween the toxicities of the several SeNPs tested. Regarding D.
magna, PAA-SeNPs were demonstrated to have the higher tox-
icity, similar to selenite, and PVP-SeNPs, although presented the
highest percentage of free Se ions, were the least toxic, since these
SeNPs more likely to agglomerate. Overall, all SeNPs could be
classified as harmful to both species, according to the Directive
93/67/EEC (CEC1996) of the European Commission for the haz-
ard classification of substances.[138]
Further studies concerning SeNPs toxicity were realized in
plant and algal cells. SeNPs were shown to have genotoxicity po-
tential in Allium cepa root meristems, demonstrating that bare
SeNPs are more toxic than stabilized SeNPs and that the sta-
bilizer agent also influences SeNPs’ toxicity. Genotoxic effects
of SeNPs included laggard, sticky, and clumped chromosomes,
disturbed metaphase chromosomes, binucleated cells, and for-
mation of chromosomal bridges (Figure 14a). SeNPs were also
shown to decrease the chlorophyll content in Chlorella sp., by
blocking the electron transfer in photocenters, and affected the
seed germination ability of Vigna radiate seeds, dimerizing its
roots length (Figure 14b).[156]
More recent studies show that SeNPs supplementation pro-
motes Capsicum annuum L. growth in low dosages of 0.5 and
1 mg L−1, while dosages of 10 and 30 mg L−1 induced malfunc-
tion in leaf and root development, with malfunctions on the vas-
cular conducting tissues due to DNA hypermethylation and po-
tential to induce epigenetic modifications. Also, while intake of
low Se dosages promoted nitrate reductase activity, high Se in-
takes were associated with increased proline concentration.[171]
SeNPs toxicity was also studied in mammalian cells like rat der-
mal fibroblasts, showing an inhibitory concentration (IC50) value
of 46.5 µg mL−1. However, concentrations up until 31 mg mL−1
induced an increase of the number of live cells, which indicates
that the SeNPs can be beneficial or toxic, depending on the con-
centration used.[5,98] Further studies demonstrated the pharma-
cokinetics and the in vivo toxicity of SeNPs in rats. SeNPs have
been dissolved and oxidized into inorganic oxoanions and Se
(IV) by both microbial and chemical activities in the gastroin-
testinal tract.[173] Analysis of the rat organs demonstrated that
the highest concentrations of Se were detected mainly in the
liver and kidney.[173,174] Therefore, it is not surprising that the
weight of these organs increased after SeNPs intake. However,
viscera indices of the heart, testicle, and thymus decreased sig-
nificantly in higher concentrations of SeNPs (8.0 mg Se per kg
body weight). Kidney and liver are the main metabolizing or-
gans of SeNPs, being able to metabolize lower concentrations
of Se. The natural GSH reductive pathway showed limited ac-
tivity, and higher concentrations of SeNPs led to the exhaus-
tion of GSH reduction, and unstable GSSeSG or selenopersul-
fide intermediates were formed, inducing Se oxidative damage
and toxicity.[173] While lower intakes of SeNPs (0.2 and 0.4 mg
Se kg−1) resulted in increased body weight, higher intakes (2.0–
8.0 mg Se kg−1) resulted in decreased body weight, which sug-
gests SeNPs toxicity. Histologic assays confirmed SeNPs toxic-
ity at higher dosages, showing hepatocyte necrosis and degen-
eration, morphological changes in the kidneys with signs of
glomerulonephritis, and renal tubule necrobiosis, signs of hem-
orrhage in lungs, and thymus and testis atrophy, which trans-
lated into immunosuppression and reduced spermatogenesis,
respectively.[174] Plasmatic selenoprotein P levels were used as a
blood biomarker to compare the range of bioavailability and in-
corporation of Se provided by both selenite and SeNPs. While
dosages of Se (IV) ranging from 0.05 to 0.5 mg Se per kg body
weight increased Selenoprotein P levels compared to control,
only the SeNPs dosage of 0.5 mg Se per kg body weight increased
selenoprotein P levels. However, since the plasmatic levels were
not considerably different for the highest dose SeNPs group com-
pared with Se (IV), and it was concluded that both Se forms
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Figure 14. SeNPs toxic effects on Allium cepa root meristems. a) Chromosomal aberrations in Allium cepa root tip cells after SeNPs treatment. b)
Influence of SeNPs concentration on A. cepa germination percentage, root growth. and seed germination index. Reproduced with permission.[156]
Copyright 2018, Elsevier.
displayed equal bioavailability, the same conclusion was valid for
the liver, plasma, and kidney Se. Se (IV) was more efficient than
SeNPs in enhancing liver and kidneys TR levels. Regarding Se
excretion, Se0 in feces was higher in rats receiving SeNPs than
those receiving Se (IV), indicating a lower absorption of Se0NPs.
Se excretion in urine as Se-methylseleno-N-acetyl-galactosamine
and the trimethylselenonium-ion was mainly increased for the
higher dosages of both Se forms. It appears that Se is mainly
excreted in the urine in the form of Se-methylseleno-N-acetyl-
galactosamine.[173] Ultimately, it was demonstrated that SeNPs
potential may directly link to human DNA, affecting its structure
into a coiled and twisted form, leading to DNA damage.[156]
4. SeNPs for Pharmaceutical Applications
SeNPs have been demonstrating several therapeutic applications
due to its antioxidant or pro-oxidant effects, depending on the
dose and duration of treatment.[175] SeNPs offer many therapeu-
tic advantages compared to the ionized Se forms, such as better
bioavailability and low toxicity, which can be extremely important
since Se is a chemical element that, although essential to human
life, presents a very narrow therapeutic window between the ben-
eficial and the toxic effect.[122,175–178] Overall, SeNPs have shown
potential in the treatment of several diseases, such as cancer, di-
abetes, inflammatory-related diseases, and by directly exercising
their effect or by being incorporated in selenoproteins.[175] SeNPs
have the possibility to be delivered by several routes, such as oral
and intravenous administration, depending on the desired ther-
apeutical application.[39]
SeNPs have been used nonfunctionalized or conjugated with
other chemical compounds, whether for stabilization of the
SeNPs or to direct them toward a specific target.[175] SeNPs
have demonstrated that they inhibit at concentrations of 1 ppm
both antibiotic-resistant gram-positive and gram-negative bac-
teria strains.[115] SeNPs larvicidal potential was also demon-
strated against the larvae of a dengue fever-causing vector Aedes
aegypti.[179] SeNPs have shown potential against diabetes, having
being proposed for insulin oral delivery, due to its antioxidant ac-
tivity, protecting the pancreas against streptozotocin (STZ) side
effects.[13] SeNPs have also shown potential against Hunting-
ton’s disease, a disease characterized by neuronal degeneration,
diminishing the patients’ physical and mental skills overtime.
SeNPs, in a dose-dependent way, reduced neuronal death in
HA759 mutated nematodes, by decreasing the protein aggrega-
tion corresponded to the HTT gene mutations and the amount
of ROS and by downregulating histone deacetylase mRNA, de-
creasing the axonal degradation and reacting better towards
stimuli.[176] SeNPs have also been shown to reduce the viability of
immortal keratinocyte cell lines, with IC50 values lower than 4 µg
mL−1 by promoting the appearance of ROS and loss of mitochon-
drial membrane potential, enhancing of amount of proapoptotic
proteins, such as tumor necrosis factor alfa (TNF-𝛼) and Bax and
downregulating anti-apoptotic proteins like Bcl-2, c-Jun, c-MET,
p-44/42 MAPK, and MMP-7, leading to cell cycle arrest at Sub
G1 phase and apoptosis by autophagy. This cytotoxic property of
SeNPs can be useful in the treatment of skin diseases related to
keratinocytes hyperproliferation, such as psoriasis, vitiligo, skin
fibrosis, and melanoma.[180]
However, most of the studies concerning SeNPs therapeutic
effects regard its anticancer properties, since Se has less prob-
ability to be pro-oxidant and to cause DNA damage in healthy
cells than in cancer cells. Se has been shown to induce apop-
tosis in cancer cells, by ROS production and activation of sev-
eral caspases, inducing cell arrest, chromatin condensation and
DNA fragmentation, loss of cellular adhesion, inducing apop-
tosis through mitochondrial pathways and formation of apop-
totic bodies. SeNPs were functionalized with compounds whose
receptors are more abundant in cancer cells than in normal
cells, such as FA, adenosine triphosphate (ATP) and sialic acid
to preferably target cancer cells. SeNPs were also studied in
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HDL Concentration Type of study Refs.
STZ only ↓ ↑ ↓ ↑ ↓ _ In vivo study [107]
Chitosan-SeNPs ↑ ↓ ↑ ↓ ↑ 2.0 mg Kg−1 In vivo study [107]
RTFP-SeNPs _ _ ↑ _ _ 2.0 mg mL−1 In vitro study [182]
CVP-SeNPs ↑ ↓ ↑ ↓ ↑ 0.5 mg Se kg−1 In vivo study [142]
MPE-SeNPs _ _ ↑ _ _ 900 µg d−1 In vivo study [181]




↑ ↓ ↑ ↓ ↑ 0.4 mg kg−1 SeNPs-metformin In vivo study [177]
↑ ↓ ↑ ↓ ↑ 500 mg/Kg bw/day metformin
and Chitosan-SeNPs 2 mg
Se/Kg/day (8 weeks treatment)
In vivo study [183]
a)
CVP, Polysaccharides from Catathelasma ventricosum; HDL, high-density lipoproteins; LDL-C, low density lipoprotein-cholesterol; MPE, Pueraria lobate extracts; RTFP,
polysaccharide extracted from Rosa roxburghi fruit; STZ, streptozotocin; Wt, animal weight.
combination with others chemotherapeutic agents such as DOX,
5-Fu, adriamycin, irinotecan, and cisplatin enhancing their activ-
ity and protecting the normal cells against their side effects (e.g.,
cisplatin nephrotoxicity and anastrozole osteoporosis).[13]
4.1. Diabetes
There are several hypoglycaemic medicines currently available
for diabetes treatment, such as biguanides and sulfonylureas,
however, these medicines have several side effects like hypo-
glycemia, gastrointestinal distress, liver, and pancreatic damage.
Se has already been shown to be an effective antioxidant to com-
bat several biomarkers relative to diabetes, acting like insulin
in STZ-induced diabetic mice, by having similar hypoglycaemic
effects,[178,181] and promoting antioxidant activities by being the
major active compound in several antioxidant proteins such as
GPx.[107]
Several experiments have studied the potential of SeNPs as
a tool to be used in diabetes therapy (Table 3), showing their
antiapoptotic potential, by influencing HSP70, SIRT1, And Bcl-
2 production.[13] Overall, in vivo studies used STZ to trig-
ger diabetes in mice/rats animal models, by destroying their
pancreatic islet 𝛽-cells, diminishing the insulin body concen-
tration and increasing their blood glucose levels.[142,177] Sev-
eral other studies have demonstrated the antidiabetic poten-
tial of SeNPs functionalized with negative charged antidia-
betic polysaccharides[142,181,182] or with combination therapy with
known antidiabetic dugs.[177] However, nonfunctionalized SeNPs
also had antidiabetic properties on their own. Chitosan–SeNPs
proved to have antidiabetic effects at the concentration of 2.0 mg
kg−1, by increasing the body weight and controlling the glycemia
on STZ-treated mice. Both concentrations of 0.5 and 4 mg kg−1
had the poorest antidiabetic activities, which suggested the ex-
istence of a therapeutic window. The antidiabetic effect of these
SeNPs was proved to be a result of their antioxidant activities,
by increasing the activity of several enzymes like GPx, catalase
(CAT), and SOD, which led to a decrease of LDL-C, triglyceride,
and total cholesterol levels and an increase of HDL levels, show-
ing these NPs as possible antidiabetic supplements.[107]
Functionalization of SeNPs with several polysaccharides, such
as RTFP-3, collected from Rosa roxburghi fruit, have also poten-
tial synergistic antidiabetic properties. RTFP-3 is a known antiox-
idant and 𝛼-glucosidase inhibitor and its use as a functionaliz-
ing agent resulted in stable SeNPs with excellent antidiabetic ef-
fects. The resulting SeNPs exhibited great antioxidant properties
in both DPPH and ABTS radical scavenging activity assays, and
in the oxygen radical absorbance capacity (ORAC) assay. Also,
the viability of islet 𝛽-cells incubated with H2O2 was improved
with the administration of RTFP-SeNPs, by decreasing the mi-
tochondria oxidative stress, via downregulation of UCP-2 expres-
sion, a protein associated with the reduction of the mitochondrial
membrane potential and, and thereby reducing the caspase acti-
vation (caspases-8/-9 and 3). Therefore, RTFP-SeNPs have shown
to reverse the cell arrest at G1 phase caused by H2O2, increasing
mainly the cells in the S phase.[182]
SeNPs have been demonstrated to have synergistic antidiabetic
effects when functionalized with polysaccharides from Catathe-
lasma ventricosum (CVP). CVP-SeNPs recovered the body weight
and decreased the blood sugar in mice treated with STZ, espe-
cially at the concentration of 0.5 mg Se kg−1. CVP-SeNPs de-
creased the oxidative stress produced by the diabetes-derived hy-
perglycemia, by increasing the activity of antioxidant enzymes,
such as GPx and SOD, and diminishing the activity of malondi-
aldehyde (MDA), an organic compound that produces oxidative
stress. In addition, the levels of cholesterol, LDL-C, and triglyc-
eride, increasing the HDL. These SeNPs also exhibited a syner-
gistic effect with vitamin E towards the previous parameters.[142]
SeNPs were also functionalized for oral delivery with Pueraria
lobate extracts (MPE), which are traditionally used in diabetes
treatment, due to their potential to stimulate insulin excretion,
inhibit 𝛼-glucosidase and enhance glucose use. About 900 µg d−1
of MPE-SeNPs were administered daily to rats (human equiva-
lent to 150 µg d−1). MPE decreased the SeNPs first-pass effect,
enhancing their oral bioavailability and increased its transport to-
ward liver, through the portal vein, as well as showing the ability
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Figure 15. Fluorescent histomorphologies of the pancreatic islet of diabetic rats treated with MPE-NPs and MPE-SeNPs for 2 weeks. Cy3-conjugated
antibody was used to specifically label insulin, and DAPI was used for nuclei labeling. After SeNPs treatment, a dramatic increase of the insulin secreted
cells was observed. Reproduced with permission.[181] Copyright 2019, Springer Nature.
to sustain their release. MPE-SeNPs have been shown to enter the
cells through several pathways, such as clathrin- and caveolin-
mediated endocytosis. Similar to previous studies, MPE-SeNPs
have been shown to have antioxidant activities, protecting islet 𝛽
cells in oxidant environments (Figure 15).[181]
El-Borady et al. studied SeNPs antidiabetic potential when
capped with glucose and PVP. The SeNPs demonstrated caused
weight loss and a decline in food consumption, and to revert the
increase of glucose levels in mice in which diabetes was STZ-
induced. The SeNPs also decrease the levels of ROS, while in-
creasing the levels of the antioxidant enzymes GSH and GPx,
restoring the atrophic islets of Langerhans to their normal shape,
and protecting the pancreatic tissues from oxidative damage. In-
terestingly, it was observed that the plasmatic levels of insulin in
the SeNPs-control group were dramatically reduced when com-
pared to the control group, which can be explained by the fact
that Se itself has insulin-like properties.[178]
SeNPs have also shown to have a synergistic effect when
combined with metformin.[177,183] The therapeutic combination
showed synergic effects, increasing ROS scavenging, and con-
trolling the weight and blood sugar better than the SeNPs or met-
formin alone, increasing the serum levels of insulin and the via-
bility/activity of islet 𝛽 cells, and enhancing liver and kidney func-
tions. This combination therapy reduced triglycerides levels and
increased high density lipoproteins (HDL) levels, better than the
therapeutics used in monotherapy. This combination therapy has
also shown to decrease the inflammation STZ-induced, by reduc-
ing the protein level of p65- NF-𝜅B and COX-2, decreasing the
expression of several cytokines and interleukins related to hep-
atic inflammation and damage. This combination also seemed
to activate pIRS-1, pAKT, pGSK, and pAMPK pathways, enhanc-
ing insulin sensitivity and action.[177] More recently, Mohamed
et al. also studied the synergy between metformin and SeNPs
against diabetes induced by a high-fat diet and in STZ in rats,
demonstrating that the concomitant treatment of metformin and
SeNPs for 8 weeks not only prevented body weight loss and the
increase in the fasting blood glucose levels, while controlling the
insulin levels, but also restored the levels of hepatic enzymes as-
sociated with liver injury to that of healthy rats. Furthermore, the
simultaneous administration of SeNPs and metformin regulated
the lipid profile, reducing dyslipidemia in diabetes-induced rats,
ameliorated the activity of several enzymatic antioxidants (CAT
and SOD), and stabilized the gene expression of proapoptotic
proteins (caspase-3, Bax, Fas, Fas-L), while up-regulating Bcl-2 ex-
pression. The combination therapy also improved the pattern of
cardiac injury markers, reducing the levels of troponin I and cre-
atin kinase -MB isoenzyme. Histology studies demonstrated that,
although STZ induced both cardiomyopathy and liver damage,
the combined therapy reduced the cardiac and hepatic lesions to
almost normal.[183]
4.2. Alzheimer’s Disease
Studies indicate that high concentrations of metal ions, such
as Cu2+, Zn2+, Fe2+ bind and trigger the aggregation of A𝛽,
as well as contribute to the formation of cytotoxic ROS.[184]
Therefore, therapeutics against Alzheimer’s disease have focused
on reducing these oxidant species and protecting the immune
system.[185] However, the blood-brain barrier (BBB) is an obstacle
for drug delivery, since more than 98% of low molecular weight
drugs cannot cross it and alternatives, such as intracranial injec-
tion, have the risk of causing more neurotoxicity and physical
damage.[186]
SeNPs have been shown to reduce A𝛽 aggregation and in-
duce their disaggregation, in addition to acting as an antioxi-
dant in the brain, either directly or by being part of GPx, sev-
eral studies have functionalized them with specific molecules,
such as sialic acid and epigallocatechin-3-gallate, a component
of green tea, to enhance their permeability toward the BBB.[32,187]
SeNPs have also been studied together with other compounds
that also shown properties against Alzheimer’s disease, such as
resveratrol (Res),[188] curcumin (Cur),[184] chiral D-penicillamine
(DPen),[167] and chlorogenic acid (CGA) (Figure 17).[64,185]
Res has already shown potential against Alzheimer’s disease
due to its antioxidant and neuroprotective properties, neutral-
izing the A𝛽 aggregation and its oxidative effects. Res-SeNPs
have been shown to specifically bind to A𝛽 by N-donors exist-
ing in the aminoacids, creating a Se–N bond, increasing the Res
inhibition on Cu2+-induced A𝛽 aggregation (Figure 16a). Res-
SeNPs have also been shown to decrease cell membrane dam-
age, which Res is not capable of doing by itself. Res-SeNPs are
not only harmless to neuroblastic cells (PC12 cells), but also have
decreased their A𝛽-induced apoptosis, protecting them from
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Figure 16. Res-SeNPs effect on Cu2+-induced Aß42 aggregation. a) While A𝛽42 monomers in 3 d incubation formed well-delineated aggregates, espe-
cially in presence of Cu2+, Res-SeNPs inhibits the formation of these aggregates; and b) A TUNEL-DAPI costaining assay, Res-SeNPs demonstrated to
inhibit A𝛽42-Cu2+ complexes, while decreasing DNA fragmentation (stained in green) in PC12 cells. Reproduced with permission.[188] Copyright 2018,
Wiley-VCH GmbH.
oxidant stress, showing a possible synergism between SeNPs and
Res (Figure 16b).[188]
Cur, another natural compound, derived from Curcuma longa,
has shown potential synergism with SeNPs against Alzheimer’s
disease. PLGA-stabilized Cur-SeNPs have displayed good viabil-
ity for kidney, lung, liver, and heart cell lines. These NPs were
able to cross the BBB and bound to A𝛽, having antioxidant, anti-
inflammatory anti-A𝛽, and Anti-Tau hyperphosphorylation prop-
erties. It was shown that Cur binds A𝛽 by hydrophobic interac-
tions at the A𝛽 nonpolar regions, developing their antioxidant
and anti-inflammatory activity along with Se.[184] Pen has two
enantiomers, LPen and DPen, and in spite of the low neuropro-
tective effect of the first enantiomer, the second one showed high
potential to inhibit ion-induced A𝛽 and to enhance the memory.
Pen-SeNPs were produced through formation of Se–S links, be-
ing that DPen-SeNPs were far more efficient in preventing A𝛽
formation and improving mice memory than the SeNPs formu-
lated with the other enantiomer. LPen-SeNPs have been shown
to be neurotoxic, mainly due to the L-enantiomer, while the D-
enantiomer were much less toxic when functionalizing SeNPs,
especially at low concentrations (less than 20 µg mL−1).[167]
SeNPs conjugation with CGA, an anti-inflammatory, antioxi-
dant, and neuroprotective compound, has also been studied for
Alzheimer’s disease. CGA-SeNPs have been shown to reduce A𝛽-
generated ROS in a dose-dependent way, inhibiting their neuro-
toxicity and, therefore, decreasing the apoptosis rate, being also
able to bind on the A𝛽 proteins N-donors, forming a Se-N bond,
blocking their aggregation, which was translated in a synergic ef-
fect between CGA and SeNPs.[185] CGA-SeNPs have also demon-
strated that they interact with several potential neurotoxic met-
als, such as Cu(II), possibly due to its reactive aromatic ─OH
groups. CGA-SeNPs also demonstrated to have better antioxi-
dant capacity than chitosan-SeNPs and several inorganic and or-
ganic selenium species. However, Vicente-Zurdo et al. noticed
that, while CGA-SeNPs did not inhibit A𝛽 aggregation and in the
fibril length, chitosan-SeNPs prevented A𝛽 aggregation and di-
minished both the number and fibril width in the presence of
Zn(II), Fe(II), and Cu(II). Furthermore, chitosan-SeNPs also de-
cline the Fe(II)-induced a A𝛽 aggregation.[64]
More recently, Gao et al. produced SeNPs conjugated with
chondroitin sulfate (CS), an extracellular matrix compound with
anti-inflammatory, antioxidant, and neuroprotection activities,
involved in neurogenesis, axon growth, synaptic plasticity, and
neuron regeneration in the form of CS proteoglycan. Negatively
charged CS-SeNPs were produced using L-cysteine as reducing
agent at a CS/L-cys/Na2SeO3 ratio of 2:2:1, with the formation of
C─O···Se and C─N···Se bonds responsible for the high stability
of the nanosystem. CS-SeNPs showed an improved inhibitory ef-
fect on A𝛽1-42 formation and aggregation into toxic A𝛽1-42 fibrils
when compared to SeNPs and CS alone, decreasing 𝛽-sheet fibril
formation in congo red assays. In vitro studies using a neural cell
line (SH-SY5Y cells) indicated that CS-SeNPs inhibit A𝛽 fibrilla-
tion and reduced A𝛽1-42-induced cytotoxicity. Also, CS-SeNPs pro-
tected the neural actin cytoskeleton from okadaic acid-induced in-
stability, while reducing the amount of ROS and MDA produced
by A𝛽1-42, while increasing GPx levels, thereby decreasing the
oxidative damage in neural cells. Furthermore, CS-SeNPs were
shown to decrease tau protein hyperphosphorylation at Ser396
and Ser404 by controlling GSK3𝛽 activity, and overall decelerate
the progression of AD.[189]
The functionalization of SeNPs toward A𝛽 has also been stud-
ied (Figure 17), by targeting two peptides, LPFFD and TGN in a
1:1ratio, stabilizing these NPs with chitosan. The positive-charge
SeNPs produced could overcome the BBB and strongly recog-
nize the 𝛽-sheet structures of the A𝛽, blocking their aggregation.
These two peptides have different effects in SeNPs efficacy. TGN
enhances the amount of SeNPs crossing the BBB, also having
a synergistic effect with Chitosan. LPFFD increases the linkage
between SeNPs and A𝛽 through hydrophobic interactions, in ad-
dition to the electrostatic ones between the negative charged A𝛽
and the positive charged chitosan, inhibiting A𝛽 formation and
the corresponding ROS, and improving neuro cell viability.[186]
Vicente-Zurdo et al. compared the neuroprotective properties of
several Se compounds with SeNPs stabilized with chitosan and
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Figure 17. Mechanisms behind the SeNPs action against AD. Figure cre-
ated with Biorender.
CGA, a substance known to promote brain activity, as well as hav-
ing cardioprotective, anti-inflammatory, antiobesity, and antioxi-
dant properties. The GCA-SeNPs not only demonstrated to form
chelates with several neurotoxic metals and to have better antioxi-
dant properties compared to chitosan–SeNPs, but also prevented
metal-induced A𝛽 aggregation and disaggregated the A𝛽 fibrils
formed, unlike the others Se compounds studied.[64]
Therefore, SeNPs have been demonstrated to have potential
for Alzheimer’s disease treatment, not only due to their an-
tioxidant properties, but also by loading and functionalization
with other potential therapeutic compounds, which have syner-
gic therapeutic potential (Figure 17).
4.3. Anti-Inflammatory and Antioxidant Applications
SeNPs have been shown to have anti-inflammatory and an-
tioxidant properties, exhibiting immunomodulatory and organ-
protective properties.[190,191] For example, studies indicated that
SeNPs protected the male reproductive system from aflatoxin
B1 toxicity, decreasing the number of aberrant spermatozoa and
the DNA fragmentation induced by aflatoxin B1, while increas-
ing sperm count, motility and viability and fertilization in mice.
Furthermore, histological studies demonstrated that SeNPs im-
proved the structural architecture of testis, reducing the atro-
phy caused by aflatoxin B1 in the seminiferous tubules, although
without full recovery.[72]
SeNPs also reduced radiation and carrageenan-induced in-
flammation in rats, decreasing several inflammation indicators,
such as several cytokines (TNF-𝛼 and IL-1𝛽), PGE2, ROS, and
thiobarbitune acid reactive substances, a by-product of lipid per-
oxidation, decreasing the number of leukocytes, monocytes and
granulocytes, the exudate volume and associated pain. SeNPs
demonstrated not only anti-inflammatory activity, but also anti-
hyperalgesia, by modulating peripheral pain mediators, with-
out exerting any effect in the central nervous system. SeNPs
immunomodulatory potential was also described, being able
to prevent monocyte differentiation into macrophages, as well
as diminish L-selectin expression through a metalloproteinase-
dependent mechanism, preventing neutrophil migration and
lymphocytes adhesion to endothelial cells.[191] SeNPs also show
antioxidant potential, by directly diminishing the level of several
oxidant species, and by increasing GPx levels,[42,78] which scav-
enge H2O2 and lipid and phospholipidic hydroperoxides, turn-
ing them into water and alcohols, respectively.[42] Additionally,
SeNPs loaded with CAT and functionalized with FA and HA are
shown to target activated macrophages associated with rheuma-
toid arthritis and atherosclerosis via CD44 and FR-𝛽 receptors
which are higher expressed in these cells. Therefore, SeNPs
specifically destroyed proinflammatory-activated macrophages
responsible for producing high levels of H2O2, without affect-
ing non-activated macrophages.[190] More recently, Huang et al.
produced SeNPs using L-GSH, D-GSH, and DL-GSH, demon-
strating that SeNPs chirality may influence their antioxidant
properties. L-GSH-SeNPs presented higher antioxidant capac-
ity than D-GSH-SeNPs, decreasing the oxidative effect and de-
rived cytotoxic of palmitic acid in INS-1E cells (insulinoma cell
line). Since L-GSH-SeNPs strongly adhere to INS-1E cells, result-
ing in a higher uptake compared to its L- and DL-counterpart,
they also presented better ROS scavenging properties, prevent-
ing mitochondrial fragmentation and reducing caspase-8 and
caspase-9 activities.[108] SeNPs also prevent neurotoxicity asso-
ciated with cypermethrin, a substance used to control house-
hold insects. This substance can modify the sodium ion chan-
nels function, leading to motor deficit problems, which trans-
lated into an increased number of crossed squares, stops, and
immobility duration in rats. However, Ali et al. verified amelio-
rating of these symptoms associated with cypermethrin neuro-
toxicity when SeNPs were administered at the dosage of 2.5 mg
Kg−1, three times a week for 21 d. SeNPs improved liver pa-
rameters, attenuated the decrease of gamma-aminobutyric acid
levels in the brain tissue, reducing the levels of several inflam-
matory cytokines and oxidant compounds, such as MDA, while
raising GSH levels. Also, histological studies demonstrated that
SeNPs were able to decrease cypermethrin cytotoxicity on pyra-
midal cells, with a decline in faint shrunken cells with pyknotic
nuclei and reducing the number of congested blood vessels in
the cerebral cortex and pia mater.[192] Overall, SeNPs are a pow-
erful tool that can be used for the treatment of diseases with a
pathology based on inflammatory and oxidant compounds.[33,190]
Rheumatoid arthritis (RA) is a chronic disease characterized by
several joint inflammations and tissue damage promoted by in-
creased ROS production.[193] SeNPs, unlike selenite, have shown
good cellular viability, while decreasing paw size and cartilage
degradation better than approved corticosteroids in Wistar rats
with induced RA. Inflammation biomarkers, such as C-reactive
protein, PGE2, TNF-𝛼, IL-1𝛽, IL-6, and MCP-1, although elevated
in RA-induced rats, decrease after treatment with SeNPs. Also,
the levels of antioxidant enzymes, usually decreased in RA, were
restored in both liver, kidney, and spleen.[33,193] However, differ-
ent SeNPs doses were proposed: while Malhotra et al. have shown
results with 250 µg per kg body weight,[193] Ren et al. proposes
an intake of 500 µg per kg body weight as the daily therapeutic
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Figure 18. SeNPs protecting role against stroke. a) TTC staining indicating that treatment with OX26-PEG-SeNPs represents a decrease of infarct vol-
ume compared with MCAO group (non-infarcted brain areas are red while the infarcted ones appeared as white). b) Nissl staining of hippocampal
CA1 subregion demonstrating that OX26-PEG-SeNPs augmented neuronal survival under oxidative stress (Green arrows indicate normal cells while
red arrows indicate represents the necrotic ones). c) LFB staining of hippocampal CA1 subregion demonstrated that OX26-PEG-SeNPs reversed the de-
creased of myelinated hippocampal area observed with MCAO (blue, myelinated fibers; pink, neutrophils; and purple, nerve cells); and d) Bielschowsky’s
silver staining of hippocampal CA1 subregion revealed that OX26-PEG-SeNPs preserved the number of axons compared MCAO groups (axons, black).
Reproduced with permission.[135] Copyright 2019, Nature.
dosage in RA-induced rats.[33] Combination therapy of SeNPs
and tripterine was also studied. Tripterine is a substance that
has shown antioxidant, anti-inflammation, and immunoregula-
tion potential, and its combination with SeNPs show synergic
effects in reducing inflammation and joint swelling, as well as
decreasing NO and cytokine levels in vitro. Therefore, the com-
bination of these two compounds demonstrated potential prop-
erties for treatment of RA.[194] The potential of biogenic SeNPs
produced using Trachyspermum ammi seed extract against RA
was also studied. Although the produced SeNPs increased the
urea levels in mice, these SeNPs successfully reduced paw edema
and swelling, while restoring liver alkaline phosphatase levels.
The biogenic SeNPs also shown high antioxidant activity, espe-
cially at concentrations of 5 mg kg−1 of SeNPs (when compared
to 10 mg kg−1 of SeNPs), as well as decreased synovial hyper-
plasia and lymphocytic cellular infiltration in histopathological
analysis of the damaged areas around the paw tissue.[96] As a re-
sult of its anti-inflammatory and antioxidant properties, SeNPs
also demonstrated potential for the treatment of cardiovascular
diseases, such as coronary disease, stroke, and peripheral artery
disease.[195] Epidemiologic studies correlated low plasmatic lev-
els of Se and respective selenoproteins to cardiomyopathies.[127]
50 µg kg−1 of SeNPs has shown potential to reduce atheroscle-
rosis, by decreasing triglycerides, enhancing HDL levels, and re-
ducing the number of lesions in the vascular smooth muscle cells
of ApoE−/− mice subjected to a hypercholesteremic diet. SeNPs
mechanism of action was demonstrated to be related to the reduc-
tion of the mRNA expression of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase, an enzyme responsible for cholesterol biosyn-
thesis, and the enhancing of the enzyme cholesterol 7 alpha-
hydroxylase, responsible for converting cholesterol into bile acid.
Additionally, the enhancing of selenoprotein levels by SeNPs con-
sumption shown to have an important role in decreasing the
oxidative stress that enhances vascular injury risk and reduced
the damages in the liver and kidney caused by the hypercaloric
diet.[195]
In addition, PEG-SeNPs were also used for stroke therapy,
using an anti-Tfr receptor monoclonal antibody (OX26) as a
functionalizing agent. OX26-PEG-SeNPs revealed to have a role
in protecting neuronal cells against stroke, reducing the cel-
lular swelling caused by abnormal entry of Na+ ions. SeNPs
were able to reduce the infarction volumes in Wistar rats sub-
jected to middle cerebral artery occlusion (MCAO) (Figure 18a)
and at the same time, decrease the number of necrotic cells
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Figure 19. Anti-inflammatory therapeutic applications and mechanisms of SeNPs. Figure created with Biorender.
(Figure 18b), while increasing the myelinated areas (Figure
18c) and negate the loss of axons in hippocampus region
caused by the artery occlusion (Figure 18d). The molecu-
lar mechanisms behind SeNPs neuroprotective action seem
to be related to several cellular signaling pathways that con-
trol neuronal metabolic state (TSC1/TSC2,p-mTOR, mTORC1),
antioxidant (FoxO1, 𝛽-catenin/Wnt, Yap1) and inflammatory sys-
tem (jak2/stat3, Adamts-1), autophagy and apoptotic cell death
(Mst1, ULK1, Bax, Caspase-3 and Bcl-2), and the maintenance
of the hippocampal neurons (rictor/mTORC2).[135] Interestingly,
chitosan-SeNPs film also shows potential for cardiac repair, en-
hancing the electrical conductivity of myocardial cells, and en-
hancing the tensile strength and elasticity of the natural my-
ocardium. The SeNPs used for this purpose had rough surfaces,
which decreased the possibility of immune reactions and implant
rejections after transplantation. These properties make Chitosan-
SeNPs film a suitable tool to be used to produce electrical conduc-
tivity in the cardiac patches.[127]
SeNPs have also exhibited in vivo anti-inflammatory protec-
tive properties for liver[128,196] and lungs.[197] SeNPs supplemen-
tation display Se liver retention abilities, increasing selenopro-
teins’ activity and their antioxidant potential, improving liver
biomarkers: alanine aminotransferase (ALT), aspartate amino-
transferase (AST), and lactato desidrogenase (LDH), and dimin-
ishing the liver damage induced by concanavalin-A.[128] Further-
more, SeNPs also demonstrated the ability to protect against
hexavalent chromium hepatotoxicity, by reducing the amount
of free radicals, and downregulating the mRNA expressions of
fatty acid synthase (essential for de novo lipogenesis) and upreg-
ulating the mRNA expression level of acyl-coenzyme A oxidase
1 (limits fatty acid 𝛽-oxidation), protecting against the anoma-
lous fatty acid metabolism, promoted by chromium.[196] Also,
SeNPs demonstrated anti-inflammatory properties against pul-
monary fibrosis only in early stages of the disease, due to its
ability to reduce the levels of cytokines, such as TGF-𝛽1 and
TNF-𝛼. In addition, SeNPs diminished interstitial collagen de-
position, reversed the thickening of alveolar septal provoked by
pulmonary fibrosis and controlled the infiltration of inflamma-
tory cells, such as fibroblasts, improving the lung histological
structure.[197] More recently, Lesnichaya et al. diminished car-
bon tetrachloride hepatic damage, reducing the levels of lipid
peroxidation products and the hepatic enzymes ALT and AST,
probably due to the antioxidant effect of Se due to its role
in the biosynthesis of several antioxidant enzymes. However,
they also verified that, in healthy mice, the administration of
an excessive amount of SeNPs resulted in dysfunction of the
excretion system, with increased urea, AST, and MDA levels.
Also, SeNPs excessive administration may augment ROS lev-
els due to its interaction with GSH.[198] Overall, SeNPs have
potential to treat several inflammation-related diseases across
the body, such as cardiopathies, RA and pulmonary fibrosis
(Figure 19).
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Figure 20. In vitro and in vivo studies concerning the antibacterial properties of Ru-Se@GNPs-RBCM: a) Fluorescence microscopic observation
(LIVE/DEAD) indicating that the complex has a synergic bacterial activity, with only a small percentage of cells alive (green) and a large number of
dead cells (red) compared to SeNPs or Ru-SeNPs. b) SEM images translating the effect of the Se-Ru nanocomplex on the bacteria cells after 2 h in-
cubation, causing shrinking of the cell walls, rupture and morphology alteration; and c) Photos of mice wound area infected with MRSA and treated
with SeNPs, Ru-SeNPs, Ru-Se@G NPs, Ru-Se@G NPs-RBCMs, and vancomycin, using untreated mice as control groups, in which it is observed the
potential of the nanosystem in the healing and treatment of the infected injury. Reproduced with permission.[202] Copyright 2019, American Chemical
Society.
4.4. Antimicrobial Applications
SeNPs also demonstrated antimicrobial applications against bac-
teria, fungi, and viral infection (Figure 20).[13] Bacterial infec-
tions are a critical problem of worldwide healthcare due to re-
sistances caused by continuous overuse of highly concentrated
antibiotics,[155] and, although several NPs shown antibacterial
properties,[105,199] several metalloid and metal-based NPs, such
as silver NPs, also demonstrated several side effects during ad-
ministration of high dosages or prolonged therapy.[105,155,200] Un-
like other metals, Se is an essential element in the human body
and SeNPs have been shown to have bactericidal effects mainly
against MRSA at 1 ppm, however were less effective against E.
coli, probably due to the negative nature of its outer membrane,
which repulse the also negative SeNPs.[157,199] Antibacterial ac-
tivity of the SeNPs is negatively correlated to its size, being that
81 nm SeNPs were found to be more effective against MRSA
(inhibitory capability of 25 µg mL−1) than 124 nm SeNPs (in-
hibitory capability of 140 µg mL−1).[199] Chung et al. produced
BSA-stabilized SeNPs with a size less than 40 nm with antibac-
terial properties against S. aureus. The SeNPs produced accom-
plished IC50 values much lower than those for the human dermal
fibroblasts, which translated into a promising safety window for
its use as an antibacterial agent.[97]
Also, SeNPs at 0.5 mg Se mL−1 inhibited MRSA adherence by
more than 60% on glass and catheter surface (polystyrene sur-
face), demonstrated their potential against biofilms formed in
medical devices.[201] Furthermore, biosynthesized SeNPs also in-
hibited fungi biofilms, without affecting the viability of human
cells, such as fibroblasts and dendritic cells.[86]
Functionalization of SeNPs was also studied in order to de-
velop better targeting towards bacteria cells.[105,155,202] The incor-
poration of Se into Se-MSNPs was attempted. Se-MSNPs showed
better antibacterial activity than bare SeNPs for MRSA, although
being ineffective against E. coli.[155] In another study, SeNPs
were also functionalized with quercetin and acetylcholine, show-
ing a synergic effect against both E. coli and MRSA at 25 µg
mL−1, not only killing them but also inhibiting their cellular
division. Quercetin is itself a bactericidal molecule, and acetyl-
choline was used to enhance bacterial permeability to SeNPs.[105]
In more recent studies, SeNPs were loaded with Ruthenium
(Ru) and, afterwards, were encapsulated into bacteria-sensitive
gelatin NPs, coated by red blood cell membranes (RBCM), de-
veloping a multilayer nanosystem with a size of approximately
152 nm with antibacterial properties against gram positive and
negative strains (Figure 21a). Synergic antibacterial effects were
achieved in vivo: 1) RBCMs had a camouflage effect from the
phagocytosis of macrophages and increased the nanosystem’s
internalization by bacteria; 2) The nanocore absorbed the bac-
terial exotoxins, neutralizing their virulence, and gelatin is de-
graded into aminoacids by bacterial gelatinases, inducing Ru-
SeNPs release; 3) Ru enabled monitoring the treatment through
fluorescence signal, besides having additional bacterial effect;
and 4) SeNPs attack the bacterial cells, increasing the amount
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Figure 21. Antimicrobial activity of SeNPs and the associated pathways.
Figure created with Biorender.
of cellular ROS and triggering bacterial lysis (Figure 21b). In
vitro assays show the antibacterial potential of these NPs against
MRSA, Staphylococcus epidermidis and P. aeruginosa, although
with less effect on E. coli. In vivo studies in mice demonstrated
that these SeNPs not only escape the immune system, and attack
bacterial cells, but also accelerate skin tissue repair (Figure 21c).
They were quickly metabolized, having only a residual concen-
tration within the liver and kidney (organs responsible for their
metabolism), not presenting any toxicity at therapeutic dosages
(2 mg kg−1).[202] Overall the antibacterial potential of SeNPs
seems to be due to: metabolic dysfunction due to decreasing of
ATP concentrations;[199] increase of the intracellular concentra-
tion of ROS, causing oxidation stress,[105,155,199,202] which results
in a loss of bacterial resistance to SeNPs;[105,202] inhibition of pro-
tein synthesis and DNA mutation and damage;[105,155,200] depolar-
ization and destruction of the bacterial membrane.[105,155,199,202] A
nanohybrid containing SeNPs and lysozyme, a biomolecule that
has a defensive role in the immune system against gram-positive
bacteria, has shown synergic activity, specifically against MRSA,
although having some activity against E. coli. The lysozyme af-
fected the gram-positive bacteria by hydrolyzing 1,4-𝛽-linkages
of its cell wall, due to its activity as a 𝛽-glucosidase. However,
due to the lipopolysaccharide layer, its enzymatic effect cannot
be achieved. Furthermore, SeNPs are negatively charged, being
repulsed by the lipopolysaccharide gram-negative bacteria, such
as E. coli, contributing to its lower sensitivity toward SeNP.[203]
Also, Golmohammadi et al. prepared a hydrogel consisting of
chitosan-cetyltrimethylammonium bromide entrapping SeNPs
and mupirocin. The therapeutic combination within the hydrogel
demonstrated synergic activities against mupirocin-methicillin-
resistant S. aureus (MMRSA) inoculated in an injury created in
a diabetic rat model, while improving the wound healing associ-
ated with the bacterial infection, stimulating epidermal growth,
and decreasing the associated inflammation, suggesting its po-
tential for treatment of diabetic wound infections.[204] SeNPs pro-
duced by biosynthesis using Lactococcus lactis had a protective
effect on intestinal infection by E. coli, preserving the intestinal
epithelial barrier due to its antioxidant and anti-inflammatory ef-
fects and by increasing occludin an claudin-1 expression.[78]
More recently, Huang et al. used a recombinant spider silk pro-
tein eADF4(𝜅16) to produce positive charged SeNPs in order to
improve SeNPs antibacterial activity against gram-negative bacte-
ria, such as E. coli, comparing their activity with negative charged
SeNP, produced using PVA. The eADF4(𝜅16)-SeNPs produced
had a mean diameter of 46 nm and a 𝜁 -potential of +46.0 ±
0.6 mV. As a result of its small size and extremely positive charge,
eADF4(𝜅16)-SeNPs showed a high antibacterial potential against
E. coli with a minimum bacterial concentration of 8 ± 1 µg mL−1,
50 times lower than that of negatively charged SeNPs, and a con-
centration not considered toxic to human cells. Therefore, the
positive charge enabled a better electrostatic attraction between
the SeNPs and the negatively charged bacterial cells. However,
these SeNPs had a low stability in culture broth. To overcome
this issue, eADF4(𝜅16)-SeNPs were immobilized in positively
charged spider silk films, which retained SeNPs bactericidal ac-
tivity against E. coli. Moreover, it was observed that the SeNPs
release from the film surface was essential to exert their antibac-
terial effects, and that this release can be regulated by the charge
of the film surface itself.[200]
El-Sayyad et al. also demonstrated the SeNPs antimicrobial po-
tential against a wide range of pathogens involved in resistant
urinary tract infections. El-Sayyad et al. produced SeNPs using
both Penicillium chrysogenum filtrate biosynthesis and gentamicin
(CN) drug as stabilizer agent and gamma radiation as reducing
agent. While the biogenic SeNPs had a cubic crystalline structure
and a size ranging from 12.12 to 84.15 nm, the CN-SeNPs had an
amorphous structure and a mean diameter of 33.84 nm. The CN-
SeNPs demonstrated to have better antibacterial potential than
the biogenic SeNPs, inhibiting both gram-positive bacteria (S. au-
reus and Bacillus subtilis) and gram-negative (E. coli and P. aerugi-
nosa), with the exception of Klebsilla pneumoniae, with minimum
inhibitory concentrations (MICs) ranging from 3.950 to 0.245 µg
mL−1. CN-SeNPs also inhibited the formation of E. coli biofilms,
by provoking cell wall hardness and distortion, inducing bacterial
lysis. Therefore, CN and SeNPs developed a synergic impact that
translated into a higher antibacterial effect towards most bacterial
strains studied.[114]
SeNPs were also studied for tuberculosis therapy. Their load-
ing with Isoniazid, a medicine already used against tuberculo-
sis, and manipulation with mannose, resulted in synergic ef-
fects, inducing not only antibacterial effects, mainly through
ROS stress, but also targeting the phagocytic macrophages
through their mannose receptors, releasing the Isoniazid in their
acidic lysosomes. Therefore, this nanosystem promotes not only
the destruction of the M. tuberculosis bacillus that infected the
macrophages and escaped the phagolysosome, but also the au-
tophagy and apoptosis of the infected macrophages, by ROS
stress and PI3K/AKT/mTOR signaling pathways.[158] Further-
more, more recently, Estevez et al. demonstrated that chitosan–
SeNPs by themselves have antibacterial properties against both
Mycobacterium smegmatis and M. tuberculosis with MIC values of
0.400 and 0.195 µg mL−1, respectively.[205]
Other pathogenic agents that have acquired resistances against
their treatment are fungi, making the development of new an-
tifungal therapeutic agents crucial.[206,207] Since Se compounds
have been used as antifungal agents, there have been sev-
eral studies regarding SeNPs antifungal potential.[206–208] Ini-
tial studies demonstrated that biogenic SeNPs show antifun-
gal potential against C. albicans and Aspergillus fumigatus at
MICs of 70 and 100 µg mL−1, respectively.[206] Further studies
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demonstrated SeNPs potential to reduce the expression of CDR1
and ERG11 genes in C. albicans, decreasing its resistance to anti-
fungal drugs.[207] More recent studies used Chitosan-SeNPs pre-
pared by PLA. In this study, despite bare SeNPs exhibiting an
IC50 of 21.7 ppm for C. albicans, the IC50 of chitosan–SeNPs was
3.5 ppm, which indicates a synergic effect between SeNPs and
Chitosan, that alone show some degree inhibition against C. al-
bicans biofilms.[208] Also, SeNPs have shown potential against se-
borrheic dermatitis, a fungal infection caused by Malassezia fur-
fur that occurs in the skin regions rich in oil glands. SeNPs and
ketoconazole nanoparticles were integrated into a HA hydrogel
using cross-linking methodology. This formulation was shown to
have improved antifungal activity when compared to SeNPs and
ketoconazole, with a zone of inhibition of 35±1.67 mm, proba-
bly due to the combined therapy of ketoconazole, that inhibit the
production of ergosterol, and SeNPs, which kill fungal cells by
provoking ROS stress. The hydrogel also had anti-inflammatory
properties in vivo and the use of NPs was shown to increase the
skin permeability to the therapeutic compounds.[132]
SeNPs also show antiviral activity, especially against H1N1, a
virus responsible for a very infectious respiratory disease respon-
sible for 8768 deaths in 207 countries in 2009.[209,210] In an ini-
tial study, functionalized SeNPs with oseltamivir demonstrated
synergic antiviral activity against H1N1, increasing the viability
of infected cells and viral destruction at a MIC of 0.3 × 10−9
m. The mechanisms behind this antiviral activity are: 1) inhi-
bition of hemagglutinin and neuraminidase activities, glycopro-
teins important for virus transport into host cells; 2) caspase-3
and ROS stress inhibition in host cells, probably by modulation
of the p53- and AKT-signaling pathways (p53 activation and AKT
phosphorylation).[209] Other studies using SeNPs also demon-
strated their synergic antiviral activity when loaded with aman-
tadine and ribavirin.[210,211] SeNPs functionalized with amanta-
dine had a MIC of 0.1 × 10−6 m, and showed similar antivi-
ral pathways as SeNPs functionalized with oseltamivir, dimin-
ishing neuraminidase activity, ROS stress, mitochondrial dys-
function and caspase-3 activation, besides activating the phos-
phorylation of AKT, thus preventing cell apoptosis.[210] In vivo
studies also demonstrated the potential of SeNPs functional-
ized with ribavirin for the protection of lung alveoli from H1N1
infection, besides bringing new information about the mecha-
nisms behind the antiviral activity exhibited. In fact, SeNPs in-
hibited the upregulation of cleaved Poly-ADP-ribose polymerase
(PARP), caspase-8, Bax, p38, JNK and p53 induced by H1N1, pro-
tecting the lung cells from apoptosis.[211] Interestingly, SeNPs
functionalized with oseltamivir also exhibited antiviral activity
against hand-foot-mouth disease, also by decreasing the activity
of caspase-3, enhancing mitochondrial potential and inhibiting
ROS generation, avoiding the apoptosis of host cells.[212]
Lin et al. also studied the potential of SeNPs against En-
terovirus 71, which is responsible for several neuronal, hand,
foot, and mouth diseases. SeNPs were capped with PEI and
loaded with siRNA targeting the enterovirus 71 VP1 gene, pro-
ducing PEI-SeNPs@siRNA-VP1 with the size of 80 nm, with an-
tiviral potential towards Enterovirus 71. PEI-SeNPs@siRNA-VP1
was able to reduce VP1 expression and inhibit the proliferation of
Enterovirus 71, increasing the cellular viability of SK-N-SH cells
(nerve cell line) by inhibiting the Bax signalizing pathway, and
reducing the number of cells arrested at sub-G1 phase.[213]
More recently, SeNPs were used for production of a detec-
tion test for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), based on the IgM and IgG in human serum and
blood. Based on the fact that SeNPs have higher levels of sensi-
tivity and stability, besides being cheaper, than colloidal gold in
qualitative lateral flow immunoassays, Wang et al. developed a 10
min kit test based on SeNPs produced by chemical reduction with
SDS and PEG as templates. The tests developed demonstrated a
limit of detection of 20 ng L−1 and 5 ng mL−1 for IgM and IgG,
respectively, without false positives in human serum. Also, the
tests have shown sensitivity and specificity values of 93.33% and
97.34%, respectively, and positive and negative predictive values
of 92.31% and 97.71%, respectively.[214]
Furthermore, SeNPs have shown antiparasitic properties
against chronic toxoplasmosis. The biogenic SeNPs produced us-
ing Bacillus sp. were demonstrated to have antiparasitic prop-
erties, especially at higher concentrations and when adminis-
tered concomitantly with atovaquone. Oral administration of
10 mg Kg−1 SeNPs with atovaquone 100 mg kg−1 in male BALB/c
mice infected with Toxoplasma gondii demonstrated to com-
pletely eliminate all tissue cysts, without presenting any toxic-
ity. SeNPs also increased the level of the immune mediator com-
pounds IFN-𝛾 , TNF-𝛼, IL-12, and iNO, while reducing IL-10 lev-
els. Thereby, it was proposed that the stimulation of the immune
system was the main therapeutic effect by which the SeNPs in-
duce their antiparasitic activity.[215]
4.5. Cancer Treatment and Theragnostic Applications
Cancer is still one of the most problematic and deadly dis-
eases worldwide[216] and, although the most common therapeu-
tic strategies are surgery after chemotherapy, radiation, or com-
bination of both, their side effects can be very severe for the
patient.[36,133] Nanotechnology has presented advantages com-
pared to current chemotherapy,[133,216] and SeNPs are promising
therapeutic agents, due to their high bioavailability and lower tox-
icity when compared to organic and inorganic Se, besides having
demonstrated to have stronger anticancer activity, stimulating se-
lenoproteins and triggering cell apoptosis in cancer cells, while
protecting the healthy cells, preventing ROS stress and DNA
damage.[13,36,144] However, in spite of SeNPs exhibiting more an-
tiproliferative properties towards cancer cells than the healthy
ones, some normal cells, such as prostate cells and hepatocytes
seems to be more sensitive than their cancer counterparts, being
necessary to functionalize the SeNPs with specific compounds
that enable the targeted delivery towards cancer cells.[217] Sev-
eral bioconjugations and functionalizations were attempted for
SeNPs, and their physical and therapeutic characteristics seem to
depend on the type of functionalization and cancer cell used in
the study.[36] Several molecules have been used to provide target
selectivity to SeNPs, such as FA,[100] RGD-peptide[36] and Tfr,[121]
and, according to the molecule and the type of cancer studied,
SeNPs are internalized and destroy malign cells through sev-
eral molecular pathways, the most common being the production
of ROS and activation of the intrinsic pathway of apoptosis.[36]
Also, when loaded with chemotherapeutic drugs, SeNPs were
able to protect the healthy organs from their toxic effects, while
also avoiding clearance through macrophage phagocytosis.[13]
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Figure 22. Schematic figure of the principle behind SeNPs dot-blot immunoassays tests. a) Scheme of the detection of human Pro-GRP by colloidal
SeNPs. b) TEM images of colloidal SeNPs. c) TEM images of Se@Goat antimouse IgG. d,e) Result after serum test (3 min) for 100 and 0 pg mL−1
goat anti-mouse IgG, respectively (concentration of pro-GRP was 25 pg mL−1). SEM images of blank nitrocellulose membrane—f) blocked nitrocellu-
lose membrane and g) nitrocellulose membrane after h,i) dot-blot immunoassays. Reproduced with permission.[223] Copyright 2018, Royal Society of
Chemistry.
Additionally, the size of SeNPs also demonstrated to inversely in-
fluence their antitumor activity, since smaller SeNPs were asso-
ciated with elevated ROS production, having more antiprolifera-
tion activity towards cancer cells.[104] SeNPs have demonstrated
anticancer potential against liver,[30,31] prostate,[35,218,219] bone,[133]
breast[219,220] and lung cancer,[219] Dalton’s lymphoma,[101,221]
glioma,[222] and cell lines, among others.[36]
SeNPs have also demonstrated potential to be incorporated
into endoprosthesis implants to combat osteosarcoma. Stolzoff
et al. demonstrated the possibility of precipitated SeNPs in an
engineering material used for orthopedic applications, PLLA,
wherein SeNPs prevented bacterial adhesion and attacked cancer
tissue while they enhanced the renewal of bone tissue.[133] SeNPs
also exhibited prophylactic properties against peritoneal carcino-
matosis, a major complication of abdominally located cancers re-
lated to surgical complications. After injection of H22 cells into
Kunming mice, their weight started to increase as a result of the
large amount of ascitic fluid provoked by the malignant cells and,
after 14 days, the mice died. However, the intraperitoneally ad-
ministration of SeNPs at a dose of 4.5 mg Se per kg body weight
at 1 h after H22 inoculation resulted in the survival of all mice.
Interestingly, the administration of 6 mg Se per kg body weight
resulted in 33% mouse death within a weak, which suggests the
existence of a therapeutic window between SeNPs beneficial and
toxic effects.[217]
SeNPs were also studied for cancer diagnosis. SeNPs pro-
duced by TiO2 photocatalysis self-assembly on imprinting sites
of zeolite-chitosan-TiO2 microspheres were successfully used in
dot-blots sandwich enzyme immunoassays to detect antigens typ-
ical of human lung cancer, such as Pro-GRP (Figure 22), using a
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Table 4. Mechanisms behind SeNPs antitumor activity against several types of cancer.
Cancer cell type Biochemical mechanism Effects Refs.
Breast Cancer ↓Er𝛼
↑pp38, Bax and cytochrome c
Apoptosis [220]
Dalton’s lymphoma ↑ROS stress, ↓mitochondria membrane
potential in tumor cells
↑F-actin activity, CD54 (ICAM-1) expression,
CD47 and CD172a receptors in tumor
activated macrophages
DNA fragmentation, cell cycle arrest at
G0/G1 and apoptosis of tumor cells.
↑ Phagocytosis of tumor cells
[221]
Glioma cancer ↑ROS stress and caspase-3 activity
↓ glycolysis
Apoptosis [222]
Hepatocellular carcinoma ↑ ROS stress and mitochondria dysfunction Apoptosis and cell cycle arrest at sub-G1 [112]
Ovarian cancer According to the cancer cell line:
• SKOV: increased stiffness and surface
roughness
• OVCAR: decreased surface roughness
Apoptosis [225]
Cervical Cancer – ↓ Cellular viability, migration and
neovascularization
[95]
Prostate cancer ↓ Androgen receptor and PSA
↑ Caspase activity
Apoptosis [219]
↑ROS stress, ↓mitochondria membrane
potential
↑TNF and ERF1 mRNA, RIP1 kinase
↓ PSA
Necroptosis RIP1 kinase dependent [35,218]
↑ Caspase-3, Bax and p21 mRNA
↑ miR-16 → ↓ Bcl-2, cyclin D1
Apoptosis and cell cycle arrest [159]
nitrocellulose membrane to set up the position of the hole. This
serodiagnosis technique took 5 min and its sensitivity was 75 pg
mL−1.[223] Also, Korany et al. studied the use of SeNPs radiola-
belled with 99mTc, producing 99mTc-GSH/SeNPs with liver cancer
theragnosis potential in male Swiss albino mice. The nanosys-
tem produced presented the size range (21 ± 5 nm) indicated for
passive targeting through the enhanced permeability and reten-
tion (EPR) effect, and a great antioxidant potential, that would
increase their uptake and retention by tumor cells, thereby in-
creasing the 99mTc-GSH/SeNPs amount in the solid tumor trans-
planted into the mice.[224]
4.5.1. Antitumor Mechanisms
SeNPs have demonstrated to have antiproliferative properties to-
wards a variety of cancer cell lines, however the pathway behind
its antitumor activity seems to be dependent on the possible func-
tionalization directed to a specific target or on if the SeNPs are
loaded with another compound. Overall, SeNPs seem to exer-
cise their activity in a dose-dependent way,[36] mainly by being
reduced by both the glutaredoxin and thioredoxin antioxidant sys-
tems, with production of HSe, oxidation of nicotinamide ade-
nine dinucleotide phosphate (NADPH) and oxygen to its radi-
cal forms.[17] Thereby, by enhancing the ROS production and the
stress associated, SeNPs induce cell cycle arrest and apoptosis,
while being much less cytotoxic for healthy cells (Table 4).[17,36]
Initial studies have demonstrated that SeNPs have better an-
tiproliferative properties for MCF-7 cells (IC50 value of 25 µg
mL−1) than MDA-MB-231, reflecting their antitumor potential
for early-stage breast cancer (estrogen receptor 𝛼 (ER𝛼) pos-
itive) than late-stage breast (ER𝛼 negative) cancer treatment.
SeNPs decreased the ER𝛼 expression, while increasing the ex-
pression of pp38, Bax and cytochrome c, both proteins that are
involved in apoptosis. In vivo assays shown that administration
of 0.4 mg/kg/day significantly reduced tumor growth, which sug-
gests that the antiproliferative activity of SeNPs in breast cancer is
related to ER𝛼 levels. Se can also decrease procarcinogen activa-
tion and metabolism, by preventing phase I enzymes activity and
stimulating phase II enzymes, being that, while phase I enzymes
are members of the cytochrome P450 that concert chemical car-
cinogens into reactive adducts that attack DNA, while phase II
enzymes are detoxifying enzymes, and their activation represents
the mechanism behind SeNPs tumor suppression.[220]
SeNPs also show antitumor potential towards Dalton’s lym-
phoma, by enhancing ROS stress and decreasing mitochondria
membrane potential, which ultimately led to DNA fragmenta-
tion, cell cycle arrest at G0/G1 and apoptosis. However, in tumor-
associated macrophages, SeNPs decrease ROS levels, increase
polarization of F-actin, the expression of CD54 (ICAM-1), and the
number of CD47 and CD172a receptors, which translated into in-
creased ability to adhere and phagocyte the tumor cells.[221]
Another study concerning SeNPs potential against glioma
cancer shown that they had antiproliferative properties against
glioma cells resistant to several chemotherapeutic-approved
agents, such as adriamycin, carmustine, cisplatin, pirarubicin,
and teniposide. SeNPs enhanced ROS stress, thereby increas-
ing caspase-3 activity, while decreasing the levels of hexokinase
2 and pyruvate kinase, which resulted in reduced glucose up-
take, lactase production, and ATP levels, decreasing cell energy
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and ultimately leading to apoptosis of cancer cells, indicating that
SeNPs decrease the glucose metabolism through an increase of
ROS.[222]
SeNPs also demonstrated suppressive effects against
androgen-dependent prostate cancer cell lines. SeNPs re-
duced the levels of androgen receptor, a protein associated with
cancer cell survival, at both a transcriptional and translational
level. On the one hand, mRNA levels of both androgen receptor
and prostate-specific antigen (PSA) were downregulated. On
the other hand, SeNPs induced androgen receptor and Mdm2
phosphorylation by AKT, which led to the ubiquitination and
proteolysis of the androgen receptor by proteasomes, increased
levels of caspase-3, caspase-8, and caspase-9 levels, as well as
their substrate PARP, which result in the inhibition of prostate
cancer cells growth and apoptosis.[219]
A further study concerning the antiproliferative activity of
SeNPs against prostate cancer showed that biogenic SeNPs pro-
duced using Bacillus licheniformis JS2 at a concentration of 2 µg Se
mL−1 enhanced ROS production and diminished mitochondrial
membrane potential, which led to a decrease in ATP levels. Curi-
ously, these SeNPs enhanced the levels of TNF and ERF1 mRNA,
which suggests the death of tumor cells by necroptosis, modu-
lated by RIP1 kinase, but independent of RIP3 and MLKL.[218]
Sonkusre et al. also studied the potential of biogenic SeNPs for
prostate cancer therapy. SeNPs produced using Bacillus licheni-
formis biosynthesis induced necroptosis of cancer cells by the
same biochemical mechanisms, while reducing the expression
of PSA. However, the caspase activity was reduced, which sug-
gests that the antitumor effect of SeNPs was independent of any
caspase pathway. In vivo studies also demonstrated that SeNPs
are less toxic compared to L-SeMet, causing less liver damage.[35]
More recently, Liao et al. also study the anticancer application
of biogenic SeNPs prepared using E. coli towards several can-
cer cells lines. These SeNPs displayed antiproliferative potential
against colon, liver, cervical, breast, melanoma, and prostate can-
cer cells, both androgen-dependent and androgen-independent
prostate cancer cells, by increasing the expression of p21 and
Bax mRNA and enhancing caspase-3 activity. SeNPs also demon-
strated to upregulate miR-16, which, therefore bound to cyclin
D1 and Bcl-2 genes at a GCUGCU sequence site, inhibiting
the expression of these anti-apoptotic proteins, thereby induc-
ing cell cycle arrest and apoptosis of cancer cells.[159] More re-
cently, Rajkumar et al. studied the anticancer potential of bio-
genic SeNPs produced by P. stutzeri using 8% banana peel extract
with 0.25 × 10−3 m tryptophan as medium culture. The resultant
biogenic SeNPs inhibited HeLa (cervical cancer cell line) cells
viability at low concentration such as 5 µg mL−1, while also show-
ing anti-angiogenic potential, decreasing the cancer cells migra-
tion/invasiveness and neovascularization, without showing toxi-
city towards normal cells, even at high concentrations.[95]
PEG–SeNPs produced by dissolving gray Se power in PEG so-
lution at 210–220 °C under magnetic stirring also shown antipro-
liferative properties against HepG2 cells (hepatocarcinoma cell
lines) with an IC50 value of 3.27 µg mL
−1, while a mixture of
PEG200 and SeNPs demonstrated a lower anticancer effect (IC50
value: 38.2 µg mL−1). Also, HK-2 cells (human kidney cell lines)
were much less affected by PEG-SeNPs, suggesting a therapeutic
window for its use as anticancer agents. PEG-SeNPs increased
ROS levels, decreasing the mitochondrial membrane potential,
which led to a loss of cell-to-cell contact, cell shrinkage, and ulti-
mately apoptosis and cell cycle arrest at sub-G1.[112]
SeNPs stabilized with Val, Asp, and Lys were also studied
against several cancer cell lines. These SeNPs also increased ROS
overproduction and caspase-activation, inducing both intrinsic
and extrinsic apoptosis pathways, with IC50 values from 5.0 ×
10−6 to 9.6 × 10−6 m, being that the Lys-SeNPs shown better an-
ticancer activity, followed by Val-SeNPs and the irregular shaped
Asp-SeNPs shown the weakest anticancer activity.[23]
More recently, Toubhans et al. compared the potential of
SeNPs stabilized by BSA (negative charged) and chitosan (pos-
itive charged) with selenite for two types of ovarian cancer cell
lines, OVCAR-3 and SKOV-3, concluding that although OVCAR-
3 cells were more sensitive to SeNPs, selenite was more effec-
tive in SKOV-3 cellular inhibition, which suggests that the cell
lines are differently affected to each Se treatment. However, upon
treatment with SeNPs, the SKOV-3 cells presented an increased
surface roughness and cellular stiffness, therefore reducing their
elasticity and migratory ability to create metastasis, which was not
identified in selenite treatment. Though, both selenite and SeNPs
treatment decreased OVCAR-3 cell surface roughness.[225]
Since SeNPs demonstrated to have anticancer effects, several
studies used specific compounds whose receptors are overex-
pressed in tumor cells to specifically target them (Table 5).[36] For
example, Zhang et al. functionalized SeNPs with ATP, by adsorp-
tion via an Se─N bond. ATP, once decorating SeNPs, specifically
target P2 receptor in the plasma membrane of hepatocellular car-
cinoma cell lines. Upon inside the tumor cells, ATP-SeNPs in-
duce PAPR cleavage and caspase-3, caspase-8 and caspase-9 ac-
tivation, through ROS overproduction and mitochondria stress,
which leads to cell arrest at sub-G1 phase, DNA fragmentation
and apoptosis through both extrinsic and intrinsic pathways.[226]
Also, several studies reported the anticancer potential of
SeNPs when stabilized with mushroom polysaccharides.[28]
Zeng et al. studied the antitumor potential of SeNPs stabi-
lized with polysaccharides from the fungi species PTR, Poly-
porus rhinoceros, Coriolus versicolor, and Ganoderma lucidum. The
SeNPs produced entered the cells by endocytosis, inducing in-
trinsic mitochondria-mediated apoptosis, by increasing the ac-
tivity of caspases-3/7/9, Bad, Bax, Bim, Bid, Puma, and Bak,
while decreasing the activity of the antiapoptotic proteins Bcl-
2 and Bcl-XL, resulting in DNA fragmentation and cell arrest
at sub-G1 in gastric adenocarcinoma AGS cells. In vivo as-
says demonstrated the inhibition of Ki67 cells and downregu-
lation of VEGFR2, which is deeply involved in angiogenesis,
without presenting noticeable toxicity to normal organs.[28] Fol-
lowing this study, Huang et al. conjugated SeNPs with PTR
polysaccharide–protein complexes and applicate them against
colorectal cancer cell lines. PTR-SeNPs entered the cells through
energy-dependent caveolae-mediated endocytosis toward Golgi
apparatus and clathrin-mediated into the lysosome. Then, PTR-
SeNPs activated the Bcl-2 family (proapoptotic proteins Bax and
Bak) and down-regulate cyclin D1 and D3, and cyclin-dependent
protein kinase (CDK) 2/4/6, all regulators of G1/S phase, lead-
ing to DNA fragmentation, apoptosis, and cell arrest at G2/M
phase arrest. Afterward, by using a pEGFP-LC3 plasmid trans-
fection model, PTR-SeNPs upregulated the autophagy initiator
Beclin 1 and decreased p62 levels, promoting autophagy. The
relation between autophagy and apoptosis was established by
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Table 5. Mechanisms behind functionalized SeNPs antitumor activity against several types of cancer.
Functionalization Cancer cell type Endocytosis mechanism Biochemical mechanism Effects Refs.
ATP-SeNPs Hepatocelular carcinoma – ROS stress, mitochondria
dysfunction, PARP cleavage
↑ caspases 3,8 and 9







↓ ABC family proteins
↑ ROS stress, p53 phosphorylation,
caspase 8/9 and PARP cleavage




Fer-SeNPs - ↑ ROS and mitochondria
disruption, cytochrome c release
and caspase -3/9 activation
DNA-binding properties
Apoptosis [31]
















↑ ROS and mitochondria
dysfunction
Preferential in vivo accumulation at
tumor sites, with inhibitory
effects towards formation and
motility of cancer-related blood















SeHAN - ↓ Ki-67, VEGF and MMP-9
Formation of calcium deposits
↑ ROS stress





Bone Cancer - ↑ ROS stress, mitochondria
dysfunction and cytochrome c,
caspase-3/8/9 and truncated Bid
Apoptosis [229]
BFP-Se, Acute myeloid leukemia ↑ Mitochondria dysfunction
↑ GSH
↓ c-Jun activation domain-binding
protein 1
↓ thioredoxin 1
Apoptosis and cell arrest
at G1 phase in U937






Gastric adenocarcinoma – ↑cappases-3/7/9, Bad, Bax, Bim,
Bid, Puma, and Bak,
















Lentinan-SeNPs Malignant ascites Caveolae-mediated,
mediated by TLR4 and
caveolin 1
↑ ROS and mitochondria
dysfunction
↑ caspase-3
↓ ATP levels and inflammatory
cytokines
In vitro: cell apoptosis







Colorectal cancer Caveolae and
clathrin-mediated
↑ Bax and Bak,
↓ cyclin D1 and 3, CDK 2/4/6
↑Beclin 1
Apoptosis and cell cycle
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Table 5. (Continued).
Functionalization Cancer cell type Endocytosis mechanism Biochemical mechanism Effects Refs.
FA-SeNPs Breast cancer Folate receptor-mediated ↑ ROS production,
Ca2+intracellular concentration
and mitochondria dysfunction, ↑
caspases-3/9 activity





and cell cycle arrest at
S phase
[29,30]
IONP Initial studies: Se:IONPs shown antiproliferative activity against breast cancer cells, reducing their
viability to 40.5% in Se:IONPs concentration of 1 µg mL−1. However, these results point to the use
of SeNPs functionalized with IONPs to magnetically target cancer cells
[232]






– ↑ ROS production and
mitochondria dysfunction
↑ caspase-3
Apoptosis and cell cycle
arrest at S phase
[148]
Beclin 1 connection to Bcl-2, promoting the activation of Bax and
Bak.[141] SeNPs stabilized with laminarin, the active substance
from the Laminaria digitata, also showed antiproliferative prop-
erties against HepG2 cells (IC50 value of 23.4 ± 2.7 × 10−6 m)
though increased expression of Bax and cleavage of caspase-9,
and decrease of Bcl-2, thereby inducing the mitochondria in-
trinsic apoptosis pathway. Moreover, treatment with laminarin-
SeNPs enhanced the levels of LC3-II, indicating initial autophagy,
while decreasing P62 and inducing lysosomes alkalinization,
thereby inhibiting the late phase of autophagy and disabled the
self-protection mechanism of cancer cells.[139] SeNPs stabilized
with 1,6-𝛼-D-glucan from Castanea mollissima also shown anti-
cancer properties against HeLa cells (cervical cancer cell line),
inducing apoptosis by mitochondria intrinsic pathway and pos-
sible cell arrest at S phase, by increasing ROS production, de-
creasing the mitochondrial membrane potential and activating
caspase-3 activity.[148] More recently, Jin et al. studied the anti-
cancer potential of BFP-Se against acute myeloid leukemia, using
both U937, HL60, and Molm-13 cell lines. BFP-Se strongly inhib-
ited the proliferation of all malignant cell lines, demonstrating
an IC50 value of 118.3 µg mL
−1 for U937 cells, without present-
ing major toxicity towards normal cells such as hematopoietic
stem cells and T cells. BFP-Se mechanism of action was based
on decreasing the mitochondrial membrane potential, promot-
ing apoptosis and cell arrest at G1 phase in U937 cells and at
S phase in HL60 cells. In vivo studies using B-NSG mice also
demonstrated the anticancer properties of BFP-Se when admin-
istered at low dosages (0.05 mg kg−1), decreasing the number of
leukemia cells, and improving mice survival rate. Also, BFP-Se
increased the GSH levels, preventing oxidative stress common in
relapses of leukemia patients, while decreasing the expression of
c-Jun activation domain-binding protein 1 and thioredoxin 1, two
proteins overexpressed in leukemia cells, with a role in tumori-
genesis promotion and progression.[147] Also, Liu et al. function-
alized SeNPs with lentinan, a 𝛽-glucan obtained from Lentinus
edode used in China for treatment of malignant ascites, produc-
ing lentinan-SeNPs with the size of 53.8 nm and with antiprolif-
erative potential towards OVCAR-3 (ovary adenocarcinoma) and
EAC cells (ascites tumor). In vivo studies in mice demonstrated
that lentinan-SeNPs decreased the body weight and volume of
ascites provoked by the malignant cells, reducing the associ-
ated hemorrhage. The functionalization with lentinan improves
the SeNPs uptake efficiency by caveolae-mediated endocytosis,
by targeting TLR4 and caveolin 1, inducing cell membrane in-
vaginations responsible for SeNPs uptake. Afterward, it was ob-
served that the endocytic vesicles formed by lentinan-SeNPs and
TLR4/caveolin 1 enter the mitochondria by membrane fusion
mediated by a protein complex composed by TLR4, TNF receptor-
associated factor 3 and mitofusin-1. Lentinan-SeNPs act by en-
hancing ROS and decreasing the mitochondrial membrane po-
tential, thereby inducing caspase-3 expression and reduction of
ATP levels, while decreasing the expression of several inflamma-
tory cytokines (IL-1𝛽, IL-6, and TNF-𝛼), which led to cell shrink-
age and formation of apoptotic bodies.[227] The anticancer prop-
erties of SeNPs stabilized with another fungus polysaccharide,
PUP, were also studied. PUP-SENPs successfully inhibited sev-
eral cancer cell lines (HT29, HeLa, HepG2, and MDA-MB-231)
proliferation in a dose-dependent manner, with no apparent tox-
icity towards normal cells. PUP-SeNPs exhibited the highest cy-
totoxic properties toward MDA-MB-231 (breast cancer cell line),
with an IC50 of 6.27 × 10−6 m. PUP-SeNPs enhanced ROS stress,
leading to Bax upregulation, PARP cleavage and induction of cas-
pases 3, 8, and 9, suggesting activation of both intrinsic and ex-
trinsic apoptosis pathways, which resulted in morphologic cel-
lular dysfunctions, such as loss of intercellular contact and cell
shrinkage, with increased early and late apoptosis.[144]
SeNPs conjugated with HA also shown in vivo antiprolifera-
tive assays against hepatocellular cancer cells. 4.32 mg kg−1 HA-
SeNPs show antitumor effects, while preventing the side-effects
demonstrated with 5-Fu treatment, such as leukopenia and in-
creased AST and ALT activities, by stabilizing the levels of SOD
in the liver and reducing the formation of MDA.[30]
FA-SeNPs have been shown to inhibit MCF-7 breast cancer
cells at an inhibitory concentration (IC50) of 2.47 µg mL
−1, while
presenting an IC50 of 22.52 µg mL
−1 for normal cells. After FA-
SeNPs entered the cancer cells by endocytosis mediated by the
folate receptor, they were incorporated into endocytic vesicles,
whose acidic environment protonated the carboxyl groups of the
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folate receptor, promoting the release of FA–SeNPs from endo-
cytic vesicles into the cytoplasm. Here, the NPs were incorpo-
rated into the mitochondria, causing its disruption via ROS pro-
duction, and then were transported into the nucleus, causing in-
terference on the DNA synthesis and chromatin condensation.
Therefore, FA-SeNPs induced mitochondria-mediated apoptosis
by inducing caspase-3/9 activities, increasing the intracellular
Ca2+ concentration and therefore changing the cancer cells mor-
phology by interfering with F-actin structure, causing cell arrest
at S phase and apoptosis.[131] FA-SeNPs have also shown anti-
cancer properties against 4T1 breast cancer cells, drastically de-
creasing the mortality of mice injected with this type of cancer
cell, while reducing the tumor volume.[100] FA-SeNPs were also
tested against hepatocellular cancer, inhibiting the expression of
ABC family proteins, and thereby overcoming the multidrug re-
sistance effect.
Liu et al. studied the use of FA-SeNPs for delivery of Ru
polypyridyl (RuPOP) against multidrug resistance hepatic can-
cer cells (R-HepG2). FA-SeNPs@RuPO entered the cancer cells
via nystatin-dependent lipid raft-mediated and clathrin-mediated
pathways and decreased the expression levels of ABC family pro-
teins, overcoming the multidrug resistance cancer, and having
better an antiproliferative effect for drug-resistant HepG2 (IC50
of 0.24 ± 0.02 × 10−6 m) than HepG2 (0.33 ± 0.02 × 10−6 m). FA-
SeNPs enhanced ROS production, increasing the expression and
phosphorylation at Ser 15 site of p53. Also, p-ATM, p-BRCA1 and
phosphorylated histone H2A.X were also elevated, which sug-
gested that FA-SeNPs induced apoptosis by ROS-modulated p53
phosphorylation. The levels of caspase-8/9 and PARP cleavage
were also enhanced, which indicated apoptosis through extrin-
sic and intrinsic pathways, and cell cycle arrest at sub-G1 phase
cycle. In vivo studies have also shown that FA-SeNPs had fewer
liver side-effects than SeMet and selenite treatment, presenting
much higher LD50 values (1000.3 ± 52.0 vs 30.5 ± 3.0 and 31.1 ±
4.3 mg Se kg−1, respectively). FA-SeNPs also have less influence
on ALT, AST and LDH levels and diminish liver hypertrophy and
fatty degeneration.[130]
Functionalization of SeNPs with ferulic acid (Fer) was per-
formed by Cui et al. Fer-SeNPs had an IC50 value of 11.5 ± 3.6 µg
mL−1 against HepG-2 cells. Fer–SeNPs act by enhancing ROS
stress and decreasing mitochondrial membrane potential, which
contributed to cytochrome c release and activation of caspases-
3/9, resulting in apoptosis through the intrinsic pathway. Fer-
SeNPs have also shown potential to bind to DNA.[31]
Yanhua et al. demonstrated the potential of Se incorporated
into hydroxyapatite (HAT) lattice, through phosphate ion ex-
change against hepatocellular carcinoma. HAT is the most com-
mon inorganic mineral in the hard tissues of animals and HAT-
NPs demonstrated antitumor properties. Se substituted HATNPs
(SeHATNPs) downregulated the expression of Ki-67, vascular en-
dothelial growth factor (VEGF), and matrix metallopeptidase 9
(MMP-9), proteins associated with malignant behavior, vessel for-
mation (angiogenesis), and development of metastases, respec-
tively. SeHATNPs also caused calcium deposition in cancer cells,
activating calpain protein and increasing ROS stress causing cell
arrest at S-G2/M phase, inducing both necrosis and apoptosis of
malignant cells. In vivo studies show that SeHATNPs not only
had the capability of destroying tumor cells, but also protected
the heart, liver, and kidney.[228] Wang et al. also studied the poten-
tial of SeHATNPs against bone tumor, one of the most prevalent
cancers among children and adolescents. SeHATNPs enhanced
ROS stress, causing mitochondria dysfunction and cytochrome
c release, activating caspase-3 and intrinsic apoptosis pathway as
well. Also, SeHANPs enhanced caspase-8/9 and truncated Bid
(cleaved by caspase-8), indicating that apoptosis also occurred
through the extrinsic pathway. Therefore, in vivo assays show re-
duced tumor volume, while protecting healthy tissues and filling
the bone defect generated from bone tumor removal.[229]
Other studies reveal SeNPs also inhibit tumor-associated vas-
culature. Since Ru have already been shown to inhibit the pro-
liferation of endothelial cells, Sun et al. studied the antiangio-
genetic properties of Ru–SeNPs. Ru–SeNPs stabilized by gallic
acid not only induced cancer cells and vein endothelial cells apop-
tosis but also inhibited the phosphorylation and activation of
FGFR1 and its downstream molecules, ERK and AKT, that are
correlated to tumor growth and angiogenesis. Therefore, Ru–
SeNPs show synergic activity when inducing conformal changes
in basic fibroblast growth factor (bFGF), a pathologic angiogenic
activator, demonstrating in vitro inhibitory activity against tube
formation of endothelial cells and inhibiting their migration.[230]
Another study showed that the introduction of Se into Ru com-
plexes (Se-Ru) may be a potential tool for cancer theragnosis since
Ru is a luminescent metal. Ru conjugates containing Se shown
to protonate under tumor acid environment and turns into its
activated product. Activated Ru-Se induced ROS and mitochon-
drial dysfunction, leading to Bax upregulation, Bcl-2 downreg-
ulation, and increase of cytoplasmatic Ca2+ from endoplasmic
reticulum (ER), initiating the intrinsic apoptosis pathway and
cell arrest at Sub-G1 phase and DNA fragmentation. Also, RuSe
exhibited florescent signals in vivo, making the visualization of
Ru-Se complexes biodistribution and its use as a theragnostic
agent possible.[231] Also, Sun et al. produced Ru-thiol protected
SeNPs (Ru-MUA@SeNPs), with not only anticancer and antian-
giogenetic properties, but also with fluorescence imaging prop-
erties in vivo and ex vivo. These NPs entered into HepG2 cells
(hepatocarcinoma cell line) through clathrin-mediated endocy-
tosis, and eventually escaped the lysosomes, developing a dam-
age in several organelles, such as the nuclear envelope, besides
enhancing the production of ROS, decreasing the mitochondria
membrane potential, leading to apoptosis. In vivo fluorescence
studies showed that Ru-MUA@SeNPs mostly accumulate in the
tumor, liver, and kidneys in the first 4 h after injection, devel-
oping an inhibitory effect toward tumor growth and the forma-
tion and motility of surrounding blood vessels, by suppressing
VEGF.[104]
Hauksdóttir et al. recently studied the antitumor potential of
SeNPs combined with iron oxide NPs (IONPs) that due to their
magnetic properties, can specifically target tumor areas using
magnets and can be also applied on magnetic resonance imag-
ing (MRI). The most promising Se:IONPs consisted of IONPs,
produced by thermal decomposition followed by a silane ligand
exchange, coated with chitosan and Se, wherein Se aggregation
and precipitation onto IONP’s surface was promoted by the Chi-
tosan positive charge. These Se:IONPs had a size of 5–9 nm in
diameter, a 𝜁 -potential of 29.59 mV, and magnetic properties of
35.932 emu g−1. Se:IONPs reduced the viability of breast cancer
cells, however the study itself did not clarify the mechanisms be-
hind the antitumor activity.[232]
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Figure 23. TPP-SeNPs presents antiproliferative properties against HeLa cells by increasing ROS production and inducing mitochondria dysfunction:
a) HSA@SeNPs or HSA-TPP22@SeNPs labeled with fluorescein isothiocyanate isomer I (FITC) (green) were introduced to HeLa cells and the fluores-
cent labels MitoTracker Deep Red (red)—mitochondria—and Hoechst 33342 (blue)—nuclei were added. It was observed that, although SeNPs@FITC
(green) exhibited no overlap with the mitochondria (red), incubation with TPP-SeNPs@FITC presented 34.7% colocalization signals between green
(TPP-SeNPs@FITC) and red (mitochondria) channels, with the presence of a yellow color in the “combined” channel, proving that TPP increased
the mitochondria-targeting ability of SeNPs. b) HeLa cells were incubated with both SeNPs and TPP-SeNPs and stained with 2′,7′-dichlorofluorescein
diacetate (DCFH-DA) to detect ROS. It was observed that increasing the amount of TPP groups enhanced the ROS production. c) 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazole carbocyanide iodide (JC-1) (green and red) probe was used to analyze the mitochondrial damage induced by SeNPs
and TPP-SeNPs. It was observed that blank cells without SeNPs treatment only presented a red color, typical of healthy mitochondria. Although SeNPs
presented some dose-dependent intensity of the green emission, correspondent to damaged mitochondria, treatment with TPP-SeNPs highly increased
green emission and therefore could induce mitochondrial damage more effectively, with enhanced cytotoxicity effect. Reproduced with permission.[233]
Copyright 2020, Royal Society of Chemistry.
More recently, Zhuang et al. functionalized SeNPs with triph-
enylphosphine (TPP) groups, an organic compound that specif-
ically target mitochondria, and analyzed its antiproliferative
potential against cervical carcinoma cells. TPP-SeNPs demon-
strated their ability to specifically target the cancer cells mito-
chondria (Figure 23a), inducing ROS generation (Figure 23b)
and mitochondria dysfunction (Figure 23c), having better anti-
cancer properties than nonfunctionalized SeNPs. However, nor-
mal and cancer cells demonstrated the same cellular uptake
level, being that the in vitro SeNPs anticancer effect was ex-
plained by the overproduction of ROS and by the fact that the
mitochondria transmembrane potential in cancer cells is higher
than in normal cells, making them more susceptible to TPP-
SeNPs cytotoxic effect. Also, Zhuang et al. argued that due
to the EPR effect, TPP-SeNPs will be more prone to accumu-
late in tumor environments and that the SeNPs existing within
healthy tissues could serve as a long-term chemopreventive
supplement.[233]
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SeNPs supplementation also demonstrated in vivo to be ben-
eficial when conjugated with aerobic physical exercise.[234,235]
SeNPs, when conjugated with physical exercise, increase T-
helper 1 (Th1)-like cell production in splenocytes in mice carry-
ing the 4T1 mammary cancer. The mechanism behind is linked
to the activation of TNF-𝛼 and oncostatin, both anticancer cy-
tokines, by physical exercise and the increase of interferon-
gamma levels by SeNPs. Since Th cells are responsible for start-
ing an antitumor responsive, the combination of SeNPs sup-
plemented by aerobic physical exercise may be a promising ap-
proach to decrease the tumor volume.[234] Moreover, SeNPs and
aerobic physical exercise demonstrated a synergic effect to reduce
cachexia symptoms and muscle degeneration in 4T1 breast can-
cer mice, while decreasing inflammation and enhancing TNF-𝛼,
IL-10, and IL-15 expression, which results in immune stimula-
tion towards cancer cells.[235]
4.5.2. Combination Therapy
In addition to the functionalization of SeNPs, several other stud-
ies demonstrated that SeNPs have synergic and protective proper-
ties when loaded with already approved chemotherapeutic drugs
(Table 6).[36,175] For example, Liu et al. used PEG-SeNPs for
the delivery of sesamol that although it has antioxidant, anti-
inflammatory, and anticancer properties, its low stability and oral
bioavailability, and fast elimination limits its use. Sesamol was
conjugated onto the PEG-SeNPs surface by stirring at room tem-
perature for 48 h. Spherical PEG-SeNPs@Sesamol was shown to
have antitumor activity against HepG2 cells with an IC50 value
of 68.7 µg mL−1, six times lower than PEG-SeNPs, indicating
a synergetic potential between sesamol and PEG-SeNPs. PEG-
SeNPs@Sesamol triggered ROS stress in cancer cells and mi-
tochondria dysfunction, initiating the intrinsic apoptosis path-
way, by activating caspases-3/9, decreasing Bcl-2 expression, and
upregulating Bax and PARP, which led to chromatin condensa-
tion, DNA fragmentation, and apoptosis.[134] Mary et al. have also
demonstrated the synergic anticancer properties of PEG-SeNPs
carrying Crocin, a substance known by its antioxidant, anxiolytic,
neuroprotective, and antitumor effects, against lung cancer. PEG-
SeNPs@Crocin induced apoptosis in A549 cells, with an IC50
value of 18.6 × 10−6 m for 24 h and 7.9 × 10−6 m for 48 h, by ac-
tivating the intrinsic mitochondrial apoptosis pathway, reducing
the tumor volume and weight in mice without present significant
side effects.[137] Also, concomitant administration of stabilized
SeNPs and N-Acetyl-L-cysteine (NAC) has shown advantages in
the treatment of peritoneal carcinomatosis. NAC is a ROS scav-
enger and a precursor for GSH biosynthesis, which can have both
antioxidant properties or can boost SeNPs oxidant and anticancer
properties. Therefore, although in vivo studies demonstrated that
SeNPs had potential anticancer properties against H22 cancer
cells (hepatocellular carcinoma cell line), decreasing the cancer
cells proliferation and the mice body weight, with a longer sur-
vival time than cisplatin, NAC increased SeNPs-induced ROS
production and, thereby, increased the SeNPs anticancer poten-
tial in both in vitro and in vivo studies. It was proposed that NAC
enable intracellular GSH biosynthesis, by increasing the supply
of thiols in the form of a cysteine sulfhydryl group, the main GSH
component. GSH has an important role in SeNPs biotransforma-
tion and consequent ROS overproduction in cancer cells, leading
to apoptosis and higher proliferation inhibition of cancer cells.
Also, NAC thiol groups can also directly enhance redox cycling of
SeNPs, with increased ROS production. While SeNPs adminis-
tration at the dosages of 5 or 6 mg kg−1 led to 25 or 50% survival
in healthy animals, coadministration with NAC (250 mg kg−1)
enhanced the survival to 87.5 or 100%, indicating that NAC re-
duced SeNPs lethality as well.[236] Bidkar et al. showed that SeNPs
stabilized with pluronic F-127 and loaded with paclitaxel (PTX)
inhibit the growth of A549, HeLa, HT29 and MCF7 cells with
IC50 values of 13.8 × 10−6, 8.7 × 10−6, 4.8 × 10−6, and 5.4 × 10−6
m, respectively, which represents an improved antitumor activ-
ity when compared with unloaded SeNPs. SeNPs@PTX induced
apoptosis by two main mechanisms. The first one, related to
SeNPs, consists in the production of ROS and destabilization of
the mitochondrial membrane, causing a release of Cytochrome
C into cytoplasm and activation of caspase-3, inducing the in-
trinsic apoptosis pathway. The other mechanism, associated with
PTX, consists in its binding to the microtubulin 𝛽-subunit, caus-
ing cycle arrest at G2/M phases. However, SeNPs@PTX inhib-
ited the proliferation of both normal and cancer cells, thereby
it would need an improved functionalization to specifically tar-
get these nanoparticles toward cancer cells.[237] Further studies
on PTX-SeNPs functionalized with HA (HA-SeNPs@PTX). HA-
SeNPs@PTX show inhibition activity against lung cancer cells,
being taken up into A549 cells through clathrin-mediated endo-
cytosis, and triggering Sub-G1 cell arrest and apoptosis, by en-
hancing the intrinsic apoptosis pathway (activation of caspase-3
and cleavage of PARP). Moreover, HA-SeNPs@PTX also inhib-
ited the migration and invasion of cancer cells. On top of that,
HA-SeNPs@PTX was demonstrated to be biocompatible, not be-
ing toxic to the heart, liver, spleen, lung, and kidney of mice.[29]
Also, SeNPs loading DOX were also studied in several
articles.[36] For example, HA-Se@DOX exhibits antitumor ac-
tivity against cervical carcinoma cells. HA-Se@DOX targeted
the cancer cells via CD44 and were internalized by clathrin-
mediated endocytosis (Figure 24-I). Once inside tumor cells, HA-
Se@DOX enhanced ROS stress (Figure 24-II) and caspase-3 ac-
tivation, leading to the activation of pro-apoptotic proteins Bim,
Bak, Bad, and Bax, and downregulating the anti-apoptotic Bcl-
2 and ki67 that are linked to cancer cell growth (Figure 24-III).
HA-Se@DOX was demonstrated to have better antitumor activ-
ity than SeNPs@DOX and DOX, probably due to the enhanced
cellular uptake provided by HA-specific connection to CD44. In
vivo assays also show that DOX side effects were reduced and
that the body weight of mice treated with HA-Se@DOX slightly
increased.[120] Xia et al. demonstrated SeNPs@DOX antitumor
effects against lung cancer cells, when functionalized with the
cycle peptide RGDfC. RGDfC-SeNPS@DOX were internalized
into cancer cells by clathrin-mediated endocytosis, inducing cell
arrest at sub-G1 phase, apoptosis and inhibiting the motility
and migration of cancer cells, showing better anticancer proper-
ties than DOX alone.[152] Similar to RGDfC, RGD functionaliza-
tion of SeNPs@Dox was also studied as an anticancer nanosys-
tem. RGD bound to the integrin expressed in vein endothelial
cells, thereby improving the cellular uptake of RGD-SeNPs@Dox
and preventing angiogenesis. RGD-SeNPs@Dox demonstrated
antiproliferative properties against breast cancer, by enhanc-
ing ROS stress. The levels of PARP cleavage increased and
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Table 6. Mechanisms behind SeNPs antitumor activity when loaded with other approved chemotherapeutic agents.
Functionalization Cancer cell type Endocytosis
mechanism
Biochemical mechanism Effects Refs.
Paclitaxel




Apoptosis and cell cycle arrest
at G2/M phase
[237]
HA Lung cancer Clathrin-mediated ↑ Caspase-3 and PARP
cleavage














- Melanoma Clathrin- and caveolae
mediated
↑ ROS stress, mitochondria
disfunction, cytochrome c,
caspase-3/8/9










Potential theragnostic agent [239]
Anisomycin
- Hepatocarcinoma Macropinocytosis and
clathrin-mediated
↑ phosphorylation of p21,
p27, p53 and p73;
caspase-3/8/9
↓ CDK2 and ICBP90




MUN Kidney – ↓ ROS stress, mitochondria
dysfunction, caspase-3
activity
↓ DNA fragmentation, cell
cycle arrest at sub-G1 phase,
apoptosis




- Liver and bone – ↓ ROS stress and lipid
peroxidation






















Apoptosis and cell cycle arrest
at S phase





HA Cervical cancer Clathrin mediated ↑ ROS stress and caspase-3
↑ Bim, Bak, Bad and Bax,
↓ Bcl-2, Ki67
Apoptosis
↓ Side effects compared with
DOX treatment
[120]
RGDfC Lung cancer Clathrin mediated – Apoptosis and cell cycle arrest
at sub-G1 phase
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Table 6. (Continued).
Functionalization Cancer cell type Endocytosis
mechanism







RGD Breast cancer – ↑ ROS stress, PARP cleavage
and caspase-3/8/9
↑ Phosphorylation of ATM,
ATR and p53











Clathrin-mediated ↑ caspase-3 and pp53, Bad
and Bax
↓ Bcl-xL







– ↑ Caspase-3 and PARP Apoptosis and drug resistance
reversion
[41]














↓ Bcl-xl and ERK
Apoptosis and cell cycle arrest
at sub-G1 phases
[119]
caspase-3/8/9 were upregulated, leading to DNA fragmentation,
chromatin condensation, and apoptosis through both intrinsic
and extrinsic pathways. Also, phosphorylation of the cell cycle
regulators ATM, ATR, and p53 was also observed, indicating that
RGD-SeNPs@Dox effectively caused DNA damage. On the other
hand, cyclin A and CDK2 were downregulated, inducing cell cycle
arrest at S phase, and VEGF-VEGFR2-ERK/AKT signaling axis
was also inhibited, indicating a successful decrease in cell mi-
gration and angiogenesis. In vivo studies also demonstrated that
this nanosystem reduced DOX cardiotoxicity and hepatotoxicity,
while this prolonged its blood circulation.[24]
SeNPs@DOX functionalized with GA were also studied
against hepatocellular carcinoma cells. GA is recognized by
the asialoglycoprotein receptors on cancer cells, enhancing the
SeNPs uptake by clathrin-associated endocytosis. After GA-
SeNPs@DOX enters the lysosomes, DOX is released due to the
acidic environment. GA-SeNPs@DOX escaped lysosomes to cy-
toplasm and acted by enhancing caspase-3 and phosphorylated
p53 (pp53) activity, therefore downregulating Bcl-xL and upregu-
lating Bad and Bax. Therefore, GA-SeNPs@DOX induced DNA
fragmentation, cycle arrest at sub-G1 phase and apoptosis, while
presenting insignificant side effects in the heart, liver, spleen,
lung, and kidney in vivo.[146] SeNPs@Dox were also studied
against ovarian cancer. SeNPs@Dox functionalized with FA and
chitosan show antitumor properties against both DOX-sensitive
and resistant ovarian cancer cells. FA-Chitosan-SeNPs@DOX
were internalized in tumor cells by folate-receptor mediated en-
docytosis and induced caspase-3 and PARP activation, leading to
changes in the cellular shape and adherence, which ultimately
led to apoptosis. FA-chitosan-SeNPs@Dox demonstrated to have
higher IC50 toward DOX-sensitive cancer cells (1.0 × 10−6 m)
than the resistant ones (0.89 × 10−6 m), which indicates that FA-
Chitosan-SeNPs@Dox could overcome the drug resistance.[41]
Also, Zhao et al. show the synergic antiproliferative activity of
mesoporous Se (MSe) when loaded with DOX in its frame-
work and stabilized with human serum albumin (HSA) (HSA-
MSe@DOX) against MCF-7 cells (breast cancer cell line). HSA
interacted with SPARC, a protein overexpressed in several types
of cancer, and enabled the entry of HSA-MSe@DOX into can-
cer cells via micropinocytosis and clathrin-mediated endocytosis,
and, after escaped the lysosome, was partly found in the nucleus,
causing cancer cells apoptosis. HSA-MSe@DOX presented
lower IC50 values (2.1 ± 0.3 × 10−6 m) than MSe (14.8 ± 0.2 × 10−6
m), HSA-MSe (9.9 ± 0.3 × 10−6 m), DOX (5.9 ± 0.4 × 10−6 m) and
MSe@DOX (4.6 ± 0.2 × 10−6 m), which suggested a probable
antitumor synergic activity. Also, in vivo imaging using tumor-
bearing mouse demonstrated that HSA-MSe@DOX presented
the highest DOX fluorescence in tumor sites and the lowest DOX
accumulation in the liver and kidneys, compared to free DOX and
MSe@DOX, probably due to the HSA targeting effect, demon-
strating also the highest reducing effect in tumor weight.[154]
Functionalization of SeNPs@DOX with chitosan and Tf were
also studied. Since Tf receptors are mainly overexpressed in
cancer cells, Tf-chitosan-SeNPs@DOX shows higher antiprolif-
erative assays toward the cancer cells studied (A375, HepG2,
and MCF-7) than endothelial cells. Tf-chitosan-SeNPs@DOX
uptake was performed by both dynamin-dependent lipid raft-
mediated and clathrin-mediated endocytosis. When inside the
lysosome, the acid environment protonated the amino groups
of the chitosan, leading to its dissolution and DOX release.
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Figure 24. Antiproliferative properties of HA-Se@DOX: (I) Using fluores-
cence microscopy, it was possible to observe that HA-Se@DOX uptake
was highly increased in a) HeLa cells compared to b) HUVEC, probably
due to the CD44-mediated specific targeting performed by HA. (II) Using
DCFH-DA staining, it is possible to observe that HA-Se@DOX incuba-
tion induced the highest ROS production in HeLa cells when compared
to Se@DOX and DOX. (III) Immunohistochemistry studies indicate that
HA-Se@DOX were the most effective in diminishing Ki67-positive cancer
cells, while enhancing caspase-3 activity, compared to Se@DOX and DOX,
thereby demonstrating greater antitumor properties compared with DOX
or Se@DOX. Reproduced with permission.[120] Copyright 2020, Elsevier.
Tf-chitosan-SeNPs synergistically enhanced ROS stress, thus
causing mitochondria dysfunction and activation of apoptosis-
induced proteins such as Bad, PARP, caspase-3/8/9, Bid, p53
and p38 and downregulating the expression of Bcl-xl and ERK,
without affecting the expression of Bax and Bcl-2, suggesting
that apoptosis occurred via both extrinsic and intrinsic pathways,
by activation of p55 and MAPK pathways, causing cell arrest
at sub-G1 phases.[119] Another study concerning the antitumor
activity of Se-functionalized liposomes (LPs) for DOX delivery
(SeLPs@DOX) into tumor cells, showed that this delivery strat-
egy had synergic activity towards lung adenocarcinoma cells, with
an IC50 value of 0.92 ± 0.16 µg mL−1. SeLPs@DOX entered into
the cells via clathrin-mediated endocytosis and micropinocytosis
and induced apoptosis. SeLPs@DOX were shown to reduce the
DOX cardiotoxicity and to improve its pharmacokinetics proper-
ties in vivo.[238]
Gao et al. studied SeNPs antitumor potential when loaded
with irinotecan against HCT-8 cells (ileocecal colorectal adeno-
carcinoma). These two compounds show synergic antitumor ac-
tivities, activating caspase-7/8/9 and their substrate PARP and
upregulating p53, resulting in DNA fragmentation and apopto-
sis. Also, their conjugation reduced irinotecan toxicity, including
weight loss, hepatic damage, neutropenia, anemia, and throm-
bocytopenia, while reducing the tumor growth in mice, due to
Se protective properties. Se inactivated Nrf2 and downregulated
Prx1 in tumor tissues while enhancing their expression in nor-
mal cells. Since activated Nrf2 translocates into the nucleus and
activates the expression of cytoprotective phase II detoxifying en-
zymes and antioxidants, and Prx1 is linked to resistance to several
chemotherapeutic drugs, Se not only protected normal cells from
irinotecan toxicity, but also enhanced its activity towards tumor
cells.[39]
The synergism between 5-Fu and SeNPs was studied against
melanoma. 5-Fu capped SeNPs through Se─O and Se─N bonds
and physical adsorption, which stabilized SeNPs, and prevented
their aggregation and precipitation. 5-Fu also increased cellular
uptake of SeNPs by A375 (melanoma) cells, via both clathrin-
and caveolae-mediated pathways. Once inside the cells, 5Fu-
SeNPs escaped the lysosomes and were released into the cyto-
plasm, inducing mitochondria dysfunction via ROS stress, cy-
tochrome c release and, therefore, activation of caspase-3/8/9,
leading to DNA fragmentation and nuclear condensation, cell ar-
rest at sub-G1 and initiating both extrinsic and intrinsic apop-
tosis pathways. Fu-SeNPs not only inhibited A375 cell lines,
but also MCF-7, HepG2, Colo201, and PC-3 cancer cells with
IC50 values varying from 6.2 × 10−6 to 14.4 × 10−6 m.[37] A fur-
ther study indicated that 5Fu-SeNPs had higher cytotoxic effects
against MCF7 (hormone-dependent breast cancer cell line) and
Caco-2 (colon adenocarcinoma) than MDA-MB-231 (hormone-
independent breast cancer cell line) and HCT 116 (colon can-
cer cell line) cancer cells. 5Fu-SeNPs inhibited the glucose trans-
porters, thus decreasing the intracellular glucose. Se increased
ROS levels and also influenced zinc concentration, thereby in-
ducing apoptosis in breast and colorectal cancer cells.[102] Fur-
thermore, SeNPs loaded with 5-Fu, and functionalized with
cetuximab, to target epidermal growth factor receptor (EGFR) in
cancer cells, polyamidoamine (PAMAM) and 3,3’-dithiobis (sul-
fosuccinimidyl propionate) (DTSSP) as intratumoral GSH re-
sponse agents, and gadolinium (Gd) chelate as the MRI agent,
were developed, using tween-80 as stabilizer, due to its steric
properties and hydrogen bond effect. PAMAM enabled the NPs
to be pH-sensitive. Gd, the magnetic contrast agent, and 5-Fu,
an antitumor drug, were linked to SeNPs by electrostatic inter-
action, and Se─O and Se─N bonds. These nanoplatforms had a
size of 71.4 nm and demonstrated stability in fetal bovine serum
and Dulbecco’s modified Eagle medium within 84 h. The NPs
were shown to be safe, not causing any alteration in the mor-
phology of erythrocytes, and to have powerful anticancer activ-
ity against nasopharyngeal carcinoma cells, by preventing their
proliferation, migration, and invasion. The nanoplatforms pro-
duced by Huang et al. entered into the cancer cells by dynamin-
related lipid raft-mediated endocytosis. Once inside the cell, the
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disulfide bond in DTSSP and the PAMAM protonated under the
GSH acidic environment, inducing SeNPs release, demonstrat-
ing a dual pH-sensitive activity. Also, using MRI analysis in mice
intravenously administered with these Se nanoplatforms, it was
possible to observe a considerable brightening phenomenon, es-
pecially in the tumor region, demonstrating their theragnostic
potential, as promising contrast agents for MRI.[239]
Xia et al. demonstrated the synergic effects in loading ani-
somycin (Am) into SeNPs (SeNPs@Am) against hepatocarci-
noma cells. SeNPs@Am uptake into cancer cells was size-
correlated and occurred via macropinocytosis and clathrin-
mediated endocytosis pathways. Once inside lysosomes, Am
molecules were protonated and released from SeNPs. Phospho-
rylation of p21, p27, p53, and p73 were all elevated, which re-
sulted in CDK2 inhibition, and ICBP90 degradation through
a ubiquitination-dependent protease. Since both CDK2 and
ICBP90 control cell cycle progression, their inhibition resulted
in cell cycle arrest at sub-G1 phase. Also, SeNPs@Am enhanced
the cleavage and activation of caspase-3/8/9, leading to apopto-
sis. SeNPs@Am exhibited more antitumor potential than SeNPs
and Am alone, which suggests the existence of synergy between
these two compounds.[240]
SeNPs demonstrated not only synergic effects, but also protec-
tive properties against chemotherapy drugs’ side effects. For ex-
ample, SeNPs are shown to reduce cell death caused by cisplatin
in HK-2 proximal tubular cells. SeNPs were functionalized with
1-mercapto-1-undecanol (MUN), a thiol compound with antiox-
idant properties, producing spherical MUN-SeNPs through for-
mation of a Se─S bond. MUN-SeNPs were shown better physi-
cal and antioxidant properties than bare SeNPs, decreasing the
ROS stress caused by cisplatin treatment, decreasing mitochon-
dria dysfunction and caspase-3 activation, which translated into
less DNA damage, nucleus damage, and apoptosis of noncancer
cells. The percentage of cell arrest at sub-G1 phase and cytoplas-
mic shrinkage decreased, which demonstrated the antagonist ef-
fect of the MUN-SeNPs against cisplatin-induced renal injury
through ROS scavenging.[241] More recently, Barbanente et al.
developed a nanosystem consisting of selenite-doped HANPs
loaded with a cytotoxic platinum complex, which demonstrated to
have an acidic-induced release of selenite. This nanocomplex has
shown antiproliferative properties against both human prostate
and breast cancer cells, without compromising the proliferation
of bone marrow stem cells, when the Pt/Se ratio was higher than
2, while lower rate numbers demonstrated to result in high toxi-
city towards bone marrow stem cells. However, the adsorption of
the platin complex was reduced by the amount of selenite incor-
porated into the HA matrix.[242]
In vivo studies also demonstrated that SeNPs were able to
prevent the side effects of cyclophosphamide treatment, such
as liver damage and bone marrow dysfunction. Concomitant
administration of SeNPs with cyclophosphamide is shown to
decrease ROS levels and lipid peroxidation in hepatocytes and
bone marrow cells, which indicated that SeNPs diminished cy-
clophosphamide hepatotoxicity and immunotoxicity, which was
verified by the diminution of ALT and AST levels and improve-
ment of hemoglobin, white blood cells count and red cell dis-
tribution width values. SeNPs also diminished DNA fragmenta-
tion and chromosomal aberration caused by cyclophosphamide.
Moreover, SeNPs enhanced the activity of SOD, CAT, and GPx,
which are involved in ROS scavenging. Interestingly, cyclophos-
phamide antitumor activity was enhanced when administered
concomitantly with SeNPs: ROS stress and consequent apoptosis
of cancer cells increased, and tumor-associated neovasculariza-
tion and MMP-9 decreased. Consequently, the concomitant ad-
ministration decreased the tumor volume in mice, increasing the
mean survival time. Therefore, SeNPs enhanced the antitumor
effect of cyclophosphamide at the same time that diminished its
side effects, such as hepatotoxicity and genotoxicity.[243]
SeNPs also displayed potential for oridonin loading and tar-
geted delivery for esophageal carcinoma, using GE11 as function-
alizing agent. GE11-SeNPs@Oridonin had high positive charge,
enhancing its cellular uptake into KYSE-150 cells by dynamin
mediated lipid raft endocytosis and clathrin-mediated endocy-
tosis, and, after escaping the lysosomes, this nanosystem en-
hanced ROS stress and decreased mitochondria membrane po-
tential, reducing Bcl-2 expression and activating caspases-3/9
and Bax, causing F-actin and nuclei disruption, which led to
cell arrest at S phase and apoptosis. GE11-SeNPs@Oridonin
also downregulated PI3K/AKT and Ras-Raf-MEK-ERK pathways,
decreasing EGFR levels, and reduced CD31, thereby inhibit-
ing angiogenesis. In vivo studies in mice also showed that
GE11-SeNPs@Oridonin increased cellular uptake in cancer cells
and significantly reduced the tumor growth, without affecting
the body weight and vital organs. The treatment with GE11-
SeNPs@Oridonin also increased both IL-2 and TNF-𝛼 produc-
tion, signaling the immune system toward the tumor cells.[150]
SeNPs have been also studied in chemoradiotherapy, showing
synergic effects when used concomitantly with radiation, in or-
der to reduce treatment cycles, cancer recurrences, and the side
effects characteristic of radiation.[244–247] Recently, Tian et al. ana-
lyzed the potential of SeNPs combined with radiotherapy against
lung cancer cell lines, concluding that the combined therapy re-
sulted in increased the apoptosis of cancer cells, while prevent-
ing their migration and invasion, by inhibiting CCND1, c-myc,
MMP2 and MMP9, proteins associated with cancer cell prolif-
eration and invasion. Moreover, the expression of proapoptosis
proteins, such as caspases-3/9, was enhanced.[247]
Also, PEG-SeNPs were demonstrated to potentiate lung can-
cer cells’ sensitivity to X-rays. The combination of PEG-SeNPs
with radiotherapy showed synergic effects, increasing dramati-
cally the ROS stress and the activation of caspase-3, leading to
higher apoptosis rate of cancer cells.[244] Another study demon-
strated the synergic potential of concomitant application of FA-
SeNPs and radioactive 125I seeds. FA-SeNPs demonstrated to sen-
sitive breast cancer cells to this radioisotope, increasing ROS
generation, thereby inducing the phosphorylation of MAPK pro-
teins, such as p-p38, p-JNK, and decreasing the expression of
p-ERK. PARP phosphorylation was also upregulated, leading to
cell cycle arrest at G2/M phases. Therefore, concomitant used
of FA-SeNPs and 125I seeds resulted in higher anticancer ef-
fects than FA@SeNPs and 125I seeds used separately. In vivo as-
says show that this combined therapy decreased tumor growth
and volume, without presenting side effects in the main or-
gans, or changes in blood urea nitrogen, LDH, AST and albumin
values.[245]
SeNPs were also studied for photothermal therapy (PTT),
which uses light energy for anticancer applications and is usu-
ally used for the treatment of superficial and small tumors.[248]
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SeNPs functionalized with PG-6 and RC-12, a derivative of
RGD and a cell-penetrating peptide (CPP) that recognizes in-
tegrin receptor overexpressed in cancer cells. PG-6 is identi-
fied by MM2 and MM9 in the cancer microenvironment. This
nanosystem was shown to produce heat and release DOX when
irradiated with near infrared (NIR) light. Under NIR radia-
tion, RC-PG-SeNPs@DOX shown morphologic changes, such
as decreased size from 116 to 51.2 nm and structure col-
lapse, which triggered the release of DOX. The temperature
of RC-PG-SeNPs@DOX was mainly positively influenced by
their concentration and the density of light radiated. RC-PG-
SeNPs@DOX also shown to have more toxicity towards hep-
atic cancer cells (IC50 value of 10.7 × 10−6 m) than healthy cells
(IC50 value of 24.4 × 10−6 m). RC-PG-SeNPs@DOX entered
into the cancer cells by dynamin-mediated lipid raft endocytosis
and clathrin-mediated endocytosis pathways and quickly overpro-
duce ROS species, thereby causing apoptosis and inhibiting cell
migration.[125] Wang et al. produced a Se-nanosystem consisting
of ultrasmall Se particles@porous-silica-folic acid-copper sulfide
nanocomposites loading DOX (Se@SiO2-FA-CuS/DOX) for syn-
ergic photothermal therapy and chemotherapy. This nanosystem
presented a low release profile at physiologic pH while under
acidic conditions, similar to the cancer environment, the release
was much faster, especially under NIR laser exposure. In vitro as-
says demonstrated that this nanosystem, particularly when under
laser irradiation, showed antiproliferative activity toward cancer
cell lines, in concentrations nontoxic to endothelial cells, protect-
ing them from DOX toxicity. Also, in vivo assays demonstrated
that administration of Se@SiO2-FA-CuS/DOX and concomitant
treatment with NIR induced a more remarkable anticancer activ-
ity than DOX and Se@SiO2-FA-CuS/DOX with or without NIR,
being the only treatment to not only completely eliminate the tu-
mor, but also induce mice weight gain, without side effects in
major organs.[249] More recently, Chen et al. used tellurium (Te)
and Se salts to produce 2D TeSe-based lateral heterojunction and
study the photothermal properties of this nanosystem against
hepatocellular carcinoma, using 808 nm light of the near-infrared
region. After Se doping, uniform and biocompatible TeSeNPs
were produced, with less toxicity compared to Te nanomaterials,
while they demonstrated more stability, since Te nanowires were
degraded after 2 d preparation, where TeSeNPs at a Se:Te ratio
of 1:1 was stable for 1 month without degradation. This Se:Te ra-
tio was also considered the optimal for anticancer applications,
since the resultant TeSeNPs exhibited the highest accumulating
efficiency and cytotoxic effect toward cancer cells, compared to
the other ratios studied, without presenting any signs of toxicity
in mice at the dose of 6.0 mg kg−1. Also, this TeSeNPs was found
to have the highest photothermal efficiency, generating PTT of
60 °C and fully eliminating the tumor cells, while TeSeNPs pro-
duced using ratios Se:Te of 2:1 reached 50 °C, and only partially
decreased the tumor, which quickly rebounded. The TeSeNPs
(1:1) decreased, not only Ki67+ tumor cells, but also the neovas-
cularization, promoting hypoxia in the tumor tissues. Therefore,
Chen et al. suggested the use of these nanosystems in monother-
apy or combined with radiotherapy or other chemotherapeutic
agents.[248] Recently, Mohammadi et al. compared the combined
therapy of phototherapy and sonotherapy with Cur-SeNPs ad-
ministration for melanoma treatment. Although Cu-SeNPs re-
duced cell viability in a concentration-dependent manner, the
cells treated with only laser light showed a 7% cell viability re-
duction and the treatment with only ultrasonic waves resulted
in a 23% decrease in cell viability. However, the combined treat-
ment of 100 µg mL−1 of Cur-SeNPs with laser light or ultrasound
waves resulted in decreased cell viability of 33.9 and 22.9%, re-
spectively. This increased antiproliferative effect is explained by
the fact that Cur-SeNPs acted as a NIR light and ultrasound ab-
sorbing agent, and therefore the use of laser radiation increased
Cur-SeNPs-induced ROS overproduction along with sonotherapy
in melanoma cancer cells.[250]
Also, Zheng et al. produced a biocompatible nanocomposite
constituted by Se and bismuth and a silica shell (Se@SiO2@Bi
NCs), with anticancer properties, especially when in synergy
with radiotherapy and photothermal therapy. Se@SiO2@Bi NCs
were not only mainly accumulated at the tumor site, with pH-
dependent release, but also strongly absorbed NIR light and con-
verted it to heat, raising the temperature to 54 °C in vivo, which
could effectively kill the cancer cells, while also showing opti-
mal radiation sensibilization for cancer cells, and protecting the
healthy cells from X-ray’s damage. Therefore, the combined ther-
apy of Se@SiO2@Bi NCs with PTT and radiotherapy totally elim-
inated the cancer cells in mice after 14 d of treatment, without
major side effects, while also presenting computed tomography
imaging properties.[251]
Liu et al. also studied the potential of SeNPs for photother-
mal/photodynamic synergistic therapy. Photodynamic therapy
uses photosensitizers to induce ROS overproduction and can-
cer cell apoptosis. Liu et al. produced a nanosystem composed
by molybdenum selenide nanoparticles loaded by the photosen-
sitizer Indocyanine green (ICG), and functionalized by the active
targeting agent HA and a pH-responsive release molecule poly-
dopamine (PDA) (MoSe2@ICG-PDA-HA). The nanosystem en-
hanced ICG stability and cellular uptake and, under laser irradi-
ation, presented a better photothermal effect (around 62 °C) than
both ICG and MoSe2NPs, which indicates a possible photother-
mal synergy between ICG and MoSe2NPs. MoSe2@ICG-PDA-
HA presented anticancer properties against 4T1 mouse breast
cancer cells, by enhancing ROS production by up to three times
that of free ICG under laser irradiation, inducing also photocy-
totoxicity. In vivo assays also demonstrated that MoSe2@ICG-
PDA-HA were the most effective in inhibiting 4T1 cancer cells,
while presenting the least liver and kidney accumulation, when
compared to MoSe2@ICG-PDA and ICG, with increased nuclear
dissolution and fragmentation, and reduction of ki-67[252]
On the other hand, Xiao et al. studied the SeNPs poten-
tial for chemodynamic therapy, by synthesizing SeNP-coated in
manganese carbonate-deposited iron oxide (MCDION-Se), with
a pH-sensitive release and good biocompatibility. MCDION-Se
displayed theranostic properties, while promoting the produc-
tion of superoxide anion radicals and decreasing the ATP lev-
els, which resulted in cancer cell apoptosis, due to the synergic
activity between Se and manganese. Therefore, in vivo studies
demonstrated that MCDION-Se successfully causes cancer tis-
sue reduction and avoids drug resistance, without systemic side
effects.[253]
An Se-based nanosystem that combined immunotherapy, ra-
diotherapy, and chemotherapy approaches was also proposed
by Gao et al. This nanosystem comprised a radiation-sensitive
diselenide-containing polymer backbone, the tumor-targeting
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Figure 25. Combined therapy of PSeR/DOX and 5 Gy radiation demonstrated synergic activity towards breast cancer cell line MDA-MB-231, combining
immunotherapy, radiotherapy, and chemotherapy. a) Fluorescence microscopy images demonstrated that 5 Gy radiation treatment induced a 50% DOX
(red) release from PSeR/DOX NPs at 24 h, a value much higher than the nonradiation groups. Besides, although DOX released from the nanosystem
was mostly accumulated in the cytoplasm, the use of radiation stimulated DOX release inside the nucleus (blue). b) Hematoxylin and eosin (H&E) and
oncogene immunohistochemistry (IHC) staining demonstrate the CD49(+) NK cell infiltration within the MDA-MB-231 lung metastasis (red arrows) in
mice. Although the number of CD49b(+) NK cells was significantly decreased and an increased HLA-E expression was verified in the MDA-MB-231 lung
metastasis without treatment or with PSeR treatment, combined therapy with 5 Gy radiation resulted in HLA-E downregulation and improved CD49b(+)
NK cells count. c) TUNEL-DAPI assays, H&E staining and IHC staining was performed in the tumor tissues of mice, demonstrating that combined
treatment of PSER/DOX and radiation was the most effective in inducing cancer cell apoptosis, reducing HLA-E expression levels in tumor tissues and
enhancing NK cells infiltration in the lung metastasis foci. Reproduced with permission.[246] Copyright 2020, Wiley-VCH GmbH.
peptide RGD modified with PEG and, as a chemotherapeutic
drug, DOX (PSeR/DOX), which was also used as a theragnostic
agent. A low dose of ionizing radiation (5 Gy) induced the ox-
idization of the diselenide bond and improved DOX release in
the cancer cell nucleus (Figure 25a), with much better antiprolif-
erative properties than 5 Gy radiation, PSeR/DOX, PSeR/5Gy, or
free DOX/5Gy single treatment, suggesting the existence of syn-
ergism among the PSeR/DOX and the radiation used. Also, the
combined treatment enhanced catalase levels and deceased GPx
expression, with ROS overproduction. Furthermore, 5 Gy radia-
tion and PSeR/DOX demonstrated synergic activity in suppress-
ing human leukocyte antigen-E (HLA-E) expression in MDA-MB-
231 cancer cells, thereby blocking the interaction between HLA-
E and NK group 2A inhibitory checkpoint receptor and sensitiz-
ing this cancer cell line to NK cells (Figure 25b). In vivo stud-
ies also demonstrated that the combination therapy of 5 Gy ra-
diation and PSeR/DOX ensured NK cell lung infiltration and
anticancer response, with enhanced serum expression levels of
Granzyme B and IFN-𝛾 , improved Se concentration in the tu-
mor compared to the SeNPs average tumor concentration, and
decreased DOX blood clearance, thereby decreasing MDA-MB-
231 lung metastasis with much better results than radiation
and PSeR/DOX single-therapies, without reducing mice weight
(Figure 25c).[246]
4.5.3. Delivery of Genetic Material
Small interfering RNA has been used to inhibit the expression
level of the correspondent messenger RNA (mRNA), therefore
downregulating the expression of tumor-related proteins,[254]
being considered the best posttranscriptional gene silencing
strategy so far due to its full complementarity to mRNA.[255]
However, siRNA therapeutics are limited due to its negative
charge and instability due to nuclease degradation, which re-
sults in incapability to reach and cross the cell membrane.[254]
Recently, SeNPs have been studied as gene nanocarriers with
the goal of suppressing cellular genetic transcription and inhibit-
ing the expression of proteins associated with tumor growth,
by enhancing the delivery of genetic material while decreas-
ing its degradation (Table 7).[40,256] For example, FA-SeNPs sta-
bilized with chitosan have shown to efficiently deliver genetic
material to cancer cells, while protecting mRNA from RNase
degradation.[126]
Initial studies used SeNPs conjugated with L-/D-Arg, through
Se─NH bonds, and Ru (II) as a luminescent tracking vector,
to load siRNA. Interestingly, while D-SeNPs demonstrated a
poor capability in performing H-bonds to DNA, which resulted
in low genetic material loading and delivery, Ru-L-SeNPs ef-
ficiency loaded siRNA, protecting the genetic material from
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Table 7. Mechanisms behind SeNPs antitumor activity when loaded with siRNA.
Functionalization siRNA Cancer cell type Endocytosis
mechanism
Biochemical mechanism Effects Refs.
Ru, L-Arg MDR1 Lung cancer – ↑ p53, Bax










– ↑ ROS stress, mitochondrial dysfunction, caspase-3,





HA, PEI HES5 Hepatocellular
carcinoma
Clathrin-mediated ↓ HES5 mRNA expression
↓ CD31
Apoptosis and cell cycle
arrest at G0/G1 phases
Angiogenesis inhibition
[121]












Apoptosis and cell cycle
arrest at sub-G1 cell phase
↓ Angiogenesis
[158]
Derlin1 Cervical cancer ↓ Derlin1 gene
transcription
[151]
MEF2 Ovarian cancer ↑ ROS stress, mitochondria disruption, ↓ MEF2 gene
expression
Apoptosis and cell cycle
arrest at sub-G1 cell phase
In vivo Biocompatibility
[258]
enzymatic degradation. Therefore, Ru-L-SeNPs were used to de-
liver a siRNA targeting the MDR1 gene, responsible for the
multidrug resistance of A549R (cis-platinum resistant lung car-
cinoma cells). Ru-L-SeNPs@MDR1-siRNA successfully entered
into cancer cells, and siRNA was released into the cytoplasm. Ru-
L-SeNPs@MDR1-siRNA enhanced p53 activity, triggering apop-
tosis, DNA fragmentation, and nuclear condensation. Also, anti-
apoptotic Bcl-2 was suppressed, while proapoptotic Bax activity
was induced. Ru-L-SeNPs@MDR1-siRNA additionally inhibited
MAPKs and PI3K/AKT signaling pathways. Moreover, siRNA en-
capsulation increased its genetic silencing efficiency, decreasing
the protein levels of P-glycoprotein (P-gp), which resulted in the
reversal of multidrug resistance. In vivo studies have shown that
Ru-L-SeNPs@MDR1-siRNA were preferentially accumulated in
cancer tissues, decreasing the tumor volume, and inhibiting the
formation of blood vessels, while decreasing systemic toxicity, in-
dicating Ru-L-SeNPs@MDR1-siRNA as a vector for siRNA deliv-
ery with synergic anticancer properties.[256]
Li et al. used PEI-SeNPs to deliver the siRNA that silence
HSP70, which is overexpressed in several types of cancer, produc-
ing nanosystems that, due to their positive charge, entered eas-
ily into hepatocellular carcinoma cells. The optimal PEI-SeNPs:
HSP70 siRNA ratio was 40:1, in which almost all HSP70-siRNAs
were loaded, and the nanosystems produced were stable for at
least 30 d. PEI-SeNPs@HSP70-siRNA escaped the lysosomes
and were transported into the cytosol, inducing ROS stress and
mitochondrial dysfunction, caspase-3 activity, and PARP cleav-
age, as well as the modulation of the AKT and p53 signaling
pathways, which resulted in cytoplasmic shrinkage, loss of cel-
lular adherence, DNA fragmentation and apoptosis, without af-
fecting the cell cycle distribution. Moreover, the level of HSP70
mRNA expression was diminished, due to the downstream activ-
ity caused by HSP70-siRNA.[254]
PEI-SeNPs also demonstrated efficiency in loading siRNA tar-
geting the Hairy and enhancer of split 5 (HES5), which plays a
crucial role in cancer development. The HES5-siRNA was linked
to PEI on SeNPs surface by electrostatic interactions and after-
ward PEI-SeNPs@HES5 siRNA was then functionalized with
HA, which was responsible for active target its receptor CD44,
overexpressed on HepG2 cells. The nanosystem produced was
capable of preventing siRNA degradation from serum nucleases
and entered into the cancer cells by clathrin-mediated endocyto-
sis. HA-PEI-SeNPs@siRNA-HES5 considerably downregulated
the mRNA expression of HES5 in HepG2 cells and caused cy-
cle arrest at G0/G1 phases. Also, HA-PEI-SeNPs@siRNA-HES5
could efficiently inhibit angiogenesis, which was reflected by the
decrease of CD31 levels. In vivo studies demonstrated that HA
could direct the nanosystems towards tumor tissues, enhancing
tumor accumulation and inhibiting its growth while preventing
systemic toxicity.[121]
Also, Xia et al. functionalized SeNPs with RGDfC peptide
and subsequently anionic KLK12-siRNA was loaded onto the
surface of RGD-SeNPs, developing RGD-SeNps@siRNA-KLK12.
Kallikrein-related peptidase 12 (KLK12) targeting was chosen
since its expression is enhanced in colorectal cancer but dimin-
ished in healthy cells, is considered a cell growth factor. Load-
ing KLK12-siRNA onto RGDfC-SeNPs surface demonstrated to
decrease its degradation and selectively deliver it to the cancer
cells. RGD peptide could specifically bind to cancer cells, through
𝛼v𝛽3 integrin receptor and induce clathrin-associated endocy-
tosis of RGDfC-SeNPs@siRNA-KLK12. Once inside the cells,
RGDfC-Se@siRNA-KLK12 escapes endosomes and induces
ROS stress, provoking mitochondria dysfunction, and downreg-
ulate Ki67. KLK12-siRNA silence the KLK12 gene, downregulat-
ing its mRNA expression. Thus, RGDfC-SeNPs@siRNA-KLK12
induced cell arrest at sub-G1 cell phase and apoptosis. In vivo
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assays demonstrate that RGDfC-SeNPs@siRNA-KLK12 also in-
crease the proapoptotic proteins Bak, caspase-3 and pp53, re-
ducing the tumor volume without presenting systemic toxicity
in the heart, kidney, liver, lung and spleen. Besides, RGDfC-
SeNPs@siRNA-KLK12 suppressed cancer cells migration, inva-
sion, and angiogenesis, which is demonstrated by a decrease in
CD31 levels.[257] Xia et al. also used RGDfC-SeNPs to deliver Der-
lin1 -siRNA, since Derlin1 is a protein that transports unfolded
and misfolded proteins from endoplasmic reticulum lumen to
cytoplasm, being overexpressed in several cancer types. Indeed,
RGDfC-SeNPs@siRNA-Derlin1 shown efficiency in silence De-
clin1 gene in cervical cancer cells, inhibiting their migration and
invasion. RGDfC-SeNPs@siRNA-Derlin1 also generated ROS
overproduction and mitochondrial dysfunction, thereby induc-
ing apoptosis and cell cycle arrest at sub-G1. In vivo studies
demonstrated that RGDfC-SeNPs@siRNA-Derlin1 were well tol-
erated, without signs of cytotoxicity, while inhibiting cervical can-
cer growth, by activating pp53, caspase-3, and Bak activities.[151]
Maiyo et al. used FA-chitosan-SeNPs to deliver Fluc-siRNA to
silence luciferase gene in colorectal adenocarcinoma. Fluc-siRNA
loading into the functionalized SeNPs was realized by ionic inter-
actions, and the nanosystem produced not only was stable but
also protected the Fluc-siRNA from RNAase degradation. The
nanosystem entered into cancer cells by both non-specific endo-
cytosis and folate receptor endocytosis, inducing cytotoxicity.[255]
More recently, Xia et al. studied the potential of delivering a
siRNA to silence the myocyte enhancer factor 2 (MEF2), a tran-
scription factor correlated with the occurrence and development
of cancers, using RGDfC-SeNPs as a carrier. The RGDfC inter-
acted with 𝛼v𝛽3 integrin, which was overexpressed in the ovarian
cancer cell line used, induced the uptake of the nanosystem by
clathrin-associated endocytosis. RGDfC-SeNPs@siRNA-MEF2D
silenced the expression of the MEF2D gene, while increasing the
amount of cellular ROS and mitochondrial stress, inducing apop-
tosis with a peak at the sub-G1 phase. Further in vivo studies sup-
ported the antitumor potential of this nanosystem, while proving
their biocompatibility.[258]
The loading of mRNA inside SeNPs for cancer therapy was
also studied since mRNA is easily produced and does not require
to be deliver inside the nucleus to function. Xia et al. study the
use of SeNPs stabilized with chitosan and functionalized with FA
to load and protect Fluc-mRNA, wherein FA was conjugated to
chitosan through carbodiimide chemistry, resulting in nanosys-
tems stable for two months at 4 °C. FA-Chitosan-SeNPs@RNA
presented positive charge, which was essential for mRNA bind-
ing and association with the negatively charged cancer cell mem-
branes. Also, FA-chitosan-SeNPs were able to protect mRNA
from RNase A degradation activity, presenting moderate antipro-
liferative properties towards colorectal and colon carcinoma cells
and low cytotoxicity in the human embryonic kidney, breast ade-
nocarcinoma, and nasopharyngeal cells. Therefore, Xia et al. sug-
gested the used of chitosan-SeNPs for tumor vaccination and im-
munotherapy, due their synergic activity with mRNA.[126]
5. Conclusion and Future Perspectives
Se is an essential element for human health, its intake depends
on geographic location and the aliments consumed, although
several forms of Se supplementation are currently available. In
the human body, it is used for production of selenoproteins,
which usually incorporate Se in the form of selenocysteine in
their active center. As a result of the selenoproteins’ antioxidant,
immunomodulatory and regulatory properties, Se has a crucial
role in the human body, influencing the thyroid, liver, brain, and
the reproduction functions, besides having antitumor and an-
timicrobial properties. However, since Se has a narrow therapeu-
tic window, both deficiency and excessive Se intake can lead to
severe symptoms and are correlated with several diseases.
With the objective of reducing Se toxicity and improve its ther-
apeutic efficiency, SeNPs have been produced and study using
both microorganisms, reducing agents, and physical methods,
being that the biosynthesis of SeNPs offers several advantages
compared to the other methods, such as the inexistence of harsh
chemicals and conditions, low cost and toxicity, and the fact that
SeNPs are already stabilized according to the microorganism.
The SeNPs produced using other methods need to be stabilized,
since bare SeNPs are usually unstable and precipitate, and can
also be functionalized, according to the therapeutic application
desired.
SeNPs have demonstrated excellent properties for the preven-
tion and treatment of several diseases, such as diabetes, AD,
inflammatory-related diseases, such as RA, atherosclerosis, and
stroke, and antimicrobial infections. However, SeNPs are mostly
studied for anticancer applications, since high Se levels are more
prone to cause oxidant stress in cancer cells than in healthy ones,
existing a narrow therapeutic margin for its use as for its use
as a chemotherapeutic agent. SeNPs have been also function-
alized with several ligands, whose receptor is preferentially ex-
pressed in cancer cells, as well as loaded with several approved
chemotherapeutic drugs and genetic material, demonstrating the
ability to reduce the toxicity associated with these compounds
while developing a synergic activity. Overall, SeNPs enter can-
cer cells through clathrin-mediated endocytosis and trigger ROS
overproduction and mitochondria dysfunction, thereby activat-
ing caspase-3 activity and the intrinsic apoptosis pathway. How-
ever, the anticancer mechanism of action of SeNPs also dif-
fers according to the preparation method, the targeting moieties
used, and the loadings applied (Figure 26). Currently, the liter-
ature studies do not have the same research extension, making
it difficult to compare the chemotherapeutic potential between
different loadings, functionalizations, and cancer cell types.
Moreover, it would be important to evaluate the properties of
SeNPs prepared using the biosynthesis method, since the coat-
ing of biogenic SeNPs is specific for each microorganism.
Therefore, the main conclusions that can be taken from the
literature about SeNPs are the following:
• There are several methodologies for SeNPs production, from
the use of microorganisms to the use of chemical agents or
physical methods, such as PLA. However, all procedures in-
clude the reduction of selenium salts into Se(0) to form SeNPs.
• Different compounds can be used for the stabilization and/or
functionalization of SeNPs, conferring new therapeutic advan-
tages toward specific diseases, such as synergic therapeutic ac-
tivities or active targeting toward specific cells.
• Although SeNPs therapeutic margin is very narrow, SeNPs
have better medicinal properties than selenium salts and lower
toxicity.
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Figure 26. Antitumor mechanisms of action of SeNPs according to their coating/functionalization and loading. Figure created with Biorender.
• SeNPs potential therapeutic applications comprise AD,
diabetes, inflammatory-based diseases/conditions, such
as RA and liver fibrosis, bacterial, fungal and viral
infections.
• The most studied SeNPs medical application is cancer ther-
apy, due to the fact that cancer cells are more sensitive to the
oxidative stress caused by high levels of Se than the normal
cells.
• Also, SeNPs can be functionalized toward cancer cells, in-
ducing ROS overproduction, mitochondria dysfunction, and
caspase-3 activation and activation of the intrinsic pathway of
apoptosis.
• Furthermore, SeNPs can be loaded with approved chemother-
apeutic drugs, decreasing their side effects, while acting in
synergy against cancer cells, with potential to induce both in-
trinsic and extrinsic apoptosis pathways, depending on the
chemotherapeutic drug used.
• SeNPs have been also studied for the delivery of specific
siRNA that inhibit the expression of proteins associated with
tumor growth and invasion.
• Novel studies have also reported SeNPs potential for PTT, pho-
todynamic and chemodynamic therapy, immunotherapy and
radiotherapy synergism.
However, for their clinical translation, it is still necessary to
undertake extensive studies regarding their safety, due to their
narrow therapeutic window, and clarification of their synergic ac-
tivities with other therapeutic compounds to gain better manage-
ment and understanding of how their properties can vary accord-
ing to their loading and functionalization.
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